Satoshi Kano

Faculty of Medicine Specialized Medicine Sensory Organ MedicineAssociate Professor
Last Updated :2025/06/07

■Researcher basic information

Researchmap personal page

Research Keyword

  • 唾液腺癌
  • 頭頸部癌

Research Field

  • Life sciences, Otorhinolaryngology

Educational Organization

■Career

Career

  • Apr. 2018 - Present
    北海道大学大学院医学研究院, 耳鼻咽喉科・頭頸部外科学教室, 講師
  • Apr. 2014 - Mar. 2018
    Hokkaido University, 医学(系)研究科(研究院), 助教

■Research activity information

Papers

  • The impact of HER2-Low expression in salivary duct carcinoma: Clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapy.
    Satoshi Kano, Daisuke Kawakita, Yoshitaka Honma, Hideaki Takahashi, Masato Nakaguro, Yoshitaka Utsumi, Natsuki Saigusa, Toyoyuki Hanazawa, Kiyoaki Tsukahara, Takuro Okada, Kenji Okami, Keisuke Yamazaki, Yushi Ueki, Yuki Saito, Hiroyuki Ozawa, Tomoyuki Arai, Akira Shimizu, Kenji Hanyu, Sho Iwaki, Sae Imaizumi, Akihiro Sakai, Mayu Yamauchi, Ryoko Tanaka, Yuichiro Sato, Koji Yamamura, Mariko Sekimizu, Yorihisa Imanishi, Hideaki Hirai, Yukiko Sato, Makoto Urano, Hidetaka Yamamoto, Chihiro Fushimi, Takashi Matsuki, Toshitaka Nagao, Yuichiro Tada
    Oral oncology, 165, 107280, 107280, 18 Apr. 2025, [International Magazine]
    English, Scientific journal, OBJECTIVES: Recent advances in systemic therapy for salivary duct carcinoma (SDC) have been driven by the development of HER2- and androgen receptor (AR)-targeted therapies. Trastuzumab deruxtecan has proven effective not only in HER2-positive but also HER2-low breast and gastro-esophageal cancers. However, the significance of HER2-low expression in SDC remains unknown. This study aimed to investigate the clinicopathologic characteristics, prognostic implications, and impact on efficacy to AR-targeted therapy in HER2-low SDC. MATERIALS AND METHODS: This was a multi-center, observational study. HER2 status was reclassified as follows: HER2-positive (IHC3+ or 2+/ISH+ ), HER2-low (IHC1+ or 2+/ISH-), and HER2-zero (IHC0). The subjects were compared in three groups: total population, curative treatment cohort, and AR-targeted therapy cohort. RESULTS: The total population consisted of 526 patients, of whom, 271 (52 %), 184 (35 %), and 71 (13 %) had HER2-positive, -low, and -zero tumors, respectively. Sex, M category, histological origin, Ki67, and p53 expression differed significantly between the HER2-low and HER2-positive cases. No differences in relapse-free or overall survival were observed for HER2 status in the curative treatment cohort; however, in the AR-targeted therapy cohort, the HER2-low group had significantly better response rates (41.6 % vs. 18.9 %, Odds ratio = 0.30, P = 0.012) and longer median progression-free survival (6.9 vs. 4.2 months, Hazard ratio = 1.61, P = 0.029) than those of the HER2-positive group. CONCLUSION: HER2-low showed different clinicopathologic features from HER2-positive cases, with no prognostic differences observed in patients who underwent curative treatment. Still, HER2-low may be associated with the efficacy of AR-targeted therapy.
  • Cytoplasmic p53 Immunostaining in Salivary Duct Carcinoma: A Poor Prognostic Factor Associated With Characteristic TP53 Variants.
    Yoshitaka Utsumi, Masato Nakaguro, Daisuke Kawakita, Hideaki Hirai, Aoi Sukeda, Shinji Kohsaka, Kiyoaki Tsukahara, Toyoyuki Hanazawa, Satoshi Kano, Keisuke Yamazaki, Yushi Ueki, Kenji Okami, Yuki Saito, Hiroyuki Ozawa, Yoshitaka Honma, Akira Shimizu, Kenji Hanyu, Shota Fujii, Tomoyuki Arai, Sho Iwaki, Sae Imaizumi, Ryoko Tanaka, Mayu Yamauchi, Koji Yamamura, Mariko Sekimizu, Hideaki Takahashi, Yorihisa Imanishi, Yuichiro Sato, Takashi Matsuki, Yuichiro Tada, Toshitaka Nagao
    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 100766, 100766, 07 Apr. 2025, [International Magazine]
    English, Scientific journal, Salivary duct carcinoma (SDC) is an uncommon, high-grade malignancy. Identifying suitable prognostic factors is crucial for developing effective treatment strategies for SDC. p53 immunohistochemistry (IHC) is a potential prognostic marker for SDC. Traditionally, only the nuclear expression has been considered when evaluating aberrant p53 IHC patterns. However, recent studies on other organ cancers have highlighted the significance of the cytoplasmic p53 expression. We aimed to investigate the prognostic implications of cytoplasmic p53 positivity and its association with TP53 variants in a large cohort of patients with SDC. p53 IHC was performed in 327 SDC patients who had undergone primary curative resection. Based on the immunostaining patterns, patients were classified into four groups: wild-type (WT), overexpression (OE), complete absence (CA), and cytoplasmic (CY). Additionally, the TP53 gene status was analyzed in 239 cases by Sanger and/or next-generation sequencing. The p53 IHC patterns of 327 cases were as follows: WT (n = 125; 38.2%), OE (n = 100; 30.6%), CA (n = 75; 22.9%), and CY (n = 27; 8.3%). A TP53 genetic analysis of 239 cases revealed the following: wild-type status (n = 80; 33.5%), missense/inframe variants (n = 86; 36.0%), and truncating variants (n = 73; 30.5%). Notably, 24 of the 25 CY cases (96%) harbored TP53 variants, which were predominantly located in the domains responsible for nuclear translocation. Of these, 22 exhibited truncating variants. In a multivariate analysis, CY cases demonstrated significantly shorter disease-free survival (DFS) than WT cases (P = .01). Furthermore, patients with aberrant p53 expression patterns (OE+CA+CY) had significantly worse DFS and overall survival (OS) than those with WT (P = .003 and .002, respectively). The presence of TP53 variants was also associated with poorer DFS and OS (P = .003 and .02, respectively). Our findings suggest that the cytoplasmic expression of p53 in SDC represents a distinct aberrant pattern underlying characteristic genetic abnormalities and has significant prognostic implications.
  • Improved local control and survival outcomes with RADPLAT in T4 oropharyngeal cancer: a retrospective study
    Satoshi Kano, Takayoshi Suzuki, Daisuke Yoshida, Nayuta Tsushima, Hiroshi Idogawa, Ryohei Katsumata, Koichi Yasuda, Naoya Kinota, Koji Yamasaki, Yasushi Shimizu, Jun Taguchi, Hidefumi Aoyama, Akihiro Homma
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 27 Mar. 2025
    English, Scientific journal
  • Improved local control and survival outcomes with RADPLAT in T4 oropharyngeal cancer: a retrospective study.
    Satoshi Kano, Takayoshi Suzuki, Daisuke Yoshida, Nayuta Tsushima, Hiroshi Idogawa, Ryohei Katsumata, Koichi Yasuda, Naoya Kinota, Koji Yamasaki, Yasushi Shimizu, Jun Taguchi, Hidefumi Aoyama, Akihiro Homma
    International journal of clinical oncology, 27 Mar. 2025, [Domestic magazines]
    English, Scientific journal, BACKGROUNDS: Standard treatments for locally advanced oropharyngeal cancer (OPC) include surgery and chemoradiotherapy (CRT). While surgery offers good tumor control, it often results in significant postoperative functional impairments. Conversely, intravenous chemoradiotherapy (IV-CRT) is less effective in controlling primary tumors in T4 OPC cases and offers limited options for salvage surgery after recurrence. RADPLAT, a treatment involving intra-arterial cisplatin combined with radiotherapy, has demonstrated favorable results for other cancers and may offer an alternative treatment for OPC. METHODS: This retrospective study compared the efficacy and safety of RADPLAT and IV-CRT in the patients with T4 OPC treated at Hokkaido University Hospital between 2003 and 2022. The primary endpoint was local recurrence-free survival (LRFS), and the secondary endpoint was overall survival (OS). RESULTS: Fifty-six patients were included, with 29 in the RADPLAT group and 27 in the IV-CRT group. The RADPLAT group showed significantly better LRFS (2-year LRFS: 82.3%) and OS (5-year OS: 73.8%) compared to the IV-CRT group (2y-LRFS: 66.0%, 5y-OS: 45.7%). Multivariate analysis identified RADPLAT as an independent favorable prognostic factor for both LRFS and OS. There was no significant difference in the incidence of adverse events between the two groups, although grade 3 or higher mucositis was more common in the RADPLAT group. Swallowing function and tracheostomy rates were similar between the groups. CONCLUSION: RADPLAT provides superior local control and survival outcomes compared to IV-CRT for T4 OPC, with comparable safety and functional preservation. These findings suggest that RADPLAT may be a promising alternative to IV-CRT for cases with T4 OPC.
  • Clinical outcomes of recurrent or metastatic head and neck cancer after failure of platinum and nivolumab: a multicenter retrospective study.
    Takane Watanabe, Hiroki Oka, Kengo Nagashima, Hideaki Nishi, Yoshihiko Kumai, Hiroaki Iijima, Kenji Okami, Yasushi Shimizu, Satoshi Kano, Kazue Ito, Tomoko Yamazaki, Hideaki Takahashi, Nobuhiko Oridate, Tomoya Yokota, Taiji Koyama, Naomi Kiyota, Yasuyoshi Sato, Shunji Takahashi, Kyoko Kato, Shigenori Kadowaki, Yoshitaka Honma
    The oncologist, 30, 3, 10 Mar. 2025, [International Magazine]
    English, Scientific journal, BACKGROUND: Platinum and anti-PD-1 antibodies are the front-line systemic therapy for recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC). However, limited data are available on clinical outcomes and appropriate regimens for patients with RM-HNSCC following treatment failure with these agents. PATIENTS AND METHODS: We retrospectively analyzed the clinical data of patients with RM-HNSCC from 10 Japanese institutions in whom platinum and nivolumab treatment failed. RESULTS: Of the 480 patients included in the study, 236 were treated with the best supportive care and had a median overall survival of 3.1 months. The remaining 244 patients received salvage-line chemotherapy, which was paclitaxel + cetuximab in 72 (30%), paclitaxel or docetaxel in 89 (36%), and tegafur/gimeracil/oteracil in 48 (20%); the respective objective response rates were 54.9%, 27.9%, and 25.5%, with median progression-free survival of 5.4 months and median overall survival of 13.0 months. Multivariable analysis identified disease stabilization or response on prior nivolumab and paclitaxel + cetuximab as salvage-line chemotherapy to be associated with encouraging progression-free and overall survival. CONCLUSION: This study sheds light on clinical outcomes and prognostic factors in patients with RM-HNSCC after failure of platinum and anti-PD-1 antibody therapy. The findings provide essential baseline data for future therapeutic development in salvage-line settings.
  • Dual-type deep learning-based image reconstruction for advanced denoising and super-resolution processing in head and neck T2-weighted imaging.
    Noriyuki Fujima, Yukie Shimizu, Yohei Ikebe, Hiroyuki Kameda, Taisuke Harada, Nayuta Tsushima, Satoshi Kano, Akihiro Homma, Jihun Kwon, Masami Yoneyama, Kohsuke Kudo
    Japanese journal of radiology, 05 Mar. 2025, [Domestic magazines]
    English, Scientific journal, PURPOSE: To assess the utility of dual-type deep learning (DL)-based image reconstruction with DL-based image denoising and super-resolution processing by comparing images reconstructed with the conventional method in head and neck fat-suppressed (Fs) T2-weighted imaging (T2WI). MATERIALS AND METHODS: We retrospectively analyzed the cases of 43 patients who underwent head/neck Fs-T2WI for the assessment of their head and neck lesions. All patients underwent two sets of Fs-T2WI scans with conventional- and DL-based reconstruction. The Fs-T2WI with DL-based reconstruction was acquired based on a 30% reduction of its spatial resolution in both the x- and y-axes with a shortened scan time. Qualitative and quantitative assessments were performed with both the conventional method- and DL-based reconstructions. For the qualitative assessment, we visually evaluated the overall image quality, visibility of anatomical structures, degree of artifact(s), lesion conspicuity, and lesion edge sharpness based on five-point grading. In the quantitative assessment, we measured the signal-to-noise ratio (SNR) of the lesion and the contrast-to-noise ratio (CNR) between the lesion and the adjacent or nearest muscle. RESULTS: In the qualitative analysis, significant differences were observed between the Fs-T2WI with the conventional- and DL-based reconstruction in all of the evaluation items except the degree of the artifact(s) (p < 0.001). In the quantitative analysis, significant differences were observed in the SNR between the Fs-T2WI with conventional- (21.4 ± 14.7) and DL-based reconstructions (26.2 ± 13.5) (p < 0.001). In the CNR assessment, the CNR between the lesion and adjacent or nearest muscle in the DL-based Fs-T2WI (16.8 ± 11.6) was significantly higher than that in the conventional Fs-T2WI (14.2 ± 12.9) (p < 0.001). CONCLUSION: Dual-type DL-based image reconstruction by an effective denoising and super-resolution process successfully provided high image quality in head and neck Fs-T2WI with a shortened scan time compared to the conventional imaging method.
  • 唾液腺導管癌におけるp53免疫組織化学染色の細胞質陽性パターンはTP53遺伝子変異を反映した予後不良因子となり得る 大規模多施設共同研究
    内海 由貴, 川北 大介, 山本 善也, 平井 秀明, 塚原 清彰, 加納 里志, 花澤 豊行, 大上 研二, 小澤 宏之, 山崎 恵介, 齊藤 祐毅, 植木 雄志, 中黒 匡人, 多田 雄一郎, 長尾 俊孝
    日本唾液腺学会誌, 64, 32, 32, 日本唾液腺学会, Dec. 2024
    Japanese
  • 唾液腺導管癌におけるp53免疫組織化学染色の細胞質陽性パターンはTP53遺伝子変異を反映した予後不良因子となり得る 大規模多施設共同研究               
    内海 由貴, 川北 大介, 山本 善也, 平井 秀明, 塚原 清彰, 加納 里志, 花澤 豊行, 大上 研二, 小澤 宏之, 山崎 恵介, 齊藤 祐毅, 植木 雄志, 中黒 匡人, 多田 雄一郎, 長尾 俊孝
    日本唾液腺学会誌, 64, 32, 32, 日本唾液腺学会, Dec. 2024
    Japanese
  • [ANL Secondary Publication] 平均赤血球容積高値は頭頸部癌に食道癌を併発するリスク因子である
    対馬 那由多, 加納 里志, 鈴木 崇祥, 浜田 誠二郎, 本間 明宏
    日本耳鼻咽喉科頭頸部外科学会会報, 127, 9, 1027, 1029, (一社)日本耳鼻咽喉科頭頸部外科学会, Sep. 2024
    Japanese
  • 鼻副鼻腔粘膜悪性黒色腫におけるTRIM27の検討               
    木村 将吾, 中丸 裕爾, 鈴木 正宣, 中薗 彬, 本間 あや, 渡邉 良亮, 加納 里志, 対馬 那由多, 鈴木 崇祥, 井戸川 寛志, 本間 明宏, 渡部 昌, 近藤 豪, 畠山 鎮次
    日本鼻科学会会誌, 63, 3, 336, 336, (一社)日本鼻科学会, Sep. 2024
    Japanese
  • Apalutamide and Goserelin for Androgen Receptor–Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU
    Yoshitaka Honma, Nobuya Monden, Keisuke Yamazaki, Satoshi Kano, Hironaga Satake, Shigenori Kadowaki, Yoshitaka Utsumi, Tomohiko Nakatogawa, Ryo Takano, Koji Fujii, Yosuke Koroki, Junya Aoyama, Shohei Ouchi, Tetsuro Ogawa, Sharon McCarthy, Sabine D. Brookman-May, Suneel Mundle, Jinhui Li, Daksh Thaper, Toshitaka Nagao, Yuichiro Tada
    Clinical Cancer Research, OF1, OF12, American Association for Cancer Research (AACR), 23 Jul. 2024, [Peer-reviewed]
    English, Scientific journal, Abstract

    Purpose:

    To assess the efficacy and safety of apalutamide plus goserelin for androgen receptor (AR)–positive unresectable or recurrent/metastatic salivary gland carcinoma.

    Patients and Methods:

    This trial was an open-label, single-arm, multicenter phase II study. Patients with histologically confirmed unresectable or recurrent/metastatic salivary gland carcinoma with AR expression were included. The primary endpoint was the overall response rate (ORR) according to RECIST v1.1 by an independent central radiology review in the first 24 response-evaluable (RE) patients who had been observed at least 24 weeks from study initiation (primary RE patients). The efficacy was to be declared when at least 8 of the 24 primary RE patients responded.

    Results:

    A total of 31 patients were enrolled. In the first 24 primary RE patients with a median follow-up of 7.4 months, confirmed ORR by independent central radiology review was 25.0% [6/24 patients; 95% confidence interval, 9.8%–46.7%; P = 0.11 (one-sided)], which did not meet the predefined criteria of efficacy. Clinical benefit rate (ORR + rate of stable disease for at least 24 weeks) and median progression-free survival were 50.0% and 7.4 months, respectively. Both median duration of response and overall survival were not reached. Exploratory analyses showed a better ORR of 54.5% (6/11) in patients with AR positivity ≥70% and no history of prior systemic therapy. Grade 3 or higher treatment-emergent adverse events were reported in 35.5% (11/31), which included skin rash, anemia, leukopenia, and cancer pain.

    Conclusions:

    Although this study did not meet the predefined efficacy criteria, apalutamide plus goserelin showed clinically meaningful efficacy in a subset of patients with AR-positive salivary gland carcinoma and safety consistent with prior experience in prostate cancer.
  • The clinicopathological and prognostic significance of autonomic nerves in salivary duct carcinoma.
    Manami Kajiwara, Hideaki Takahashi, Masato Nakaguro, Daisuke Kawakita, Hideaki Hirai, Yoshitaka Utsumi, Makoto Urano, Yukiko Sato, Kiyoaki Tsukahara, Satoshi Kano, Kenji Okami, Hiroyuki Ozawa, Keisuke Yamazaki, Takuro Okada, Akira Shimizu, Kenji Hanyu, Akihiro Sakai, Mayu Yamauchi, Mariko Sekimizu, Toyoyuki Hanazawa, Yuki Saito, Yushi Ueki, Yoshitaka Honma, Tomoyuki Arai, Sho Iwaki, Koji Yamamura, Yorihisa Imanishi, Yuichiro Sato, Yuichiro Tada, Toshitaka Nagao
    Virchows Archiv : an international journal of pathology, 23 Jul. 2024, [International Magazine]
    English, Scientific journal, Many researchers have focused on the role of the autonomic nervous system in the tumor microenvironment. Autonomic nerves include the sympathetic and parasympathetic nerves, which are known to induce cancer growth and metastasis. However, in salivary duct carcinoma (SDC), a rare and highly malignant tumor, the issue should be investigated from both biological and therapeutic perspectives. We explored the clinicopathological and prognostic implications of the autonomic nerves in 129 SDCs. Immunohistochemistry was performed to determine the nature of each nerve using antibodies against S100, tyrosine hydroxylase (TH) as a sympathetic marker, and vesicular acetylcholine transporter (VAChT) as a parasympathetic marker. The area of each marker-positive nerve was digitized and evaluated quantitatively. Double immunofluorescence for TH and VAChT was performed in selected cases. The expression of the secreted neurotrophins was also examined. S100-positive nerves were present in the cancer tissue in 94 of 129 cases (72.9%). Among them, TH-positive sympathetic nerves and/or VAChT-positive parasympathetic nerves were identified in 92 cases (97.9%), and 59 cases (62.8%) had TH/VAChT-co-expressing nerves. Double immunofluorescence revealed a mosaic pattern of sympathetic and parasympathetic fibers in co-expressing nerve bundles. The presence of autonomic nerves, regardless of their area, was significantly associated with aggressive histological features, advanced T/N classification, and a poor prognosis, with shorter disease-free and overall survival. There was an association between some tumor immune microenvironment-related markers and the autonomic nerve status, but not the latter and the secreted neurotrophin expression. This study suggests that autonomic nerves might play a role in the progression of SDC.
  • アンドロゲン受容体(AR)陽性唾液腺癌に対するAR阻害薬Darolutamide(ODM-201)の第II相試験:単剤パート               
    大塚 倫之, 岡野 晋, 今村 善宣, 瓜生 英興, 大越 明, 佐野 大佑, 塚原 清彰, 大野 十央, 花澤 豊行, 加納 里志, 西尾 直樹, 長岡 真人, 長尾 俊孝, 久野 博文, 尾尻 博也, 齋藤 尚子, 篠田 覚, 三角 俊裕, 清田 尚臣, 田原 信
    頭頸部癌, 50, 2, 138, 138, (一社)日本頭頸部癌学会, May 2024
    Japanese
  • 早期声門癌に対する強度変調放射線治療の初期経験               
    服部 敬寛, 安田 耕一, 湊川 英樹, 打浪 雄介, 木下 留美子, 浜田 誠二郎, 井戸川 寛志, 鈴木 崇祥, 対馬 那由多, 加納 里志, 本間 明宏
    頭頸部癌, 50, 2, 206, 206, (一社)日本頭頸部癌学会, May 2024
    Japanese
  • 唾液腺混成癌は存在するのか? 13例の唾液腺混成癌の形態学的および遺伝子解析               
    中黒 匡人, 松木 崇, 中村 ハルミ, 加納 里志, 川北 大介, 花澤 豊行, 中島 広聖, 内海 由貴, 八木 春奈, 多田 雄一郎, 長尾 俊孝
    頭頸部癌, 50, 2, 135, 135, (一社)日本頭頸部癌学会, May 2024
    Japanese
  • 唾液腺導管癌におけるHER2低発現の臨床的意義               
    加納 里志, 川北 大介, 花澤 豊行, 塚原 清彰, 岡田 拓朗, 大上 研二, 山崎 恵介, 齊藤 裕毅, 小澤 宏之, 植木 雄志, 本間 義崇, 中黒 匡人, 長尾 俊孝, 多田 雄一郎
    頭頸部癌, 50, 2, 137, 137, (一社)日本頭頸部癌学会, May 2024
    Japanese
  • HER2低発現は唾液腺導管癌における複合アンドロゲン遮断療法の治療効果予測因子である               
    加納 里志, 川北 大介, 本間 義崇, 長尾 俊孝, 多田 雄一郎
    頭頸部癌, 50, 2, 137, 137, (一社)日本頭頸部癌学会, May 2024
    Japanese
  • 頭頸部アルミノックス治療における複合現実を用いた治療計画の3次元可視化の試み               
    鈴木 崇祥, 足利 雄一, 若林 侑輝, 鈴木 正宣, 浜田 誠二郎, 井戸川 寛志, 対馬 那由多, 加納 里志, 本間 明宏
    頭頸部癌, 50, 2, 189, 189, (一社)日本頭頸部癌学会, May 2024
    Japanese
  • 唾液腺混成癌は存在するのか? 13例の唾液腺混成癌の形態学的および遺伝子解析               
    中黒 匡人, 松木 崇, 中村 ハルミ, 加納 里志, 川北 大介, 花澤 豊行, 中島 広聖, 内海 由貴, 八木 春奈, 多田 雄一郎, 長尾 俊孝
    頭頸部癌, 50, 2, 135, 135, (一社)日本頭頸部癌学会, May 2024
    Japanese
  • 唾液腺導管癌におけるHER2低発現の臨床的意義               
    加納 里志, 川北 大介, 花澤 豊行, 塚原 清彰, 岡田 拓朗, 大上 研二, 山崎 恵介, 齊藤 裕毅, 小澤 宏之, 植木 雄志, 本間 義崇, 中黒 匡人, 長尾 俊孝, 多田 雄一郎
    頭頸部癌, 50, 2, 137, 137, (一社)日本頭頸部癌学会, May 2024
    Japanese
  • HER2低発現は唾液腺導管癌における複合アンドロゲン遮断療法の治療効果予測因子である               
    加納 里志, 川北 大介, 本間 義崇, 長尾 俊孝, 多田 雄一郎
    頭頸部癌, 50, 2, 137, 137, (一社)日本頭頸部癌学会, May 2024
    Japanese
  • アンドロゲン受容体(AR)陽性唾液腺癌に対するAR阻害薬Darolutamide(ODM-201)の第II相試験:単剤パート               
    大塚 倫之, 岡野 晋, 今村 善宣, 瓜生 英興, 大越 明, 佐野 大佑, 塚原 清彰, 大野 十央, 花澤 豊行, 加納 里志, 西尾 直樹, 長岡 真人, 長尾 俊孝, 久野 博文, 尾尻 博也, 齋藤 尚子, 篠田 覚, 三角 俊裕, 清田 尚臣, 田原 信
    頭頸部癌, 50, 2, 138, 138, (一社)日本頭頸部癌学会, May 2024
    Japanese
  • SlicerPIT: software development and implementation for planning and image-guided therapy in photoimmunotherapy.
    Takayoshi Suzuki, Satoshi Kano, Masanobu Suzuki, Seijiro Hamada, Hiroshi Idogawa, Nayuta Tsushima, Yuichi Ashikaga, Yuki Wakabayashi, Takeshi Soyama, Yasuhiro Hida, Akihiro Homma
    International journal of clinical oncology, 23 Apr. 2024, [Domestic magazines]
    English, Scientific journal, BACKGROUND: Photoimmunotherapy is a treatment modality that induces targeted cell death by binding a molecular-targeted drug activated by infrared light to the tumor cells and subsequently illuminating the lesion with infrared light. For deep lesions, a needle catheter is used to puncture the tumor, and an illumination fiber (cylindrical diffuser) is inserted into the catheter lumen for internal illumination. However, it can be challenging to place the cylindrical diffusers in an appropriate position as the deep lesions cannot be often confirmed accurately during surgery. MATERIALS AND METHODS: We have developed "SlicerPIT", a planning simulation software for photoimmunotherapy. SlicerPIT allows users to place the cylindrical diffuser with its illumination range on preoperative images in 2D and 3D and export the planning data to external image-guided surgical navigation systems. We performed seven cycles of photoimmunotherapy with SlicerPIT in three patients with recurrent head and neck cancer. RESULTS: Preoperative planning for photoimmunotherapy was conducted using SlicerPIT, which could be imported into the navigation system. During the operation, we punctured the needle catheters along with the treatment plan on the navigation screen. Subsequently, intraoperative CT imaging was performed and overlaid with the preoperative treatment plan to confirm the alignment of the cylindrical diffusers as planned, followed by infrared light illumination. Postoperative imaging showed necrosis and shrinkage of the entire tumor in all cycles. CONCLUSION: SlicerPIT allows for detailed preoperative treatment planning and accurate puncture. It may be a valuable tool to improve the accuracy of photoimmunotherapy for deep lesions and improve patient outcomes.
  • Stage I/II舌癌における潜在的リンパ節転移の予測式の確立
    野島 雄介, 鬼島 菜摘, 佐野 大佑, 西川 大輔, 後藤 聖也, 土田 宏大, 加納 里志, 有泉 陽介, 森下 洋平, 桑原 達, 向川 卓志, 志賀 清人, 朝蔭 孝宏, 松浦 一登, 折舘 伸彦, 本間 明宏, 林 隆一, 花井 信広
    日本耳鼻咽喉科頭頸部外科学会会報, 127, 4, 539, 539, (一社)日本耳鼻咽喉科頭頸部外科学会, Apr. 2024
    Japanese
  • 【頭頸部がん診療のControversy】化学放射線療法 どっちを選ぶ? Triweekly CDDP-CRT vs Weekly CDDP-CRT Weekly CDDP-CRT
    浜田 誠二郎, 加納 里志
    耳鼻咽喉科・頭頸部外科, 96, 4, 330, 333, (株)医学書院, Apr. 2024
    Japanese
  • 鼻副鼻腔粘膜悪性黒色腫の遺伝子変異を次世代シークエンサーにより解析する
    対馬 那由多, 加納 里志, 鈴木 崇祥, 浜田 誠二郎, 井戸川 寛志, 本間 明宏
    日本耳鼻咽喉科頭頸部外科学会会報, 127, 4, 540, 540, (一社)日本耳鼻咽喉科頭頸部外科学会, Apr. 2024
    Japanese
  • 治療計画ARナビゲーション・ニードルベンダーを用いた頭頸部アルミノックス治療の1例
    鈴木 崇祥, 足利 雄一, 若林 侑輝, 鈴木 正宣, 浜田 誠二郎, 井戸川 寛志, 対馬 那由多, 加納 里志, 本間 明宏
    日本耳鼻咽喉科頭頸部外科学会会報, 127, 4, 599, 599, (一社)日本耳鼻咽喉科頭頸部外科学会, Apr. 2024
    Japanese
  • Impact of adaptive radiotherapy on survival in locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapy.
    Yusuke Uchinami, Koichi Yasuda, Hideki Minatogawa, Yasuhiro Dekura, Noboru Nishikawa, Rumiko Kinoshita, Kentaro Nishioka, Norio Katoh, Takashi Mori, Manami Otsuka, Naoki Miyamoto, Ryusuke Suzuki, Keiji Kobashi, Yasushi Shimizu, Jun Taguchi, Nayuta Tsushima, Satoshi Kano, Akihiro Homma, Hidefumi Aoyama
    Radiation oncology journal, 42, 1, 74, 82, Mar. 2024, [International Magazine]
    English, Scientific journal, PURPOSE: To investigate the clinical significance of adaptive radiotherapy (ART) in locally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT). MATERIALS AND METHODS: Eligible patients were treated with concurrent chemoradiotherapy using IMRT. Planning computed tomography in ART was performed during radiotherapy, and replanning was performed. Since ART was started in May 2011 (ART group), patients who were treated without ART up to April 2011 (non-ART group) were used as the historical control. The Kaplan-Meier method was used to calculate overall survival (OS), locoregional recurrence-free survival (LRFS), progression-free survival (PFS), and distant metastasis-free survival (DMFS). LRFS for the primary tumor (LRFS_P) and regional lymph node (LRFS_LN) were also studied for more detailed analysis. Statistical significance was evaluated using the log-rank test for survival. RESULTS: The ART group tended to have higher radiation doses. The median follow-up period was 127 months (range, 10 to 211 months) in the non-ART group and 61.5 months (range, 5 to 129 months) in the ART group. Compared to the non-ART group, the ART group showed significantly higher 5-year PFS (53.8% vs. 81.3%, p = 0.015) and LRFS (61.2% vs. 85.3%, p = 0.024), but not OS (80.7% vs. 80.8%, p = 0.941) and DMFS (84.6% vs. 92.7%, p = 0.255). Five-year LRFS_P was higher in the ART group (61.3% vs. 90.6%, p = 0.005), but LRFS_LN did not show a significant difference (91.9% vs. 96.2%, p = 0.541). CONCLUSION: Although there were differences in the patient backgrounds between the two groups, this study suggests the potential effectiveness of ART in improving locoregional control, especially in the primary tumor.
  • Brain metastases in patients with salivary duct carcinoma: A retrospective study.
    Chihiro Fushimi, Hideaki Takahashi, Daisuke Kawakita, Satoshi Kano, Kiyoaki Tsukahara, Hiroyuki Ozawa, Kenji Okami, Akihiro Sakai, Keisuke Yamazaki, Takuro Okada, Toyoyuki Hanazawa, Yuichiro Sato, Yorihisa Imanishi, Akira Shimizu, Takashi Matsuki, Toshitaka Nagao, Yuichiro Tada
    Cancer medicine, 13, 5, e7037, Mar. 2024, [International Magazine]
    English, Scientific journal, BACKGROUND: Salivary duct carcinoma (SDC) is a high-grade adenocarcinoma with a 5-year survival rate of 40%. Although drug therapy has improved patients' prognosis, the impact of brain metastasis (BM) remains poorly understood. We aimed to retrospectively examine the incidence of BM in patients with SDC (n = 464) and develop a tool to estimate their prognoses. METHODS: We retrospectively examined 464 patients with SDC enrolled in a multicenter study. We investigated the incidence of BM, overall survival (OS) rates, and factors affecting prognosis in patients with BM. We also developed an SDC-graded prognostic assessment (GPA) score for disease prognostication. RESULTS: Sixty-five (14%) patients had BM. The median OS (mOS) was 13.1 months. On univariate and multivariate analyses, factors such as Eastern Cooperative Oncology Group Performance Status >1, human epidermal growth factor receptor 2-negative status, and locoregional uncontrolled disease were associated with poor OS. SDC-GPA scores according to the prognostic factors were 0, 1, 2, and 3 points, and mOS estimates were 50.5, 16.1, 3.9, and 1.2 months, respectively (p < 0.001). CONCLUSION: The SDC-GPA score emerged as a useful prognostication tool for patients with BM.
  • Improved image quality in contrast-enhanced 3D-T1 weighted sequence by compressed sensing-based deep-learning reconstruction for the evaluation of head and neck.
    Noriyuki Fujima, Junichi Nakagawa, Yohei Ikebe, Hiroyuki Kameda, Taisuke Harada, Yukie Shimizu, Nayuta Tsushima, Satoshi Kano, Akihiro Homma, Jihun Kwon, Masami Yoneyama, Kohsuke Kudo
    Magnetic resonance imaging, 108, 111, 115, 09 Feb. 2024, [International Magazine]
    English, Scientific journal, PURPOSE: To assess the utility of deep learning (DL)-based image reconstruction with the combination of compressed sensing (CS) denoising cycle by comparing images reconstructed by conventional CS-based method without DL in fat-suppressed (Fs)-contrast enhanced (CE) three-dimensional (3D) T1-weighted images (T1WIs) of the head and neck. MATERIALS AND METHODS: We retrospectively analyzed the cases of 39 patients who had undergone head and neck Fs-CE 3D T1WI applying reconstructions based on conventional CS and CS augmented by DL, respectively. In the qualitative assessment, we evaluated overall image quality, visualization of anatomical structures, degree of artifacts, lesion conspicuity, and lesion edge sharpness based on a five-point system. In the quantitative assessment, we calculated the signal-to-noise ratios (SNRs) of the lesion and the posterior neck muscle and the contrast-to-noise ratio (CNR) between the lesion and the adjacent muscle. RESULTS: For all items of the qualitative analysis, significantly higher scores were awarded to images with DL-based reconstruction (p < 0.001). In the quantitative analysis, DL-based reconstruction resulted in significantly higher values for both the SNR of lesions (p < 0.001) and posterior neck muscles (p < 0.001). Significantly higher CNRs were also observed in images with DL-based reconstruction (p < 0.001). CONCLUSION: DL-based image reconstruction integrating into the CS-based denoising cycle offered superior image quality compared to the conventional CS method. This technique will be useful for the assessment of patients with head and neck disease.
  • 両側頸動脈小体腫瘍に対して放射線治療を施行した1例               
    西川 昇, 安田 耕一, 藤田 祥博, 檜垣 朔, 志藤 元泰, 宮崎 智彦, 高橋 周平, 青山 英史, 加納 里志, 本間 明宏
    Japanese Journal of Radiology, 42, Suppl., 8, 8, (公社)日本医学放射線学会, Feb. 2024
    Japanese
  • HER2陽性唾液腺導管癌に対する抗HER2療法における臨床病理学的治療効果予測因子の探索(Clinicopathological predictors for anti-HER2 therapy in HER2-positive salivary duct carcinoma)               
    内海 由貴, 平井 秀明, 山本 善也, 本間 義崇, 加納 里志, 川北 大介, 高橋 秀聡, 長尾 俊孝, 多田 雄一郎
    日本病理学会会誌, 113, 1, 346, 346, (一社)日本病理学会, Feb. 2024
    English
  • Diagnosis of skull-base invasion by nasopharyngeal tumors on CT with a deep-learning approach.
    Junichi Nakagawa, Noriyuki Fujima, Kenji Hirata, Taisuke Harada, Naoto Wakabayashi, Yuki Takano, Akihiro Homma, Satoshi Kano, Kazuyuki Minowa, Kohsuke Kudo
    Japanese journal of radiology, 27 Jan. 2024, [Domestic magazines]
    English, Scientific journal, PURPOSE: To develop a convolutional neural network (CNN) model to diagnose skull-base invasion by nasopharyngeal malignancies in CT images and evaluate the model's diagnostic performance. MATERIALS AND METHODS: We divided 100 malignant nasopharyngeal tumor lesions into a training (n = 70) and a test (n = 30) dataset. Two head/neck radiologists reviewed CT and MRI images and determined the positive/negative skull-base invasion status of each case (training dataset: 29 invasion-positive and 41 invasion-negative; test dataset: 13 invasion-positive and 17 invasion-negative). Preprocessing involved extracting continuous slices of the nasopharynx and clivus. The preprocessed training dataset was used for transfer learning with Residual Neural Networks 50 to create a diagnostic CNN model, which was then tested on the preprocessed test dataset to determine the invasion status and model performance. Original CT images from the test dataset were reviewed by a radiologist with extensive head/neck imaging experience (senior reader: SR) and another less-experienced radiologist (junior reader: JR). Gradient-weighted class activation maps (Grad-CAMs) were created to visualize the explainability of the invasion status classification. RESULTS: The CNN model's diagnostic accuracy was 0.973, significantly higher than those of the two radiologists (SR: 0.838; JR: 0.595). Receiver operating characteristic curve analysis gave an area under the curve of 0.953 for the CNN model (versus 0.832 and 0.617 for SR and JR; both p < 0.05). The Grad-CAMs suggested that the invasion-negative cases were present predominantly in bone marrow, while the invasion-positive cases exhibited osteosclerosis and nasopharyngeal masses. CONCLUSIONS: This CNN technique would be useful for CT-based diagnosis of skull-base invasion by nasopharyngeal malignancies.
  • Correction: Treatment outcomes of radiotherapy with concurrent weekly cisplatin in older patients with locally advanced head and neck squamous cell carcinoma.
    Yusuke Uchinami, Koichi Yasuda, Satoshi Kano, Manami Otsuka, Seijiro Hamada, Takayoshi Suzuki, Nayuta Tsushima, Shuhei Takahashi, Yoshihiro Fujita, Tomohiko Miyazaki, Hajime Higaki, Jun Taguchi, Yasushi Shimizu, Tomohiro Sakashita, Akihiro Homma, Hidefumi Aoyama
    Discover. Oncology, 15, 1, 18, 18, 25 Jan. 2024, [International Magazine]
    English
  • Analysis of salivary duct carcinoma at 13 facilities in northern Japan
    Satoshi Kano, Nayuta Tsushima, Takayoshi Suzuki, Hiroshi Idogawa, Seijiro Hamada, Akira Ohkoshi, Takahiro Kusaka, Daisuke Matsushita, Kosuke Murayama, Ryosuke Sato, Yuya Miyakura, Satoshi Kubota, Satoshi Toyoma, Ai Tagawa, Shino Godo, Hiroki Tomizawa, Akina Shirotori, Akihiro Homma
    Toukeibu Gan, 50, 3, 246, 253, Japan Society for Head and Neck Cancer, 2024
    Scientific journal
  • Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma.
    Takahiro Tsujikawa, Kazuchika Ohno, Kei-Ichi Morita, Sumiyo Saburi, Junichi Mitsuda, Kanako Yoshimura, Alisa Kimura, Hiroki Morimoto, Hiroshi Ogi, Saya Shibata, Takumi Akashi, Morito Kurata, Issei Imoto, Yasushi Shimizu, Satoshi Kano, Akihito Watanabe, Tomoko Yamazaki, Yukinori Asada, Ryuichi Hayashi, Yuki Saito, Hiroyuki Ozawa, Kiyoaki Tsukahara, Nobuhiko Oridate, Daisuke Sano, Arata Horii, Yushi Ueki, Takashi Maruo, Nobuaki Mukoyama, Nobuhiro Hanai, Takahito Fukusumi, Hiroshi Iwai, Takuo Fujisawa, Takashi Fujii, Ken-Ichi Nibu, Shigemichi Iwae, Tsutomu Ueda, Nobuyuki Chikuie, Ryuji Yasumatsu, Mioko Matsuo, Hirohito Umeno, Takeharu Ono, Muneyuki Masuda, Satoshi Toh, Kyoko Itoh, Shigeru Hirano, Takahiro Asakage
    Frontiers in immunology, 15, 1390873, 1390873, 2024, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: In view of improving biomarkers predicting the efficacy of immunotherapy for head and neck squamous cell carcinoma (R/M HNSCC), this multicenter retrospective study aimed to identify clinical, tumor microenvironmental, and genomic factors that are related to therapeutic response to the anti- Programmed cell death protein 1 (PD-1) antibody, nivolumab, in patients with R/M HNSCC. METHODS: The study compared 53 responders and 47 non-responders, analyzing formalin-fixed paraffin-embedded samples using 14-marker multiplex immunohistochemistry and targeted gene sequencing. RESULTS: Of 100 patients included, responders had significantly lower smoking and alcohol index, higher incidence of immune related adverse events, and higher PD-1 ligand (PD-L1) expression in immune cells as well as PD-L1 combined positive score (CPS) than non-responders. The frequency of natural killer cells was associated with nivolumab response in patients with prior cetuximab use, but not in cetuximab-naïve status. Age-stratified analysis showed nivolumab response was linked to high CPS and lymphoid-inflamed profiles in patients aged ≥ 65. In contrast, lower NLR in peripheral blood counts was associated with response in patients aged < 65. Notably, TP53 mutation-positive group had lower CPS and T cell densities, suggesting an immune-excluded microenvironment. Patients with altered tumor suppressor gene pathways, including TP53, CDKN2A, and SMAD4 mutations, had lower CPS, higher smoking index, and were associated with poor responses. CONCLUSION: Nivolumab treatment efficacy in HNSCC is influenced by a combination of clinical factors, age, prior treatment, immune environmental characteristics, and gene mutation profiles.
  • Clinical outcomes for olfactory neuroblastoma.
    Akira Nakazono, Hiroaki Motegi, Masanobu Suzuki, Yuji Nakamaru, Shigeru Yamaguchi, Yukitomo Ishi, Satoshi Kano, Nayuta Tsushima, Aya Honma, Takayoshi Suzuki, Shogo Kimura, Seijiro Hamada, Jun Taguchi, Yasushi Shimizu, Takashi Mori, Koichi Yasuda, Hidefumi Aoyama, Ichiro Kinoshita, Miki Fujimura, Akihiro Homma
    Frontiers in oncology, 14, 1329572, 1329572, 2024, [International Magazine]
    English, Scientific journal, BACKGROUND: Olfactory neuroblastoma (ONB) is a rare malignant tumor arising from the olfactory neuroepithelium. The standard of care for ONB is surgical resection; however, detailed treatment protocols vary by institution. Our treatment protocol consists of endoscopic skull base surgery (ESBS) for endoscopically resectable cases and induction chemotherapy followed by craniotomy combined with ESBS for locally advanced cases, with postoperative radiotherapy performed for all cases. Chemoradiotherapy (CRT) is performed in unresectable cases. In this study, we evaluate our treatment protocol and outcomes for ONB. METHODS: A retrospective review of patients with ONB was conducted. Outcomes included survival outcomes and perioperative data. RESULTS: Fifteen patients (53.6%) underwent ESBS, 12 (42.9%) underwent craniotomy combined with ESBS, and 1 (3.6%) received CRT. The 5- and 10-year overall survival rates for all patients were 92.9% and 82.5%, respectively, with a median follow-up period of 81 months. The 5- and 10-year disease-free survival rates were 77.3% and 70.3%, respectively, and the 5- and 10-year local control rates were 88.2% and 80.2%, respectively. Patients undergoing ESBS demonstrated a significantly shorter operating time, period from operation to ambulation, hospitalization period, and less blood loss than those undergoing craniotomy combined with ESBS. CONCLUSION: Our treatment protocol was found to afford favorable outcomes. Patients who underwent endoscopic resection showed lower complication rates and better perioperative data than those who underwent craniotomy combined with ESBS. With appropriate case selection, ESBS is considered a useful approach for ONB.
  • Radiotherapy with or without chemotherapy for locally advanced head and neck cancer in elderly patients: analysis of the Head and Neck Cancer Registry of Japan.
    Koichi Yasuda, Yusuke Uchinami, Satoshi Kano, Jun Taguchi, Daisuke Kawakita, Megumi Kitayama, Kentaro Nishioka, Takashi Mori, Fuki Koizumi, Yuri Fujii, Yasushi Shimizu, Keiji Kobashi, Seiichi Yoshimoto, Ken-Ichi Nibu, Akihiro Homma, Hidefumi Aoyama
    International journal of clinical oncology, 29 Dec. 2023, [Domestic magazines]
    English, Scientific journal, BACKGROUND: Whether concurrent chemotherapy with radiotherapy (CRT) is effective for elderly patients with head and neck cancer is a controversial topic. This study aimed to analyze the effectiveness of CRT vs. radiation therapy (RT) among elderly patients in Japan. METHODS: Data from the Head and Neck Cancer Registry of Japan were extracted and analyzed. Patients with locally advanced squamous cell carcinoma of the oropharynx, hypopharynx, or larynx who received definitive CRT or RT between 2011 and 2014 were included. RESULTS: CRT was administered to 78% of the 1057 patients aged ≥ 70 years and 67% of the 555 patients aged ≥ 75 years. For the patients aged ≥ 75 years, the overall survival (OS) rate was significantly better in the CRT group than in the RT group (P < 0.05), while the progression-free survival (PFS) rate was not significantly different (P > 0.05). The add-on effect of CRT was significantly poor in elderly patients (P < 0.05), and it was not a significant factor in the multivariate analysis for patients aged ≥ 75 years. After propensity score matching, there were no significant differences in the OS and PFS rates between the patients aged ≥ 70 years and those aged ≥ 75 years (all, P > 0.05). CONCLUSION: Although aggressive CRT is administered to elderly patients in Japan, its effectiveness is uncertain. Further prospective randomized trials are needed to verify whether CRT is superior to RT alone for elderly patients.
  • Treatment outcomes of radiotherapy with concurrent weekly cisplatin in older patients with locally advanced head and neck squamous cell carcinoma.
    Yusuke Uchinami, Koichi Yasuda, Satoshi Kano, Manami Otsuka, Seijiro Hamada, Takayoshi Suzuki, Nayuta Tsushima, Shuhei Takahashi, Yoshihiro Fujita, Tomohiko Miyazaki, Hajime Higaki, Jun Taguchi, Yasushi Shimizu, Tomohiro Sakashita, Akihiro Homma, Hidefumi Aoyama
    Discover. Oncology, 14, 1, 226, 226, 08 Dec. 2023, [International Magazine]
    English, Scientific journal, BACKGROUND: Tri-weekly cisplatin and radiotherapy (CDDP + RT) is a standard of care for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) but is sometimes challenging to complete in older patients. Weekly CDDP + RT has shown mild toxicity compared to tri-weekly CDDP + RT for LA-HNSCC and is a promising option for older adults. We aimed to report the treatment outcomes and prognostic factors in patients with LA-HNSCC treated with weekly CDDP + RT. METHODS: We analyzed patients aged ≥ 70 years who started weekly CDDP + RT for LA-HNSCC between July 2006 and October 2022. LA-HNSCC includes cancer in the oropharynx, hypopharynx, or larynx with a clinical stage of 3 or 4 without distant metastases based on the Union for International Cancer Control staging system 8th edition. The radiation dose of 70 Gy was delivered in 35 fractions by 3-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy. The primary endpoint was the 3-year overall survival (OS), and the secondary endpoints were the 3-year progression-free survival (PFS) and 3-year cause-specific survival (CSS). The Kaplan-Meier method was used to calculate survival rates, and the log-rank test was used to evaluate statistical significance. A Cox proportional hazards model was used for the multivariate analysis of prognostic factors. RESULTS: The median age of the 49 patients was 72 (range: 70-78) years. The median CDDP dose was 200 (40-280) mg/ m2, and 47 patients completed scheduled radiotherapy. Forty-eight patients (98.0%) had a performance status of ≥ 1 at the initial visit. The 3-year OS, PFS, and CSS were 80.9% (95% confidence interval [CI]: 64.8-90.7), 68.3% (95% CI 51.8-81.2), and 85.0% (95% CI 68.7-93.4), respectively. In the multivariate analysis, the cumulative CDDP dose (< 200 or ≥ 200 mg/m2) was a significant factor for OS (hazard ratio: 0.29 [95% CI 0.08-0.97], p = 0.044). There was one case of early mortality. Grade 3 or higher late adverse events were observed in four patients (8.2%). CONCLUSIONS: Weekly CDDP + RT in older patients led to good survival outcomes with an acceptable rate of adverse events. CDDP should be administered at a dose of at least 200 mg/m2 in older patients. Trial registration Retrospectively registered.
  • Improvement of image quality in diffusion-weighted imaging with model-based deep learning reconstruction for evaluations of the head and neck.
    Noriyuki Fujima, Junichi Nakagawa, Hiroyuki Kameda, Yohei Ikebe, Taisuke Harada, Yukie Shimizu, Nayuta Tsushima, Satoshi Kano, Akihiro Homma, Jihun Kwon, Masami Yoneyama, Kohsuke Kudo
    Magma (New York, N.Y.), 21 Nov. 2023, [International Magazine]
    English, Scientific journal, OBJECTIVES: To investigate the utility of deep learning (DL)-based image reconstruction using a model-based approach in head and neck diffusion-weighted imaging (DWI). MATERIALS AND METHODS: We retrospectively analyzed the cases of 41 patients who underwent head/neck DWI. The DWI in 25 patients demonstrated an untreated lesion. We performed qualitative and quantitative assessments in the DWI analyses with both deep learning (DL)- and conventional parallel imaging (PI)-based reconstructions. For the qualitative assessment, we visually evaluated the overall image quality, soft tissue conspicuity, degree of artifact(s), and lesion conspicuity based on a five-point system. In the quantitative assessment, we measured the signal-to-noise ratio (SNR) of the bilateral parotid glands, submandibular gland, the posterior muscle, and the lesion. We then calculated the contrast-to-noise ratio (CNR) between the lesion and the adjacent muscle. RESULTS: Significant differences were observed in the qualitative analysis between the DWI with PI-based and DL-based reconstructions for all of the evaluation items (p < 0.001). In the quantitative analysis, significant differences in the SNR and CNR between the DWI with PI-based and DL-based reconstructions were observed for all of the evaluation items (p = 0.002 ~ p < 0.001). DISCUSSION: DL-based image reconstruction with the model-based technique effectively provided sufficient image quality in head/neck DWI.
  • Daily fraction dose-adjusted radiotherapy policy to avoid prolonging the overall treatment time for early glottic squamous cell carcinoma: a single-institutional retrospective study.
    Yasuhiro Dekura, Koichi Yasuda, Hideki Minatogawa, Yusuke Uchinami, Nayuta Tsushima, Takayoshi Suzuki, Satoshi Kano, Takashi Mori, Kentaro Nishioka, Keiji Kobashi, Norio Katoh, Akihiro Homma, Hidefumi Aoyama
    Journal of radiation research, 10 Nov. 2023, [International Magazine]
    English, Scientific journal, The objective of this study was to determine the outcomes of radical radiotherapy for early glottic squamous cell carcinoma (EGSCC) with the policy of increasing the fraction size during radiotherapy when the overall treatment time (OTT) was expected to be prolonged. Patients diagnosed with clinical T1-2N0M0 EGSCC, who were treated with radical radiotherapy between 2008 and 2019 at Hokkaido University Hospital, were included. Patients received 66 Gy in 33 fractions for T1 disease and 70 Gy in 35 fractions for T2 disease as our standard regimen (usual group [UG]). If the OTT was expected to extend for >1 week, the dose fraction size was increased from 2.0 to 2.5 Gy from the beginning or during radiotherapy (adjusted group [AG]). At this time, we performed a statistical analysis between UG and AG. In total, 116 patients were identified, and the treatment schedules of 29 patients were adjusted. The median follow-up was 60.9 months. In the T1 group, the cumulative 5-year local failure rate was 12.0% in the AG and 15.4% in the UG, and in the T2 group, the rate was 40.7% in the AG and 25.3% in the UG. There were no significant differences between the AG and UG. Similarly, no significant differences were observed for overall survival and progression-free survival rates. Our single-institutional retrospective analysis of EGSCC patients suggested that a method of adjusting the radiotherapy schedule to increase fraction size from the beginning or during the course may be effective in maintaining treatment outcomes.
  • 唾液腺導管癌におけるp16/CDKN2Aの予後因子としての意義 多施設共同研究
    井上 和成, 内海 由貴, 山本 善也, 平井 秀明, 花澤 豊行, 加納 里志, 塚原 清彰, 川北 大介, 岡田 拓朗, 大上 研二, 山崎 恵介, 小澤 宏之, 齊藤 祐毅, 植木 雄志, 中黒 匡人, 多田 雄一郎, 長尾 俊孝
    日本唾液腺学会誌, 63, 25, 26, 日本唾液腺学会, Nov. 2023
    Japanese
  • 唾液腺混成癌は存在するのか? 9例の唾液腺混成癌の形態学的および遺伝子解析
    中黒 匡人, 松木 崇, 中村 ハルミ, 加納 里志, 川北 大介, 花澤 豊行, 中島 広聖, 内海 由貴, 八木 春奈, 多田 雄一郎, 長尾 俊孝
    日本唾液腺学会誌, 63, 28, 29, 日本唾液腺学会, Nov. 2023
    Japanese
  • 唾液腺導管癌ではLAT1発現が抗AR療法の治療効果予測因子となり得る
    平井 秀明, 梶原 真奈美, 内海 由貴, 山本 善也, 花澤 豊行, 加納 里志, 塚原 清彰, 川北 大介, 岡田 拓朗, 大上 研二, 山崎 恵介, 小澤 宏之, 齊藤 祐毅, 植木 雄志, 中黒 匡人, 多田 雄一郎, 長尾 俊孝
    日本唾液腺学会誌, 63, 29, 30, 日本唾液腺学会, Nov. 2023
    Japanese
  • HER2低発現の唾液腺導管癌に対する臨床病学的検討
    加納 里志, 花澤 豊行, 塚原 清彰, 川北 大介, 岡田 拓朗, 大上 研二, 山崎 恵介, 小澤 宏之, 齊藤 祐毅, 植木 雄志, 中黒 匡人, 長尾 俊孝, 多田 雄一郎
    日本唾液腺学会誌, 63, 30, 31, 日本唾液腺学会, Nov. 2023
    Japanese
  • 唾液腺導管癌の臨床解析 唾液腺導管癌多施設共同研究会からの報告
    山村 晃司, 齊藤 祐毅, 川北 大介, 加納 里志, 花澤 豊行, 塚原 清彰, 岡田 拓朗, 大上 研二, 山崎 恵介, 小澤 宏之, 植木 雄志, 中黒 匡人, 長尾 俊孝, 多田 雄一郎
    日本唾液腺学会誌, 63, 31, 32, 日本唾液腺学会, Nov. 2023
    Japanese
  • Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and CTNNB1 mutations
    Nayuta Tsushima, Satoshi Kano, Kanako C. Hatanaka, Takayoshi Suzuki, Seijiro Hamada, Hiroshi Idogawa, Yuji Nakamaru, Masanobu Suzuki, Yutaka Hatanaka, Akihiro Homma
    Auris Nasus Larynx, Elsevier BV, Nov. 2023
    Scientific journal
  • 高悪性度唾液腺癌に対する術前診断モデルの開発               
    加納 里志, 対馬 那由多, 鈴木 崇祥, 井戸川 寛志, 浜田 誠二郎, 本間 明宏
    日本癌治療学会学術集会抄録集, 61回, O30, 1, (一社)日本癌治療学会, Oct. 2023
    English
  • アンドロゲン受容体陽性唾液腺癌に対するダロルタミド単剤療法の第II相臨床試験               
    今村 善宣, 岡野 晋, 瓜生 英興, 大塚 倫之, 大越 明, 佐野 大佑, 塚原 清彰, 大野 十央, 花澤 豊行, 加納 里志, 西尾 直樹, 長岡 真人, 篠田 覚, 清田 尚臣, 田原 信
    日本癌治療学会学術集会抄録集, 61回, O30, 2, (一社)日本癌治療学会, Oct. 2023
    English
  • 頭頸部癌患者血漿exosome mRNA網羅的解析によるニボルマブ治療効果予測因子の同定               
    益田 宗幸, 藤 賢史, 佐藤 晋彰, 松尾 未央子, 菅澤 正, 山崎 惠介, 植木 雄志, 中島 寅彦, 瓜生 英興, 小野 剛治, 梅野 博仁, 上田 勉, 加納 里志, 塚原 清彰
    日本癌治療学会学術集会抄録集, 61回, SP, 4, (一社)日本癌治療学会, Oct. 2023
    English
  • Prospective exploration of a prognostic biomarker of nivolumab for head and neck cancer patients (BIONEXT)
    Kuniaki Sato, Satoshi Toh, Taku Murakami, Takafumi Nakano, Takahiro Hongo, Mioko Matsuo, Kazuki Hashimoto, Masashi Sugasawa, Keisuke Yamasaki, Yushi Ueki, Torahiko Nakashima, Hideoki Uryu, Takeharu Ono, Hirohito Umeno, Tsutomu Ueda, Satoshi Kano, Kiyoaki Tsukahara, Akihito Watanabe, Ichiro Ota, Nobuya Monden, Shigemichi Iwae, Takashi Maruo, Yukinori Asada, Nobuhiro Hanai, Daisuke Sano, Hiroyuki Ozawa, Takahiro Asakage, Takahito Fukusumi, Muneyuki Masuda
    Cold Spring Harbor Laboratory, 06 Sep. 2023
    Abstract

    BACKGROUND

    Nivolumab paved a new way in the treatment of patients with recurrent or metastatic (RM) head and neck squamous cell carcinoma (RM-HNSCC). However, the limited rates of long-term survivors (< 20%) demand a robust prognostic biomarker. This nationwide multi-centric prospective study aimed to identify a plasma exosome (PEX) mRNA signature, which serves as a companion diagnostic of nivolumab and provides a biological clue to develop effective therapies for a majority of non-survivors.

    METHODS

    Pre-treatment plasmas (N= 104) of RM-HNSCC patients were subjected to comprehensive PEX mRNA analyses for prognostic marker discovery and validation. In parallel, paired treatment-naïve tumor and plasma samples (N= 20) were assayed to elucidate biological implications of the PEX mRNA signature.

    RESULTS

    A combination of 6 candidate PEX mRNAs plus neutrophil-to-lymphocyte ratio precisely distinguished non-survivors from >2-year survivors (2-year OS; 0% vs 57.7%;P= 0.000124) with a high hazard ratio of 2.878 (95% CI 1.639-5.055;P= 0.0002348). In paired samples, PEXHLA-EmRNA (a non-survivor-predicting marker) was positively corelated with overexpression of HLA-E protein (P= 0.0191) and the dense population of tumor-infiltrating NK cells (P= 0.024) in the corresponding tumor, suggesting the HLA-E-NKG2A immune checkpoint may inhibit the antitumor effect of PD-1blockade in patients with high PEXHLA-EmRNA.

    CONCLUSION

    The PEX mRNA signature could be useful as a companion diagnostic of nivolumab. The combination of an anti-NKG2A antibody (i.e., monalizumab) and nivolumab may serve as a treatment option for non-survivors predicted by a RT-qPCR-based pre-treatment measurement of PEX mRNAs.

    TRIAL REGISTRATION

    This study is registered to the UMIN Clinical Trial Registry: UMIN000037029.

    FUNDING

    This study is partly funded by JSPS KAKENHI (Grant number JP 21436707 to MM) and Sota memorial fund to MM. PEXmRNA analyses were conducted by Showa Denko America Materials. CReS Kyushu organized sample collection and transfer, and conducted clinical data management with funding provided by Ono and Bristol-Myers Squibb.

    Graphical abstract
  • Prognostic scores for patients with salivary adenoid cystic carcinoma without lymph node metastasis.
    Hikari Shimoda, Masanori Teshima, Takayuki Murase, Toshitaka Nagao, Kimihide Kusafuka, Masato Nakaguro, Makoto Urano, Ken-Ichi Taguchi, Hidetaka Yamamoto, Satoshi Kano, Yuichiro Tada, Kiyoaki Tsukahara, Kenji Okami, Tetsuro Onitsuka, Yasushi Fujimoto, Daisuke Kawakita, Kazuo Sakurai, Nobuhiro Hanai, Toru Nagao, Ryo Kawata, Naohito Hato, Ken-Ichi Nibu, Hiroshi Inagaki
    Oral oncology, 145, 106491, 106491, 22 Jul. 2023, [International Magazine]
    English, Adenoid cystic carcinoma (AdCC) of salivary gland grows relatively slowly, but occasionally develops distant metastasis. Although cervical lymph node metastasis (LNM) has been reported as a strong prognostic factor, most of AdCC do not have LNM. In this study, we investigated the prognostic factors to predict disease free survival (DFS), distant metastasis free survival (DMFS), and overall survival (OS) for 175 patients surgically treated for AdCC without LNM, and developed prognostic score (PS) determined as number of positive prognostic factors. The following emerged as significant prognostic factors: positive surgical margin in DFS, pT3/4 and positive surgical margin in DMFS, and positive surgical margin and high-histological grade in OS. 10-year DFS rates were 56.4% in PS0, and 19.1% in PS1 (p < 0.0001). 10-year DMFS rates were 86.3% in PS0, 56.4% in PS1, and 30.7% in PS2 (p < 0.0001). 10-year OS rates were 100% in PS0, 73.3% in PS1, and 38.8% in PS2 (p < 0.0001).
  • Summary of Japanese clinical practice guidelines for head and neck cancer - 2022 update edited by the Japan society for head and neck cancer.
    Akihiro Homma, Mizuo Ando, Nobuhiro Hanai, Hiroyuki Harada, Yoshitaka Honma, Tomonori Kanda, Satoshi Kano, Daisuke Kawakita, Naomi Kiyota, Yoshiyuki Kizawa, Masahiro Nakagawa, Takenori Ogawa, Hirotaka Shinomiya, Takeshi Shinozaki, Motoyuki Suzuki, Tetsuya Tsuji, Koichi Yasuda, Sadamoto Zenda, Takeshi Kodaira, Tadaaki Kirita, Ken-Ichi Nibu
    Auris, nasus, larynx, 21 Jul. 2023, [International Magazine]
    English, Scientific journal, The aim of the "Japanese Clinical Practice Guidelines for Head and Neck Cancer - 2022 Update" is to review the latest evidence regarding head and neck cancer and to present the current standard approaches for diagnosis and treatment. These evidence-based recommendations were created with the consensus of the Guideline Committee, which is composed of otorhinolaryngologists and head and neck surgeons, together with radiologists, radiation oncologists, medical oncologists, plastic surgeons, dentists, palliative care physicians, and rehabilitation physicians. These guidelines were created by the Clinical Practice Guideline Committee of the Japan Society for Head and Neck Cancer based on the "Head and Neck Cancer Treatment Guidelines 2018 Edition," and the revised draft was compiled after evaluation by the Assessment Committee and public comments. The 'Clinical questions and recommendations' section consists of 13 categories, and 59 clinical questions are described in total. Here we describe 6 clinical questions specific to other sets of guidelines with recommendations and comments.
  • Prognostic value and clinicopathological roles of the tumor immune microenvironment in salivary duct carcinoma.
    Hideaki Hirai, Masato Nakaguro, Yuichiro Tada, Natsuki Saigusa, Daisuke Kawakita, Yoshitaka Honma, Satoshi Kano, Kiyoaki Tsukahara, Hiroyuki Ozawa, Takuro Okada, Kenji Okami, Keisuke Yamazaki, Yukiko Sato, Makoto Urano, Manami Kajiwara, Yoshitaka Utsumi, Tomotaka Shimura, Chihiro Fushimi, Akira Shimizu, Takahito Kondo, Yorihisa Imanishi, Akihiro Sakai, Yuichiro Sato, Takafumi Togashi, Toyoyuki Hanazawa, Takashi Matsuki, Kazuto Yamazaki, Toshitaka Nagao
    Virchows Archiv : an international journal of pathology, 19 Jul. 2023, [International Magazine]
    English, Scientific journal, Salivary duct carcinoma (SDC) is an aggressive type of salivary gland carcinoma. Recently, immunotherapies targeting immune checkpoints, including PD1, PD-L1, CTLA4, and LAG3, have had a considerable prognostic impact on various malignant tumors. The implementation of such immune checkpoint inhibitor (ICI) therapies has also been attempted in cases of salivary gland carcinoma. The tumor immune microenvironment (TIME) is implicated in tumorigenesis and tumor progression and is closely associated with the response to ICI therapies. However, the TIME in SDC has not been fully explored. We examined the immunohistochemical expression of CD8, FOXP3, PD1, PD-L1, CTLA4, LAG3, and mismatch repair (MMR) proteins, tumor-infiltrating lymphocytes (TILs), and microsatellite instability (MSI) status in 175 cases of SDC. The associations between these TIME-related markers and the clinicopathological factors and prognosis were evaluated. An elevated expression of CD8, FOXP3, PD1, CTLA4, and LAG3 was associated with more aggressive histological features and an advanced N and/or M classification, elevated Ki-67 index, and poor prognosis. Furthermore, cases with a high PD-L1 expression exhibited more aggressive histological features and adverse clinical outcomes than those with a low expression. Alternatively, there was no significant correlation between TILs and clinicopathological factors. No SDC cases with an MSI-high status or MMR deficiency were found. The coexistence of both an immunostimulatory and immunosuppressive TIME in aggressive SDC might play a role in the presence of T-cell exhaustion. The contribution of multiple immune escape pathways, including regulatory T cells and immune checkpoints, may provide a rationale for ICI therapy, including combined PD1/CTLA4 blockade therapy.
  • The Landscape of MYB/MYBL1- and Peri-MYB/MYBL1-Associated Rearrangements in Adenoid Cystic Carcinoma.
    Kaori Ueda, Takayuki Murase, Daisuke Kawakita, Toshitaka Nagao, Kimihide Kusafuka, Masato Nakaguro, Makoto Urano, Hidetaka Yamamoto, Ken-Ichi Taguchi, Satoshi Kano, Yuichiro Tada, Kiyoaki Tsukahara, Kenji Okami, Tetsuro Onitsuka, Yasushi Fujimoto, Kazuo Sakurai, Nobuhiro Hanai, Toru Nagao, Ryo Kawata, Naohito Hato, Ken-Ichi Nibu, Hiroshi Inagaki
    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 36, 10, 100274, 100274, 07 Jul. 2023, [International Magazine]
    English, Scientific journal, Approximately 60% of adenoid cystic carcinoma (AdCC) cases are positive for MYB::NFIB or MYBL1::NFIB, whereas MYB/MYBL1 oncoprotein, a key driver of AdCC, is overexpressed in most cases. Juxtaposition of superenhancer regions in NFIB and other genes into the MYB/MYBL1 locus is an attractive oncogenic hypothesis for AdCC cases, either negative or positive for MYB/MYBL1::NFIB. However, evidence supporting this hypothesis is insufficient. We examined 160 salivary AdCC cases for rearrangements in MYB/MYBL1 loci and peri-MYB/MYBL1 areas (centromeric and telomeric areas of 10 Mb each) using formalin-fixed, paraffin-embedded tumor sections. For the detection of the rearrangements, we employed conventional fluorescence in situ hybridization split and fusion assays and a 5 Mb fluorescence in situ hybridization split assay. The latter is a novel assay that enabled us to detect any possible splits within a 5 Mb distance of a chromosome. We found MYB/MYBL1- and peri-MYB/MYBL1-associated rearrangements in 149/160 patients (93%). AdCC cases positive for rearrangements in MYB, MYBL1, the peri-MYB area, and the peri-MYBL1 area numbered 105 (66%), 20 (13%), 19 (12%), and 5 (3%), respectively. In 24 peri-MYB/MYBL1 rearrangement-positive cases, 14 (58%) were found to have a juxtaposition of the NFIB or RAD51B locus into the MYB/MYBL1 loci. On comparing with a tumor group positive for MYB::NFIB, a hallmark of AdCC, other genetically classified tumor groups had similar features of overexpression of the MYB transcript and MYB oncoprotein as detected by semiquantitative RT-qPCR and immunohistochemistry, respectively. In addition, clinicopathological and prognostic features were similar among these groups. Our study suggests that peri-MYB/MYBL1 rearrangements may be a frequent event in AdCC and may result in biological and clinicopathological consequences comparable to MYB/MYBL1 rearrangements. The landscape of MYB/MYBL1 and peri-MYB/MYBL1 rearrangements shown here strongly suggests that juxtaposition of superenhancers into MYB/MYBL1 or peri-MYB/MYBL1 loci is an alteration that acts as a key driver for AdCC oncogenesis and may unify MYB/MYBL1 rearrangement-positive and negative cases.
  • Utility of Color Doppler Ultrasonography in Monitoring of a Free Jejunal Flap
    Taku Maeda, Kosuke Ishikawa, Yoichiro Oda, Satoshi Kano, Nayuta Tsushima, Tomohiro Sakashita, Akihiro Homma, Yuhei Yamamoto, Emi Funayama
    The Laryngoscope, Wiley, 29 Jun. 2023
    Scientific journal
  • Treatment outcomes of the patient with sinonasal mucosal melanoma: the role of endoscopic resection and postoperative radiotherapy.
    Nayuta Tsushima, Satoshi Kano, Koichi Yasuda, Takayoshi Suzuki, Seijiro Hamada, Yuji Nakamaru, Masanobu Suzuki, Yusuke Uchinami, Hidefumi Aoyama, Akihiro Homma
    International journal of clinical oncology, 28, 9, 1218, 1226, 17 Jun. 2023, [Domestic magazines]
    English, Scientific journal, BACKGROUND: The standard of care for sinonasal mucosal melanoma is surgery and postoperative radiotherapy (PORT). Our treatment strategy comprises endoscopic resection and PORT. We performed combined endoscopic and open resection or applied an external approach alone when sufficient resection was difficult to achieve endoscopically. The objective of this study was to evaluate the validity of our treatment strategy. METHODS: We assessed 30 patients with sinonasal mucosal melanoma who underwent definitive therapy between January 2002 and April 2021, and conducted a retrospective analysis. The median follow-up period was 2.2 years. The primary endpoint was overall survival. The Kaplan-Meier method was used for the calculation of survival rates, the cumulative incidence of distant metastasis, and local recurrence. RESULTS: Twenty-eight patients underwent surgery. The other two patients were treated by definitive proton beam therapy. Twenty-one of 28 (75%) patients underwent resection by endoscopic approach alone. Postoperative radiotherapy was performed for all 28 patients who underwent surgery. Twenty-one patients (70%) experienced recurrence during the observation period. Overall, distant metastasis was observed in 19 patients. Twelve patients died during the observation period, with 10 of the 12 patients (83%) dying of distant metastasis. The overall survival rate at 2 and 5 years was 70% and 46%, respectively. The cumulative incidence rate of distant metastasis at 2 years was 63%, while the 2-year cumulative incidence rate of local recurrence was 6.7%. CONCLUSION: The local disease was controlled by our treatment strategy. To improve treatment outcomes, control of the distant metastasis is needed.
  • The superselective intra-arterial infusion of cisplatin and concomitant radiotherapy (RADPLAT) is effective for metastatic lymph nodes in head and neck squamous cell carcinoma.
    Satoshi Kano, Takayoshi Suzuki, Daisuke Yoshida, Nayuta Tsushima, Seijiro Hamada, Koichi Yasuda, Yusuke Uchinami, Hidefumi Aoyama, Akihiro Homma
    International journal of clinical oncology, 28, 9, 1121, 1128, 08 Jun. 2023, [Domestic magazines]
    English, Scientific journal, BACKGROUND: Superselective intra-arterial infusion of cisplatin and concomitant radiotherapy (RADPLAT) is a very promising treatment modality for locally advanced head and neck squamous cell carcinoma. However, there are some concerns regarding its potential for the control of neck lymph node metastasis. The objective of this study was to investigate whether RADPLAT provided inferior regional control compared to intravenous chemoradiotherapy (IV-CRT). METHODS: A total of 172 patients with neck lymph node metastases, 66 of whom underwent RADPLAT and 106 IV-CRT, were enrolled in this study. We retrospectively compared regional control rates between RADPLAT and IV-CRT. Furthermore, to adjust for differences in factors related to patient background between the groups, we conducted inverse probability weighting (IPW) analysis using the propensity score. RESULTS: A comparison between the two groups revealed that the regional control rates were almost equal under unadjusted conditions; however, after adjustment by IPW analysis, the RADPLAT group had a relatively better regional control rate than did the IV-CRT group (1 year regional control rate: 86.6% vs. 79.4%). In addition, the analysis of relative risk factors for regional control in the RADPLAT group showed that the absence of intra-arterial cisplatin infusion into metastatic lymph nodes was the only independent risk factor (Hazard ratio: 4.23, p = 0.04). CONCLUSION: This study showed that the regional control rate in patients treated with RADPLAT was noninferior to that for IV-CRT. Locally advanced head and neck cancers is a good indication for RADPLAT, even if the patients have neck lymph node metastases.
  • 次世代シークエンサーによる鼻副鼻腔粘膜悪性黒色腫の遺伝子発現解析
    対馬 那由多, 加納 里志, 鈴木 崇祥, 浜田 誠二郎, 安田 耕一, 清水 康, 田口 純, 本間 明宏
    頭頸部癌, 49, 2, 133, 133, (一社)日本頭頸部癌学会, May 2023
    Japanese
  • 頭頸部癌に対する化学放射線療法の効果予測マーカーとしてのSLFN11の有用性
    浜田 誠二郎, 加納 里志, 鈴木 崇祥, 対馬 那由多, 本間 明宏
    頭頸部癌, 49, 2, 187, 187, (一社)日本頭頸部癌学会, May 2023
    Japanese
  • 唾液腺腺様嚢胞癌におけるMYB/MYBL1遺伝子関連異常の検索
    上田 佳緒璃, 村瀬 貴幸, 川北 大介, 長尾 俊孝, 草深 公秀, 中黒 匡人, 浦野 誠, 山元 英崇, 田口 健一, 加納 里志, 多田 雄一郎, 塚原 清彰, 大上 研二, 鬼塚 哲郎, 藤本 保志, 櫻井 一生, 花井 信広, 長尾 徹, 河田 了, 羽藤 直人, 丹生 健一, 稲垣 宏
    頭頸部癌, 49, 2, 193, 193, (一社)日本頭頸部癌学会, May 2023
    Japanese
  • 頭頸部癌患者血漿exosome mRNA網羅的解析によるニボルマブの治療効果予測因子の同定 BIO-NEXT
    益田 宗幸, 松尾 美央子, 菅澤 正, 山崎 恵介, 中島 寅彦, 小野 剛治, 上田 勉, 加納 里志, 塚原 清彰, 渡邉 昭仁, 上村 裕和, 門田 伸也, 岩江 信法, 丸尾 貴志, 浅田 行紀, 花井 信広, 佐野 大佑, 藤 賢史
    頭頸部癌, 49, 2, 184, 184, (一社)日本頭頸部癌学会, May 2023
    Japanese
  • SlicerPIT 頭頸部アルミノックス治療の治療計画ソフトウェアの開発               
    鈴木 崇祥, 足利 雄一, 若林 侑輝, 勝俣 量平, 浜田 誠二郎, 井戸川 寛志, 対馬 那由多, 加納 里志, 本間 明宏
    頭頸部癌, 49, 2, 127, 127, (一社)日本頭頸部癌学会, May 2023
    Japanese
  • 高齢者の局所進行頭頸部扁平上皮癌患者におけるweeklyシスプラチン併用放射線治療の治療成績               
    打浪 雄介, 安田 耕一, 加納 里志, 対馬 那由多, 鈴木 崇祥, 浜田 誠二郎, 田口 純, 清水 康, 坂下 智博, 本間 明宏
    頭頸部癌, 49, 2, 134, 134, (一社)日本頭頸部癌学会, May 2023
    Japanese
  • 当院で治療した頭頸部原発横紋筋肉腫症例の検討               
    勝俣 量平, 加納 里志, 対馬 那由多, 鈴木 崇祥, 浜田 誠二郎, 清水 康, 田口 純, 安田 耕一, 打浪 雄介, 本間 明宏
    頭頸部癌, 49, 2, 161, 161, (一社)日本頭頸部癌学会, May 2023
    Japanese
  • 高齢者の頭頸部癌に対する放射線治療と化学療法併用の実態 日本頭頸部癌学会悪性腫瘍全国登録調査の解析               
    安田 耕一, 打浪 雄介, 加納 里志, 田口 純, 清水 康, 本間 明宏
    頭頸部癌, 49, 2, 171, 171, (一社)日本頭頸部癌学会, May 2023
    Japanese
  • 唾液腺癌の局所頸部制御における術後照射の有用性の検討               
    加納 里志, 対馬 那由多, 鈴木 崇祥, 浜田 誠二郎, 安田 耕一, 打浪 雄介, 本間 明宏
    頭頸部癌, 49, 2, 192, 192, (一社)日本頭頸部癌学会, May 2023
    Japanese
  • 唾液腺導管癌の臨床解析 唾液腺導管癌多施設共同研究会からの報告               
    山村 晃司, 齊藤 祐毅, 加納 里志, 塚原 清彰, 花澤 豊行, 岡田 拓朗, 富樫 孝文, 小澤 宏之, 山崎 恵介, 大上 研二, 川北 大介, 長尾 俊孝, 多田 雄一郎
    頭頸部癌, 49, 2, 171, 171, (一社)日本頭頸部癌学会, May 2023
    Japanese
  • 白金製剤・ニボルマブ不応・不耐後の再発・転移頭頸部扁平上皮癌の臨床転帰に関する後方視的多施設共同研究               
    門脇 重憲, 岡 弘毅, 長島 健悟, 西 秀昭, 熊井 良彦, 飯島 宏章, 大上 研二, 清水 康, 加納 里志, 伊東 和恵, 山崎 知子, 高橋 秀聡, 折舘 伸彦, 横田 知哉, 小山 泰司, 清田 尚臣, 佐藤 靖祥, 高橋 俊二, 加藤 恭子, 本間 義崇
    頭頸部癌, 49, 2, 137, 137, (一社)日本頭頸部癌学会, May 2023
    Japanese
  • 唾液腺腺様嚢胞癌cN0/pN0症例における予後スコアの作成               
    下田 光, 手島 直則, 村瀬 貴幸, 長尾 俊孝, 草深 公秀, 中黒 匡人, 浦野 誠, 田口 健一, 山元 英崇, 加納 里志, 多田 雄一郎, 塚原 清彰, 大上 研二, 鬼塚 哲郎, 藤本 保志, 川北 大介, 櫻井 一生, 花井 信広, 長尾 徹, 河田 了, 羽藤 直人, 丹生 健一, 稲垣 宏
    頭頸部癌, 49, 2, 193, 193, (一社)日本頭頸部癌学会, May 2023
    Japanese
  • 白金製剤・ニボルマブ不応・不耐後の再発・転移頭頸部扁平上皮癌の臨床転帰に関する後方視的多施設共同研究               
    門脇 重憲, 岡 弘毅, 長島 健悟, 西 秀昭, 熊井 良彦, 飯島 宏章, 大上 研二, 清水 康, 加納 里志, 伊東 和恵, 山崎 知子, 高橋 秀聡, 折舘 伸彦, 横田 知哉, 小山 泰司, 清田 尚臣, 佐藤 靖祥, 高橋 俊二, 加藤 恭子, 本間 義崇
    頭頸部癌, 49, 2, 137, 137, (一社)日本頭頸部癌学会, May 2023
    Japanese
  • 唾液腺導管癌の臨床解析 唾液腺導管癌多施設共同研究会からの報告               
    山村 晃司, 齊藤 祐毅, 加納 里志, 塚原 清彰, 花澤 豊行, 岡田 拓朗, 富樫 孝文, 小澤 宏之, 山崎 恵介, 大上 研二, 川北 大介, 長尾 俊孝, 多田 雄一郎
    頭頸部癌, 49, 2, 171, 171, (一社)日本頭頸部癌学会, May 2023
    Japanese
  • 唾液腺腺様嚢胞癌cN0/pN0症例における予後スコアの作成               
    下田 光, 手島 直則, 村瀬 貴幸, 長尾 俊孝, 草深 公秀, 中黒 匡人, 浦野 誠, 田口 健一, 山元 英崇, 加納 里志, 多田 雄一郎, 塚原 清彰, 大上 研二, 鬼塚 哲郎, 藤本 保志, 川北 大介, 櫻井 一生, 花井 信広, 長尾 徹, 河田 了, 羽藤 直人, 丹生 健一, 稲垣 宏
    頭頸部癌, 49, 2, 193, 193, (一社)日本頭頸部癌学会, May 2023
    Japanese
  • 唾液腺腺様嚢胞癌におけるMYB/MYBL1遺伝子関連異常の検索               
    上田 佳緒璃, 村瀬 貴幸, 川北 大介, 長尾 俊孝, 草深 公秀, 中黒 匡人, 浦野 誠, 山元 英崇, 田口 健一, 加納 里志, 多田 雄一郎, 塚原 清彰, 大上 研二, 鬼塚 哲郎, 藤本 保志, 櫻井 一生, 花井 信広, 長尾 徹, 河田 了, 羽藤 直人, 丹生 健一, 稲垣 宏
    頭頸部癌, 49, 2, 193, 193, (一社)日本頭頸部癌学会, May 2023
    Japanese
  • 胸腔鏡+頸部アプローチで頸部から摘出した巨大縦隔内甲状腺腫の一例
    浜田 誠二郎, 加納 里志, 本間 明宏
    日本気管食道科学会会報, 74, 2, s1, s1, (NPO)日本気管食道科学会, Apr. 2023
    Japanese
  • TRIM27の鼻副鼻腔粘膜悪性黒色腫におけるバイオマーカーとしての検討
    木村 将吾, 中丸 裕爾, 鈴木 正宣, 本間 あや, 中薗 彬, 加納 里志, 対馬 那由多, 鈴木 崇祥, 浜田 誠二郎, 本間 明宏
    日本耳鼻咽喉科頭頸部外科学会会報, 126, 4, 562, 562, (一社)日本耳鼻咽喉科頭頸部外科学会, Apr. 2023
    Japanese
  • 頭頸部癌細胞株におけるSLFN11遺伝子発現と薬剤感受性の検討
    浜田 誠二郎, 加納 里志, 鈴木 崇祥, 対馬 那由多, 本間 明宏
    日本耳鼻咽喉科頭頸部外科学会会報, 126, 4, 600, 600, (一社)日本耳鼻咽喉科頭頸部外科学会, Apr. 2023
    Japanese
  • TRIM27 expression is associated with poor prognosis in sinonasal mucosal melanoma.
    S Kimura, M Suzuki, Y Nakamaru, S Kano, M Watanabe, A Honma, A Nakazono, N Tsushima, S Hatakeyama, A Homma
    Rhinology, 09 Mar. 2023, [International Magazine]
    English, Scientific journal, BACKGROUND: Tripartite motif-containing 27 (TRIM27) has been implicated in the progression of various cancers. However, the role of TRIM27 in sinonasal mucosal melanoma (SNMM) remains poorly understood. MATERIALS & METHODS: We retrospectively examined 28 patients with SNMM treated with between 2003 and 2021. We undertook immunohistochemical analysis of TRIM27, Ki-67, and p-Akt1 expression in SNMM tissues. We also investigated the relationship between TRIM27 expression and clinical characteristics, prognosis, Ki-67 as a tumor growth potential marker, and p-Akt1 as one of the prognostic factors in mucosal melanoma. RESULTS: TRIM27 expression was significantly higher in T4 disease than in T3 disease and was higher in stage IV than in stage III. Patients with high-TRIM27 SNMM had a significantly poorer prognosis in terms of overall survival (OS) and disease-free survival.There was also a significantly higher rate of distant metastasis. Univariate analysis for OS revealed that TRIM27 and T classification were significant poor prognostic factors. In addition, the Ki-67 positive score and the p-Akt1 total staining score were significantly higher in the high-TRIM27 group than in the low-TRIM27 group. CONCLUSIONS: High TRIM27 expression in SNMM was associated with advanced T classification, poor prognosis and distant metastasis. We suggest that TRIM27 has potential as a novel biomarker for prognosis in SNMM.
  • FAM83Hの発現低下はケラチン分布の変化を介して皮膚有棘細胞癌の遊走と浸潤を促進する               
    得地 景子, 北村 真也, 前田 拓哉, 氏家 英之, 柳 輝希, 渡部 昌, 畠山 鎮次, 加納 里志, 田中 伸哉
    日本皮膚科学会雑誌, 133, 2, 265, 265, (公社)日本皮膚科学会, Feb. 2023
    Japanese
  • 腹臥位・人工気胸下での胸腔内剥離が有用であった巨大縦隔内甲状腺腫の1例               
    武藤 潤, 加納 里志, 山崎 雅久, 千葉 龍平, 野村 俊介, 藤原 晶, 氏家 秀樹, 樋田 泰浩, 加賀 基知三, 本間 明宏, 加藤 達哉
    日本臨床外科学会雑誌, 83, 12, 2119, 2119, 日本臨床外科学会, Dec. 2022
    Japanese
  • Detailed analysis of failure patterns using deformable image registration in hypopharyngeal cancer patients treated with sequential boost intensity-modulated radiotherapy.
    Manami Otsuka, Koichi Yasuda, Yusuke Uchinami, Nayuta Tsushima, Takayoshi Suzuki, Satoshi Kano, Ryusuke Suzuki, Naoki Miyamoto, Hideki Minatogawa, Yasuhiro Dekura, Takashi Mori, Kentaro Nishioka, Jun Taguchi, Yasushi Shimizu, Norio Katoh, Akihiro Homma, Hidefumi Aoyama
    Journal of medical imaging and radiation oncology, 67, 1, 98, 110, 14 Nov. 2022, [Peer-reviewed], [International Magazine]
    English, Scientific journal, INTRODUCTION: Sequential boost intensity-modulated radiotherapy (SQB-IMRT) uses two different planning CTs (pCTs) and treatment plans. SQB-IMRT is a form of adaptive radiotherapy that allows for responses to changes in the shape of the tumour and organs at risk (OAR). On the other hand, dose accumulation with the two plans can be difficult to evaluate. The purpose of this study was to analyse patterns of loco-regional failure using deformable image registration (DIR) in hypopharyngeal cancer patients treated with SQB-IMRT. METHODS: Between 2013 and 2019, 102 patients with hypopharyngeal cancer were treated with definitive SQB-IMRT at our institution. Dose accumulation with the 1st and 2nd plans was performed, and the dose to the loco-regional recurrent tumour volume was calculated using the DIR workflow. Failure was classified as follows: (i) in-field (≥95% of the recurrent tumour volume received 95% of the prescribed dose); (ii) marginal (20-95%); or (iii) out-of-field (<20%). RESULTS: After a median follow-up period of 25 months, loco-regional failure occurred in 34 patients. Dose-volume histogram analysis showed that all loco-regional failures occurred in the field within 95% of the prescribed dose, with no marginal or out-of-field recurrences observed. CONCLUSION: The dosimetric analysis using DIR showed that all loco-regional failures were within the high-dose region. More aggressive treatment may be required for gross tumours.
  • Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling.
    Shinji Kohsaka, Yuichiro Tada, Mizuo Ando, Masato Nakaguro, Yukina Shirai, Toshihide Ueno, Shinya Kojima, Hideaki Hirai, Natsuki Saigusa, Satoshi Kano, Kiyoaki Tsukahara, Takafumi Togashi, Hiroyuki Ozawa, Takahito Kondo, Kenji Okami, Hideaki Takahashi, Daisuke Kawakita, Chihiro Fushimi, Takayoshi Suzuki, Akira Shimizu, Isaku Okamoto, Takuro Okada, Yuichiro Sato, Yorihisa Imanishi, Yoshihiro Watanabe, Akihiro Sakai, Koji Ebisumoto, Yukiko Sato, Makoto Urano, Yoshitaka Honma, Keisuke Yamazaki, Yushi Ueki, Toyoyuki Hanazawa, Yuki Saito, Tomotaka Shimura, Toshitaka Nagao, Hiroyuki Mano
    NPJ precision oncology, 6, 1, 82, 82, 04 Nov. 2022, [International Magazine]
    English, Scientific journal, Molecular targets and predictive biomarkers for prognosis in salivary duct carcinoma (SDC) have not been fully identified. We conducted comprehensive molecular profiling to discover novel biomarkers for SDC. A total of 67 SDC samples were examined with DNA sequencing of 464 genes and transcriptome analysis in combination with the clinicopathological characteristics of the individuals. Prognostic biomarkers associated with response to combined androgen blockade (CAB) treatment were explored using mRNA expression data from 27 cases. Oncogenic mutations in receptor tyrosine kinase (RTK) genes or genes in the MAPK pathway were identified in 55 cases (82.1%). Alterations in the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway were identified in 38 cases (56.7%). Interestingly, patient prognosis could be predicted using mRNA expression profiles, but not genetic mutation profiles. The risk score generated from the expression data of a four-gene set that includes the ADAMTS1, DSC1, RNF39, and IGLL5 genes was a significant prognostic marker for overall survival in the cohort (HR = 5.99, 95% confidence interval (CI) = 2.73-13.1, p = 7.8 × 10-6). Another risk score constructed from the expression of CD3E and LDB3 was a strong prognostic marker for progression-free survival for CAB treatment (p = 0.03). Mutations in RTK genes, MAPK pathway genes, and PI3K/AKT pathway genes likely represent key mutations in SDC tumorigenesis. The gene expression profiles identified in this study may be useful for stratifying patients who are good candidates for CAB treatment and may benefit from additional systemic therapies.
  • 唾液腺導管癌における自律神経(交感神経・副交感神経)の臨床・分子病理学的意義
    梶原 真奈美, 高橋 秀聡, 川北 大介, 平井 秀明, 内海 由貴, 浦野 誠, 中黒 匡人, 佐藤 由紀子, 塚原 清彰, 加納 里志, 大上 研二, 小澤 宏之, 富樫 孝文, 岡田 拓朗, 多田 雄一郎, 長尾 俊孝
    日本唾液腺学会誌, 62, 38, 39, 日本唾液腺学会, Nov. 2022
    Japanese
  • 唾液腺導管癌の癌免疫微小環境の臨床病理学的特徴とその予後に関する検討
    平井 秀明, 川北 大介, 梶原 真奈美, 内海 由貴, 浦野 誠, 中黒 匡人, 佐藤 由紀子, 塚原 清彰, 加納 里志, 大上 研二, 小澤 宏之, 富樫 孝文, 岡田 拓朗, 山崎 一人, 多田 雄一郎, 長尾 俊孝
    日本唾液腺学会誌, 62, 41, 42, 日本唾液腺学会, Nov. 2022
    Japanese
  • 唾液腺導管癌における自律神経(交感神経・副交感神経)の臨床・分子病理学的意義               
    梶原 真奈美, 高橋 秀聡, 川北 大介, 平井 秀明, 内海 由貴, 浦野 誠, 中黒 匡人, 佐藤 由紀子, 塚原 清彰, 加納 里志, 大上 研二, 小澤 宏之, 富樫 孝文, 岡田 拓朗, 多田 雄一郎, 長尾 俊孝
    日本唾液腺学会誌, 62, 38, 39, 日本唾液腺学会, Nov. 2022
    Japanese
  • Pretreatment elevated mean corpuscular volume as an indicator for high risk esophageal second primary cancer in patients with head and neck cancer.
    Nayuta Tsushima, Satoshi Kano, Takayoshi Suzuki, Seijiro Hamada, Akihiro Homma
    Auris, nasus, larynx, 10 Oct. 2022, [International Magazine]
    English, Scientific journal, OBJECTIVE: Esophageal cancer is the most common second primary cancer (SPC) in patients with head and neck cancer (HNC). Esophageal SPC has a negative impact on survival. Elevated mean corpuscular volume (MCV) is an accepted predictor of esophageal cancer risk. The aim of this study was to elucidate the usefulness of elevated MCV as an indicator of a high risk for esophageal SPC. METHODS: We retrospectively reviewed the medical records of patients with oropharyngeal, hypopharyngeal, and laryngeal squamous cell carcinoma who underwent chemoradiotherapy between 2003 and 2012. We excluded patients younger than 20 years or who had received treatment for esophageal cancer and who had a histologically unproven lesion. Patients were divided into two groups according to their MCV. The cut-off for MCV was defined by receiver operating characteristics curve analysis. The primary endpoint was the cumulative incidence of esophageal SPC. RESULTS: A total of 295 patients were included. The median follow-up period for surviving patients was 7.4 years and the optimal cut-off point was 99.0 fL. One hundred ninety-five patients (66%) had an MCV < 99.0 fL and 100 (34%) had an MCV ≥ 99.0 fL. The 5-year cumulative incidence in patients with an MCV < 99.0 fL and ≥ 99.0 fL was 8.7% and 27%, respectively. In the multivariate analysis, an MCV ≥ 99.0 fL (HR=2.2; 95%CI, 1.1-4.2) was an independent risk factor. CONCLUSION: MCV ≥ 99.0 fL was found to be a risk factor for esophageal SPC. We, therefore, recommend that patients with an MCV ≥ 99.0 fL should undergo intensive monitoring.
  • Utility of the deep learning technique for the diagnosis of orbital invasion on CT in patients with a nasal or sinonasal tumor.
    Junichi Nakagawa, Noriyuki Fujima, Kenji Hirata, Minghui Tang, Satonori Tsuneta, Jun Suzuki, Taisuke Harada, Yohei Ikebe, Akihiro Homma, Satoshi Kano, Kazuyuki Minowa, Kohsuke Kudo
    Cancer imaging : the official publication of the International Cancer Imaging Society, 22, 1, 52, 52, 22 Sep. 2022, [International Magazine]
    English, Scientific journal, BACKGROUND: In nasal or sinonasal tumors, orbital invasion beyond periorbita by the tumor is one of the important criteria in the selection of the surgical procedure. We investigated the usefulness of the convolutional neural network (CNN)-based deep learning technique for the diagnosis of orbital invasion, using computed tomography (CT) images. METHODS: A total of 168 lesions with malignant nasal or sinonasal tumors were divided into a training dataset (n = 119) and a test dataset (n = 49). The final diagnosis (invasion-positive or -negative) was determined by experienced radiologists who carefully reviewed all of the CT images. In a CNN-based deep learning analysis, a slice of the square target region that included the orbital bone wall was extracted and fed into a deep-learning training session to create a diagnostic model using transfer learning with the Visual Geometry Group 16 (VGG16) model. The test dataset was subsequently tested in CNN-based diagnostic models and by two other radiologists who were not specialized in head and neck radiology. At approx. 2 months after the first reading session, two radiologists again reviewed all of the images in the test dataset, referring to the diagnoses provided by the trained CNN-based diagnostic model. RESULTS: The diagnostic accuracy was 0.92 by the CNN-based diagnostic models, whereas the diagnostic accuracies by the two radiologists at the first reading session were 0.49 and 0.45, respectively. In the second reading session by two radiologists (diagnosing with the assistance by the CNN-based diagnostic model), marked elevations of the diagnostic accuracy were observed (0.94 and 1.00, respectively). CONCLUSION: The CNN-based deep learning technique can be a useful support tool in assessing the presence of orbital invasion on CT images, especially for non-specialized radiologists.
  • Association of gene mutations with clinicopathologic features in patients with external auditory canal squamous cell carcinoma.
    Shinya Morita, Satoshi Kano, Kanako C Hatanaka, Yutaka Hatanaka, Takayoshi Suzuki, Atsushi Fukuda, Kimiko Hoshino, Keishi Fujiwara, Yuji Nakamaru, Akihiro Homma
    International journal of clinical oncology, 27, 9, 1394, 1403, Sep. 2022, [Domestic magazines]
    English, Scientific journal, BACKGROUND: External auditory canal squamous cell carcinoma (EACSCC) is a rare form of malignant tumor. Due to the extremely limited understanding of the genomic landscape in EACSCC, the association between gene mutations and clinicopathologic features remains unclear. This study aimed to explore somatic gene mutations associated with the clinicopathological features in patients with EACSCC, and to identify the candidate gene mutations for predicting survival outcome in EACSCC. METHODS: Twenty-two tissue samples obtained from patients with EACSCC were analyzed for genetic mutations based on targeted next-generation sequencing and genetic expression based on IHC staining to investigate the driver of tumorigenesis and/or the candidates of genes for predicting clinical outcome in EACSCC. RESULTS: Gene alterations were most frequently observed in TP53 (59.1%), followed by CREBBP (9.1%). TP53 mutations showed significant correlation with T classification (P = 0.027) and p53 expression phenotype (P < 0.001). The 5-year overall survival (OS) rates for EACSCC patients with TP53 mutations and wild-type TP53 were 45.0% and 75.0%, respectively. Multivariable analysis using the Cox proportional hazards model demonstrated that TP53 mutations were independent predictors of OS rates for EACSCC patients (P = 0.007). CONCLUSION: This study has suggested that TP53 mutations have potential for use as a biomarker for identifying individuals at high risk of developing tumors and for predicting survival outcome in EACSCC. IHC staining for p53 might play a useful role as screening tool for detecting TP53 mutations in patients with EACSCC.
  • The utility of diffusion-weighted T2 mapping for the prediction of histological tumor grade in patients with head and neck squamous cell carcinoma.
    Noriyuki Fujima, Yukie Shimizu, Masami Yoneyama, Junichi Nakagawa, Hiroyuki Kameda, Taisuke Harada, Seijiro Hamada, Takayoshi Suzuki, Nayuta Tsushima, Satoshi Kano, Akihiro Homma, Kohsuke Kudo
    Quantitative imaging in medicine and surgery, 12, 8, 4024, 4032, Aug. 2022, [International Magazine]
    English, Scientific journal, Background: In head and neck cancers, histopathological information is important for the determination of the tumor characteristics and for predicting the prognosis. The aim of this study was to assess the utility of diffusion-weighted T2 (DW-T2) mapping for the evaluation of tumor histological grade in patients with head and neck squamous cell carcinoma (SCC). Methods: The cases of 41 patients with head and neck SCC (21 well/moderately and 17 poorly differentiated SCC) were retrospectively analyzed. All patients received MR scanning using a 3-Tesla MR unit. The conventional T2 value, DW-T2 value, ratio of DW-T2 value to conventional T2 value, and apparent diffusion coefficient (ADC) were calculated using signal information from the DW-T2 mapping sequence with a manually placed region of interest (ROI). Results: ADC values in the poorly differentiated SCC group were significantly lower than those in the moderately/well differentiated SCC group (P<0.05). The ratio of DW-T2 value to conventional T2 value was also significantly different between poorly and moderately/well differentiated SCC groups (P<0.01). Receiver operating characteristic (ROC) curve analysis of ADC values showed a sensitivity of 0.76, specificity of 0.67, positive predictive value (PPV) of 0.62, negative predictive value (NPV) of 0.8, accuracy of 0.71 and area under the curve (AUC) of 0.73, whereas the ROC curve analysis of the ratio of DW-T2 value to conventional T2 value showed a sensitivity of 0.76, specificity of 0.83, PPV of 0.76, NPV of 0.83, accuracy of 0.8 and AUC of 0.82. Conclusions: DW-T2 mapping might be useful as supportive information for the determination of tumor histological grade in patients with head and neck SCC.
  • Amide proton transfer imaging for the determination of human papillomavirus status in patients with oropharyngeal squamous cell carcinoma.
    Noriyuki Fujima, Yukie Shimizu, Masami Yoneyama, Junichi Nakagawa, Hiroyuki Kameda, Taisuke Harada, Seijiro Hamada, Takayoshi Suzuki, Nayuta Tsushima, Satoshi Kano, Akihiro Homma, Kohsuke Kudo
    Medicine, 101, 28, e29457, 15 Jul. 2022, [International Magazine]
    English, Scientific journal, The aim of this study was to investigate the utility of amide proton transfer (APT) imaging for the determination of human papillomavirus (HPV) status in patients with oropharyngeal squamous cell carcinoma (SCC). Thirty-one patients with oropharyngeal SCC were retrospectively evaluated. All patients underwent amide proton transfer imaging using a 3T magnetic resonance (MR) unit. Patients were divided into HPV-positive and -negative groups depending on the pathological findings in their primary tumor. In APT imaging, the primary tumor was delineated with a polygonal region of interest (ROI). Signal information in the ROI was used to calculate the mean, standard deviation (SD) and coefficient of variant (CV) of the APT signals (APT mean, APT SD, and APT CV, respectively). The value of APT CV in the HPV-positive group (0.43 ± 0.04) was significantly lower than that in the HPV-negative group (0.48 ± 0.04) (P = .01). There was no significant difference in APT mean (P = .82) or APT SD (P = .13) between the HPV-positive and -negative groups. Receiver operating characteristic (ROC) curve analysis of APT CV had a sensitivity of 0.75, specificity of 0.8, positive predictive value of 0.75, negative predictive value of 0.8, accuracy of 0.77 and area under the curve (AUC) of 0.8. The APT signal in the HPV-negative group was considered heterogeneous compared to the HPV-positive group. This information might be useful for the determination of HPV status in patients with oropharyngeal SCC.
  • 内視鏡を用いたカダバー手術トレーニングにより喉頭全摘出術を咽頭側から理解する
    対馬 那由多, 加納 里志, 鈴木 崇祥, 浜田 誠二郎, 本間 明宏
    頭頸部癌, 48, 2, 192, 192, (一社)日本頭頸部癌学会, May 2022
    Japanese
  • 咽喉頭癌に対するシスプラチン超選択的動注併用放射線治療(RADPLAT)による頸部制御の検討               
    加納 里志, 対馬 那由多, 鈴木 崇祥, 浜田 誠二郎, 吉田 大介, 打浪 雄介, 安田 耕一, 本間 明宏
    頭頸部癌, 48, 2, 151, 151, (一社)日本頭頸部癌学会, May 2022
    Japanese
  • 高齢の頭頸部悪性腫瘍に対する放射線治療の後ろ向き検討               
    安田 耕一, 打浪 雄介, 浜田 誠二郎, 鈴木 崇祥, 対馬 那由多, 田口 純, 清水 康, 加納 里志, 本間 明宏
    頭頸部癌, 48, 2, 200, 200, (一社)日本頭頸部癌学会, May 2022
    Japanese
  • 再発・転移唾液腺導管癌に対する抗HER2・抗AR療法の生存への寄与               
    川北 大介, 長尾 俊孝, 塚原 清彰, 加納 里志, 小澤 宏之, 大上 研二, 富樫 孝文, 近藤 貴仁, 多田 雄一郎
    日本耳鼻咽喉科頭頸部外科学会会報, 125, 4, 706, 706, (一社)日本耳鼻咽喉科頭頸部外科学会, Apr. 2022
    Japanese
  • Salivary mucoepidermoid carcinoma: histological variants, grading systems, CRTC1/3-MAML2 fusions, and clinicopathological features.
    Satsuki Nakano, Yoshihide Okumura, Takayuki Murase, Toshitaka Nagao, Kimihide Kusafuka, Makoto Urano, Hidetaka Yamamoto, Satoshi Kano, Kiyoaki Tsukahara, Kenji Okami, Daisuke Kawakita, Toru Nagao, Nobuhiro Hanai, Hiroshi Iwai, Ryo Kawata, Yuichiro Tada, Ken-Ichi Nibu, Hiroshi Inagaki
    Histopathology, 80, 4, 729, 735, Mar. 2022, [International Magazine]
    English, Scientific journal, AIMS: To investigate the histological diversity of salivary mucoepidermoid carcinoma (MEC), its clinicopathological features, and its associations with CRTC1/3-MAML2 fusions. METHODS AND RESULTS: Salivary MEC cases (n = 177) were examined for CRTC1/3-MAML2 fusions, histological variants were classified, and tumours were graded according to four different grading systems. Adverse histological features considered to be unusual in MEC were also investigated. Of the 177 MEC cases, 110 were positive for CRTC1/3-MAML2 fusions. The classical variant was the most frequent in the fusion-positive case group, the fusion-negative case group, and the total case group. The clear/oncocytic variant was the second most frequent in the fusion-positive and total case groups. Oncocytic, Warthin-like and spindle variants were seen in the fusion-positive case group only. Clear cell, sclerosing, mucinous and central variants were seen in both the fusion-positive case group and the fusion-negative case group. No case was classified as a ciliated variant, as a mucoacinar variant, or as a high-grade transformation. As compared with the classical variant, non-classical variants were characterised by frequent CRTC1/3-MAML2 fusions and a low clinical stage in all cases. Of the four histological features considered to be unusual in MEC, marked nuclear atypia, frequent mitoses (>10/10 high-power fields) and extensive necrosis were found independently of the fusion status, and were present in 3-5% of all cases. However, none of the cases showed overt keratinisation. On comparison, the Armed Forces Institute of Pathology and modified Healey grading systems downgraded tumours, the Brandwein system upgraded tumours, and the Memorial Sloan Kettering system provided a moderate means of assessment. CONCLUSION: Recognition of the histological diversity of MEC, its clinicopathological features and its associations with CRTC1/3-MAML2 fusions is helpful for an accurate diagnosis of this carcinoma.
  • The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy
    Natsuki Saigusa, Hideaki Hirai, Yuichiro Tada, Daisuke Kawakita, Masato Nakaguro, Kiyoaki Tsukahara, Satoshi Kano, Hiroyuki Ozawa, Takahito Kondo, Kenji Okami, Takafumi Togashi, Yukiko Sato, Makoto Urano, Manami Kajiwara, Tomotaka Shimura, Chihiro Fushimi, Akira Shimizu, Isaku Okamoto, Takuro Okada, Takayoshi Suzuki, Yorihisa Imanishi, Yoshihiro Watanabe, Akihiro Sakai, Koji Ebisumoto, Yuichiro Sato, Yoshitaka Honma, Keisuke Yamazaki, Yushi Ueki, Toyoyuki Hanazawa, Yuki Saito, Hideaki Takahashi, Mizuo Ando, Shinji Kohsaka, Takashi Matsuki, Toshitaka Nagao
    Frontiers in Oncology, 11, Frontiers Media SA, 03 Feb. 2022
    Scientific journal, ObjectiveSalivary duct carcinoma (SDC) is a highly aggressive and uncommon tumor arising not only de novo but also in pleomorphic adenoma. Androgen receptor (AR)- and HER2-targeted therapy have recently been introduced for SDC as promising treatment options; however, no predictive biomarkers have yet been established. EZH2 and H3K27me3 are closely linked to the development and progression of various cancers, and EZH2 is also expected to be a desirable therapeutic target. We therefore explored the clinicopathological and prognostic implications of EZH2 and H3K27me3 in a large cohort of SDC patients, focusing on their impact on the therapeutic efficacy of AR- or HER2-targeted therapy.

    Materials and MethodsThe EZH2 and H3K27me3 immunohistochemical expression and EZH2 Y646 gain-of-function mutation status were examined in 226 SDCs, and the relationship with the clinicopathological factors as well as clinical outcomes were evaluated within the three groups depending on the treatment: AR-targeted (combined androgen blockade with leuprorelin acetate and bicalutamide; 89 cases), HER2-targeted (trastuzumab and docetaxel; 42 cases), and conventional therapy (112 cases).

    ResultsEZH2 and H3K27me3 were variably immunoreactive in most SDCs. A positive correlation was found between the expression of EZH2 and H3K27me3. The EZH2 expression in the SDC component was significantly higher than that in the pre-existing pleomorphic adenoma component. EZH2 Y646 was not identified in any cases. EZH2-high cases more frequently had an advanced clinical stage and aggressive histological features than EZH2-low cases. An EZH2-high status in patients treated with AR-targeted therapy was associated with a significantly shorter progression-free and overall survival as well as a lower objective response rate and clinical benefit rate. In addition, a H3K27me3-high status in patients treated with AR-targeted therapy was related to a shorter overall survival. Conversely, there was no association between the EZH2 and H3K27me3 expression and the clinical outcomes in the conventional or HER2-targeted therapy groups.

    ConclusionsA high expression of EZH2 and H3K27me3 in SDC might be a predictor of a poor efficacy of AR-targeted therapy. Our data provide new insights into the role of EZH2 and H3K27me3 in therapeutic strategies for SDC.

  • Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy.
    Seijiro Hamada, Satoshi Kano, Junko Murai, Takayoshi Suzuki, Nayuta Tsushima, Takatsugu Mizumachi, Masanobu Suzuki, Tsuyoshi Takashima, Daiki Taniyama, Naoya Sakamoto, Yoichiro Fujioka, Yusuke Ohba, Akihiro Homma
    Frontiers in oncology, 12, 978875, 978875, 2022, [International Magazine]
    English, Scientific journal, Recently, Schlafen family member 11 (SLFN11) has been reported to increase the sensitivity of cancer cells to DNA-damaging agents, including platinum derivatives; thus, SLFN11 may be a predictive biomarker for platinum-based chemoradiotherapy (CRT). In this study, we examined whether SLFN11 expression was associated with the therapeutic outcome of platinum-based CRT in head and neck squamous cell carcinoma (HNSCC). We performed immunohistochemical analyses for SLFN11 expression in 161 HNSCC tissues from patients who had been administered cisplatin-based CRT and examined the correlation between SLFN11 expression and progression-free survival (PFS). Additionally, SLFN11 expression was examined in 10 paired samples obtained before and after CRT in patients with local failure. Furthermore, in vitro experiments were performed using several HNSCC cell lines and isogenic SLFN11-knockout cells to assess the association between SLFN11 expression and drug sensitivity. PFS was found to be significantly better in the SLFN11-positive group than in the SLFN11-negative group among the 161 patients (5-year PFS: 78.8% vs. 52.8%, respectively, p < 0.001). Similar results were observed for the PFS at each primary site. The percentage of SLFN11 positivity was lower in tumor samples from patients with local failure after CRT than that in the corresponding primary tumors before CRT in 8 of 10 cases. Results of the in vitro assay demonstrated that SLFN11-knockout cells exhibited reduced sensitivity to DNA-damaging agents but not to the non-DNA-damaging agent docetaxel. Our findings suggest that SLFN11 may serve as a potential biomarker for predicting the response of HNSCC patients to platinum-based CRT.
  • Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.
    Daisuke Kawakita, Toshitaka Nagao, Hideaki Takahashi, Satoshi Kano, Yoshitaka Honma, Hideaki Hirai, Natsuki Saigusa, Kohei Akazawa, Kaori Tani, Hiroya Ojiri, Kiyoaki Tsukahara, Hiroyuki Ozawa, Kenji Okami, Takahito Kondo, Takafumi Togashi, Chihiro Fushimi, Tomotaka Shimura, Akira Shimizu, Isaku Okamoto, Takuro Okada, Yorihisa Imanishi, Yoshihiro Watanabe, Kuninori Otsuka, Akihiro Sakai, Koji Ebisumoto, Yuichiro Sato, Keisuke Yamazaki, Yushi Ueki, Toyoyuki Hanazawa, Yuki Saito, Mizuo Ando, Takashi Matsuki, Masato Nakaguro, Yukiko Sato, Makoto Urano, Yoshitaka Utsumi, Shinji Kohsaka, Takashi Saotome, Yuichiro Tada
    Therapeutic advances in medical oncology, 14, 17588359221119538, 17588359221119538, 2022, [International Magazine]
    English, Scientific journal, Background: The efficacy and safety of human epidermal growth factor receptor 2 (HER2)-targeted therapy and androgen deprivation therapy (ADT) for locally advanced or recurrent or metastatic (LA/RM) salivary duct carcinoma (SDC) have been reported in prospective studies. However, the survival benefit of these therapies to conventional therapy remains controversial, and whether HER2-targeted therapy or ADT should be chosen in HER2- and androgen receptor (AR)-positive SDC patients remains unknown. Methods: Overall, 323 LA/RM SDC patients treated at seven institutions between August 1992 and June 2020 were retrospectively enrolled. The primary aim was to analyze the effect of HER2-targeted therapy and ADT on overall survival from the diagnosis of LA/RM disease to death from any cause (OS1). The secondary indicators included the overall response rate (ORR), clinical benefit rate (CBR), overall survival from therapy initiation for LA/RM disease (OS2), progression-free survival (PFS), time to second progression (PFS2), duration of response (DoR), and duration of clinical benefit (DoCB) of HER2-targeted therapy or ADT as first-line therapy for HER2-positive/AR-positive SDC. Results: Patients treated with HER2-targeted therapy or ADT had longer OS1 than those treated without these therapies (Median OS1: historical control, 21.6 months; HER2-targeted therapy, 50.6 months; ADT, 32.8 months; HER2-targeted therapy followed by ADT, 42.4 months; and ADT followed by HER2-targeted therapy, 45.2 months, p < 0.001). Among HER2-positive/AR-positive SDC patients, although HER2-targeted therapy had better ORR, CBR, and PFS than those of ADT as first-line therapy, we found no significant differences between HER2-targeted therapy and ADT regarding OS2, PFS2, DoR, and DoCB. Conclusion: Patients treated with HER2-targeted therapy and ADT showed longer survival in LA/RM SDC. HER2-targeted therapy can be recommended prior to ADT for HER2-positive/AR-positive SDC. It is warranted to establish a biomarker that could predict the efficacy of clinical benefit or better response in ADT.
  • 唾液腺導管癌におけるPTEN欠損とその臨床病理学的意義 多施設共同研究               
    山本 善也, 平井 秀明, 三枝 奈津季, 浦野 誠, 中黒 匡人, 佐藤 由紀子, 塚原 清彰, 加納 里志, 近藤 貴仁, 大上 研二, 小澤 宏之, 富樫 孝文, 川北 大介, 多田 雄一郎, 長尾 俊孝
    日本唾液腺学会誌, 61, 43, 44, 日本唾液腺学会, Nov. 2021
    Japanese
  • 唾液腺導管癌においてEZH2高発現は複合アンドロゲン遮断療法の効果不良予測因子になりうる               
    平井 秀明, 三枝 奈津季, 浦野 誠, 中黒 匡人, 佐藤 由紀子, 塚原 清彰, 加納 里志, 近藤 貴仁, 大上 研二, 小澤 宏之, 富樫 孝文, 川北 大介, 多田 雄一郎, 長尾 俊孝, SDC多施設共同研究会
    日本唾液腺学会誌, 61, 48, 49, 日本唾液腺学会, Nov. 2021
    Japanese
  • 再発・転移唾液腺導管癌に対する抗HER2・抗AR療法の生存への寄与 大規模個別データを用いた後ろ向きコホート研究               
    川北 大介, 長尾 俊孝, 加納 里志, 本間 義崇, 塚原 清彰, 小澤 宏之, 大上 研二, 近藤 貴仁, 富樫 孝文, 高橋 秀聡, 伏見 千宙, 多田 雄一郎
    日本唾液腺学会誌, 61, 41, 41, 日本唾液腺学会, Nov. 2021
    Japanese
  • 再発・転移唾液腺導管癌に対する抗HER2・抗AR療法の生存への寄与 大規模個別データを用いた後ろ向きコホート研究               
    川北 大介, 長尾 俊孝, 加納 里志, 本間 義崇, 塚原 清彰, 小澤 宏之, 大上 研二, 近藤 貴仁, 富樫 孝文, 高橋 秀聡, 伏見 千宙, 多田 雄一郎
    日本唾液腺学会誌, 61, 41, 41, 日本唾液腺学会, Nov. 2021
    Japanese
  • 唾液腺導管癌におけるPTEN欠損とその臨床病理学的意義 多施設共同研究               
    山本 善也, 平井 秀明, 三枝 奈津季, 浦野 誠, 中黒 匡人, 佐藤 由紀子, 塚原 清彰, 加納 里志, 近藤 貴仁, 大上 研二, 小澤 宏之, 富樫 孝文, 川北 大介, 多田 雄一郎, 長尾 俊孝
    日本唾液腺学会誌, 61, 43, 44, 日本唾液腺学会, Nov. 2021
    Japanese
  • 唾液腺導管癌においてEZH2高発現は複合アンドロゲン遮断療法の効果不良予測因子になりうる               
    平井 秀明, 三枝 奈津季, 浦野 誠, 中黒 匡人, 佐藤 由紀子, 塚原 清彰, 加納 里志, 近藤 貴仁, 大上 研二, 小澤 宏之, 富樫 孝文, 川北 大介, 多田 雄一郎, 長尾 俊孝, SDC多施設共同研究会
    日本唾液腺学会誌, 61, 48, 49, 日本唾液腺学会, Nov. 2021
    Japanese
  • Loss of FAM83H promotes cell migration and invasion in cutaneous squamous cell carcinoma via impaired keratin distribution.
    Keiko Tokuchi, Shinya Kitamura, Takuya Maeda, Masashi Watanabe, Shigetsugu Hatakeyama, Satoshi Kano, Shinya Tanaka, Hideyuki Ujiie, Teruki Yanagi
    Journal of dermatological science, 104, 2, 112, 121, Nov. 2021, [International Magazine]
    English, Scientific journal, BACKGROUNDS: FAM83H is essential for amelogenesis, but recent reports implicate that FAM83H is involved in the tumorigenesis. We previously clarified that TRIM29 binds to FAM83H to regulate keratin distribution and squamous cell migration. However, little is known about FAM83H in normal/malignant skin keratinocytes. OBJECTIVE: To investigate the expression of FAM83H in cutaneous squamous cell carcinoma (SCC) and its physiological function. METHODS: Immunohistochemical analysis and RT-PCR of human SCC tissues were performed. Next, we examined the effect of FAM83H knockdown/overexpression in SCC cell lines using cell proliferation, migration, and invasion assay. To investigate the molecular mechanism, immunoprecipitation of FAM83H was examined. Further, Immunofluorescence staining was performed. Finally, we examined the correlation between the expressions of FAM83H and the keratin distribution. RESULTS: FAM83H expression was lower in SCC lesions than in normal epidermis and correlated with differentiation grade. The mRNA expression levels of FAM83H in SCC tumors were also lower than in normal epidermis. The knockdown of FAM83H enhanced SCC cell migration and invasion, whereas the overexpression of FAM83H led to decreases in both. Furthermore, the knockdown of FAM83H enhanced the cancer cell metastasis in vivo. FAM83H formed a complex with TRIM29 and keratins. The knockdown of FAM83H altered keratin distribution and solubility. Clinically, the loss of FAM83H correlates with an altered keratin distribution. CONCLUSION: Our findings reveal a critical function for FAM83H in regulating keratin distribution, as well as in the migration/invasion of cutaneous SCC, suggesting that FAM83H could be a crucial molecule in the tumorigenesis of cutaneous SCC.
  • Notch Signaling in Acquired Middle Ear Cholesteatoma.
    Atsushi Fukuda, Satoshi Kano, Yuji Nakamaru, Shinya Morita, Kimiko Hoshino, Keishi Fujiwara, Akihiro Homma
    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 42, 9, e1389-e1395, 01 Oct. 2021, [International Magazine]
    English, Scientific journal, HYPOTHESIS: We hypothesized that an anomalous change of Notch signaling might be involved in the pathophysiology of cholesteatoma. BACKGROUND: The Notch signaling pathway regulates integrated growth and differentiation control of keratinocytes. Its involvement in cholesteatoma proliferation has not been elucidated. METHODS: We obtained cholesteatoma and external auditory canal (EAC) skin samples from patients with middle ear cholesteatoma who underwent tympanomastoid surgery. We performed polymerase chain reaction using the RT2 Profiler™ PCR Array Human Notch Signaling Pathway (Qiagen) in the cholesteatoma and EAC skin samples (n = 6 each). This was followed by immunohistochemical staining of Notch1, enhancer of split-1 (HES1), and p53 in 41 and 8 cholesteatoma and EAC skin samples, respectively. RESULTS: The fold change of Notch1 gene expression was lowest in cholesteatoma, with a statistically significant difference (p = 0.0424). Moreover, the fold change of HES1 expression decreased (p = 0.272). The positive rates of Notch1 and HES1 protein expressions in the cholesteatoma (48.5 ± 32.4% and 44.9 ± 17.8%, respectively) were significantly lower than in the EAC skin (83.4 ± 17.5% and 55.7 ± 7.1%, respectively) (p < 0.001 and p < 0.01). In contrast, the positive rate of p53 expression in the cholesteatoma (8.5 ± 11.4%) was significantly higher than in the EAC skin (0.5 ± 0.7%) (p < 0.001). CONCLUSION: The decreases in Notch1 and HES1 protein expression might play an important role in the hyperproliferative character of the keratinizing squamous epithelium in cholesteatoma. An increase in p53 might reflect the reaction to cellular hyperproliferation.
  • Prediction of the local treatment outcome in patients with oropharyngeal squamous cell carcinoma using deep learning analysis of pretreatment FDG-PET images.
    Noriyuki Fujima, V Carlota Andreu-Arasa, Sara K Meibom, Gustavo A Mercier, Minh Tam Truong, Kenji Hirata, Koichi Yasuda, Satoshi Kano, Akihiro Homma, Kohsuke Kudo, Osamu Sakai
    BMC cancer, 21, 1, 900, 900, 06 Aug. 2021, [International Magazine]
    English, Scientific journal, BACKGROUND: This study aimed to assess the utility of deep learning analysis using pretreatment FDG-PET images to predict local treatment outcome in oropharyngeal squamous cell carcinoma (OPSCC) patients. METHODS: One hundred fifty-four OPSCC patients who received pretreatment FDG-PET were included and divided into training (n = 102) and test (n = 52) sets. The diagnosis of local failure and local progression-free survival (PFS) rates were obtained from patient medical records. In deep learning analyses, axial and coronal images were assessed by three different architectures (AlexNet, GoogLeNET, and ResNet). In the training set, FDG-PET images were analyzed after the data augmentation process for the diagnostic model creation. A multivariate clinical model was also created using a binomial logistic regression model from a patient's clinical characteristics. The test data set was subsequently analyzed for confirmation of diagnostic accuracy. Assessment of local PFS rates was also performed. RESULTS: Training sessions were successfully performed with an accuracy of 74-89%. ROC curve analyses revealed an AUC of 0.61-0.85 by the deep learning model in the test set, whereas it was 0.62 by T-stage, 0.59 by clinical stage, and 0.74 by a multivariate clinical model. The highest AUC (0.85) was obtained with deep learning analysis of ResNet architecture. Cox proportional hazards regression analysis revealed deep learning-based classification by a multivariate clinical model (P < .05), and ResNet (P < .001) was a significant predictor of the treatment outcome. In the Kaplan-Meier analysis, the deep learning-based classification divided the patient's local PFS rate better than the T-stage, clinical stage, and a multivariate clinical model. CONCLUSIONS: Deep learning-based diagnostic model with FDG-PET images indicated its possibility to predict local treatment outcomes in OPSCCs.
  • Predictors of the need for prophylactic percutaneous endoscopic gastrostomy in head and neck cancer patients treated with concurrent chemoradiotherapy.
    Satoshi Kano, Nayuta Tsushima, Takayoshi Suzuki, Seijiro Hamada, Taizo Yokokawa, Hiroshi Idogawa, Koichi Yasuda, Hideki Minatogawa, Yasuhiro Dekura, Hidefumi Aoyama, Akihiro Homma
    International journal of clinical oncology, 26, 7, 1179, 1187, Jul. 2021, [Domestic magazines]
    English, Scientific journal, BACKGROUND: We investigated whether prophylactic percutaneous endoscopic gastrostomy (PEG) is used effectively for patients treated with definitive concurrent chemoradiotherapy (CCRT) and the predictors of the need for PEG. METHODS: 326 patients with laryngeal, oropharyngeal or hypopharyngeal cancers were retrospectively reviewed. RESULTS: The PEG tube use group had more favorable results than the total parenteral nutrition and nasogastric tube groups in terms of rate of serum albumin loss, incidence of severe fever and aspiration pneumonia, CCRT completion rate and hospitalization period. However, it was inferior to oral intake. Analysis of the relative risk of requiring enteral or parenteral nutrition revealed that performance status (PS) 2, primary site (supraglottis, oropharynx, or hypopharynx), N3 disease, and cisplatin were predictors of the need for nutritional support. CONCLUSIONS: Prophylactic PEG is effective for patients treated with definitive CCRT and is especially required for patients with PS2 or oropharyngeal cancer.
  • 咽喉頭扁平上皮癌IMRTの照射中における線量分布変化に関する解析               
    安田 耕一, 打浪 雄介, 湊川 英樹, 小泉 富基, 大塚 愛美, 藤田 祥博, 井戸川 寛志, 鈴木 崇祥, 対馬 那由多, 加納 里志, 本間 明宏
    頭頸部癌, 47, 2, 210, 210, (一社)日本頭頸部癌学会, May 2021
    Japanese
  • CCRTを施行した頭頸部癌患者に対する予防的胃瘻増設の有用性の検討               
    加納 里志, 対馬 那由多, 鈴木 崇祥, 井戸川 寛志, 浜田 誠二郎, 横川 泰三, 安田 耕一, 湊川 英樹, 打浪 雄介, 本間 明宏
    頭頸部癌, 47, 2, 211, 211, (一社)日本頭頸部癌学会, May 2021
    Japanese
  • Salvage surgery improves the treatment outcome of patients with residual/recurrent maxillary sinus cancer after superselective intra-arterial cisplatin infusion with concomitant radiation therapy.
    Nayuta Tsushima, Satoshi Kano, Takayoshi Suzuki, Hiroshi Idogawa, Daisuke Yoshida, Koichi Yasuda, Manami Otsuka, Hidefumi Aoyama, Akihiro Homma
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 279, 2, 899, 905, 18 Apr. 2021, [International Magazine]
    English, Scientific journal, PURPOSE: We have performed superselective intra-arterial cisplatin infusion with concomitant radiotherapy (RADPLAT) for patients with maxillary sinus cancer. The promising treatment outcomes of this non-surgical treatment were reported in past studies. However, few clinical studies have been conducted to evaluate the outcome of salvage surgery following RADPLAT. The purpose of this study was to analyze the treatment outcomes of salvage surgery for patients with recurrent maxillary sinus cancer after RADPLAT. METHODS: We assessed 45 patients who had recurrence following RADPLAT between 1999 and 2017, and conducted a retrospective analysis. We excluded patients who did not complete RADPLAT. Patients were not considered to have completed RADPLAT if they underwent intra-arterial cisplatin less than three times or received a total radiation dose of less than 60 Gy. The primary endpoint was overall survival. The median follow-up period for surviving patients after recurrence was 5.1 years. RESULTS: Twenty-five of the 45 (56%) patients underwent salvage surgery. The 5-year overall survival rate was 68% in patients who underwent salvage surgery, while all patients who did not undergo salvage surgery died during the observation period. Fifteen of 24 (63%) patients with local recurrence underwent salvage surgery. Eight patients did not undergo salvage surgery because of unresectable disease; five of the eight patients had unresectable posterior extension. All nine patients with nodal recurrence underwent neck dissection. CONCLUSION: Treatment outcomes of salvage surgery following RADPLAT were favorable enough for it to be generally recommended. To reduce unresectable recurrence, the posterior section should be eradicated by RADPLAT.
  • Analysis of acute-phase toxicities of intensity-modulated proton therapy using a model-based approach in pharyngeal cancer patients.
    Koichi Yasuda, Hideki Minatogawa, Yasuhiro Dekura, Seishin Takao, Masaya Tamura, Nayuta Tsushima, Takayoshi Suzuki, Satoshi Kano, Takatsugu Mizumachi, Takashi Mori, Kentaro Nishioka, Motoyasu Shido, Norio Katoh, Hiroshi Taguchi, Noriyuki Fujima, Rikiya Onimaru, Isao Yokota, Keiji Kobashi, Shinichi Shimizu, Akihiro Homma, Hiroki Shirato, Hidefumi Aoyama
    Journal of radiation research, 62, 2, 329, 337, 10 Mar. 2021, [International Magazine]
    English, Scientific journal, Pharyngeal cancer patients treated with intensity-modulated proton therapy (IMPT) using a model-based approach were retrospectively reviewed, and acute toxicities were analyzed. From June 2016 to March 2019, 15 pharyngeal (7 naso-, 5 oro- and 3 hypo-pharyngeal) cancer patients received IMPT with robust optimization. Simulation plans for IMPT and intensity-modulated X-ray therapy (IMXT) were generated before treatment. We also reviewed 127 pharyngeal cancer patients with IMXT in the same treatment period. In the simulation planning comparison, all of the normal-tissue complication probability values for dysphagia, dysgeusia, tube-feeding dependence and xerostomia were lower for IMPT than for IMXT in the 15 patients. After completing IMPT, 13 patients completed the evaluation, and 12 of these patients had a complete response. The proportions of patients who experienced grade 2 or worse acute toxicities in the IMPT and IMXT cohorts were 21.4 and 56.5% for dysphagia (P < 0.05), 46.7 and 76.3% for dysgeusia (P < 0.05), 73.3 and 62.8% for xerostomia (P = 0.43), 73.3 and 90.6% for mucositis (P = 0.08) and 66.7 and 76.4% for dermatitis (P = 0.42), respectively. Multivariate analysis revealed that IMPT was independently associated with a lower rate of grade 2 or worse dysphagia and dysgeusia. After propensity score matching, 12 pairs of IMPT and IMXT patients were selected. Dysphagia was also statistically lower in IMPT than in IMXT (P < 0.05). IMPT using a model-based approach may have clinical benefits for acute dysphagia.
  • Pathological evaluation of tumor grade for salivary adenoid cystic carcinoma: A proposal of an objective grading system.
    Naruhiko Morita, Takayuki Murase, Kaori Ueda, Toshitaka Nagao, Kimihide Kusafuka, Masato Nakaguro, Makoto Urano, Ken-Ichi Taguchi, Hidetaka Yamamoto, Satoshi Kano, Yuichiro Tada, Kiyoaki Tsukahara, Kenji Okami, Tetsuro Onitsuka, Yasushi Fujimoto, Daisuke Kawakita, Kazuo Sakurai, Toru Nagao, Nobuhiro Hanai, Ryo Kawata, Naohito Hato, Naoki Otsuki, Ken-Ichi Nibu, Hiroshi Inagaki
    Cancer science, 112, 3, 1184, 1195, Mar. 2021, [International Magazine]
    English, Scientific journal, Three pathological grading systems advocated by Perzin/Szanto, Spiro, and van Weert are currently used for adenoid cystic carcinoma (AdCC). In these systems, the amount or presence of the solid tumor component in AdCC specimens is an important index. However, the "solid tumor component" has not been well defined. Salivary AdCC cases (N = 195) were collected after a central pathology review. We introduced a novel criterion for solid tumor component, minAmax (minor axis maximum). The largest solid tumor nest in each AdCC case was histologically screened, the maximum oval fitting the solid nest was estimated, and the length of the minor axis of the oval (minAmax) was measured. The prognostic cutoff for the minAmax was determined using training and validation cohorts. All cases were evaluated for the four grading systems, and their prognostic impact and interobserver variability were examined. The cutoff value for the minAmax was set at 0.20 mm. Multivariate prognostic analyses showed the minAmax and van Weert systems to be independent prognostic tools for overall, disease-free, and distant metastasis-free survival while the Perzin/Szanto and Spiro systems were selected for overall survival but not for disease-free or distant metastasis-free survival. The highest hazard ratio for overall survival (11.9) was obtained with the minAmax system. The reproducibility of the minAmax system (kappa coefficient of 0.81) was scored as very good while those of the other three systems were scored as moderate. In conclusion, the minAmax is a simple, objective, and highly reproducible grading system useful for prognostic stratification for salivary AdCC.
  • The role of endoscopic resection for selected patients with sinonasal squamous cell carcinoma.
    Yuji Nakamaru, Masanobu Suzuki, Satoshi Kano, Takatsugu Mizumachi, Nayuta Tsushima, Takayoshi Suzuki, Aya Honma, Akira Nakazono, Shogo Kimura, Rikiya Onimaru, Koichi Yasuda, Hiroki Shirato, Akihiro Homma
    Auris, nasus, larynx, 48, 1, 131, 137, Feb. 2021, [International Magazine]
    English, Scientific journal, OBJECTIVE: Despite of rapid advances in endoscopic surgery, the gold standard for sinonasal squamous cell carcinoma (SNSCC) surgery has remained the open approach with en-block resection due to the aggressive nature of SNSCC, including frequent recurrence and high mortality rate. For that reason, few studies have focused on SNSCC treated by endoscopic surgery alone. The objective of this study was to evaluate the usefulness of endoscopic surgery for patients with SNSCC. METHODS: A retrospective analysis was performed for 15 consecutive SNSCC patients who underwent endoscopic surgery without an open approach. We carefully selected patients whose tumor attachment sites could be fully visualized and completely resected through an endonasal approach. RESULTS: Of the fifteen patients, 4 patients (27%) were diagnosed with T1, 7 (47%) with T2, 4 (27%) with T3, and no patients with T4a or T4b disease. Four of the 15 (27%) patients showed positive surgical margins. The 5-yr overall survival, disease-specific survival, and local control rate was 72.4%, 79.6%, and 92.9%, respectively. The 5-yr disease-specific survival for T1, T2, and T3 disease was 100% and 75% and 75%, respectively. Patients with negative surgical margins had a better disease-specific survival rate than did those with positive surgical margins (p = 0.0253). CONCLUSION: Endoscopic surgery for patients with SNSCC appears to afford an effective method in selected cases. The achievement of negative surgical margins with a good view of the tumor attachment site was considered to be critical to the management of SNSCC.
  • Multiparametric Analysis of Tumor Morphological and Functional MR Parameters Potentially Predicts Local Failure in Pharynx Squamous Cell Carcinoma Patients.
    Noriyuki Fujima, Yukie Shimizu, Daisuke Yoshida, Satoshi Kano, Takatsugu Mizumachi, Akihiro Homma, Koichi Yasuda, Rikiya Onimaru, Osamu Sakai, Kohsuke Kudo, Hiroki Shirato
    The journal of medical investigation : JMI, 68, 3.4, 354, 361, 2021, [Domestic magazines]
    English, Scientific journal, Purpose : To predict local control / failure by a multiparametric approach using magnetic resonance (MR)-derived tumor morphological and functional parameters in pharynx squamous cell carcinoma (SCC) patients. Materials and Methods : Twenty-eight patients with oropharyngeal and hypopharyngeal SCCs were included in this study. Quantitative morphological parameters and intratumoral characteristics on T2-weighted images, tumor blood flow from pseudo-continuous arterial spin labeling, and tumor diffusion parameters of three diffusion models from multi-b-value diffusion-weighted imaging as well as patients' characteristics were analyzed. The patients were divided into local control / failure groups. Univariate and multiparametric analysis were performed for the patient group division. Results : The value of morphological parameter of 'sphericity' and intratumoral characteristic of 'homogeneity' was revealed respectively significant for the prediction of the local control status in univariate analysis. Higher diagnostic performance was obtained with the sensitivity of 0.8, specificity of 0.75, positive predictive value of 0.89, negative predictive value of 0.6 and accuracy of 0.79 by multiparametric diagnostic model compared to results in the univariate analysis. Conclusion : A multiparametric analysis with MR-derived quantitative parameters may be useful to predict local control in pharynx SCC patients. J. Med. Invest. 68 : 354-361, August, 2021.
  • 頭頸部癌患者におけるSLFN11発現とDNA障害型抗癌剤の効果に関する検討               
    浜田 誠二郎, 加納 里志, 鈴木 崇祥, 本間 明宏, 村井 純子
    日本癌学会総会記事, 79回, OJ15, 2, (一社)日本癌学会, Oct. 2020
    English
  • アンドロゲン受容体陽性唾液腺癌対象Darolutamideの医師主導治験(Trial in progress)               
    岡野 晋, 加納 里志, 小川 武則, 花澤 豊行, 塚原 清彰, 大野 十央, 志村 英二, 佐野 大佑, 丸尾 貴志, 今村 善宣, 大塚 倫之, 中島 寅彦, 田原 信
    日本癌治療学会学術集会抄録集, 58回, P, 16, (一社)日本癌治療学会, Oct. 2020
    Japanese
  • アンドロゲン受容体陽性唾液腺癌対象Darolutamideの医師主導治験(Trial in progress)               
    岡野 晋, 加納 里志, 小川 武則, 花澤 豊行, 塚原 清彰, 大野 十央, 志村 英二, 佐野 大佑, 丸尾 貴志, 今村 善宣, 大塚 倫之, 中島 寅彦, 田原 信
    日本癌治療学会学術集会抄録集, 58回, P, 16, (一社)日本癌治療学会, Oct. 2020
    Japanese
  • Prognostic impact of CRTC1/3‐MAML2 fusions in salivary gland mucoepidermoid carcinoma: A multiinstitutional retrospective study
    Yoshihide Okumura, Satsuki Nakano, Takayuki Murase, Kaori Ueda, Daisuke Kawakita, Toshitaka Nagao, Kimihide Kusafuka, Makoto Urano, Hidetaka Yamamoto, Satoshi Kano, Kiyoaki Tsukahara, Kenji Okami, Toru Nagao, Nobuhiro Hanai, Hiroshi Iwai, Ryo Kawata, Yuichiro Tada, Ken‐Ichi Nibu, Hiroshi Inagaki
    Cancer Science, Wiley, 14 Sep. 2020
    Scientific journal
  • Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Jun Taguchi, Yasushi Shimizu, Shin Ariga, Tomohiro Goda, Yoshihito Ohhara, Rio Honma, Takuro Noguchi, Satoshi Takeuchi, Ichiro Kinoshita, Toraji Amano, Takatsugu Mizumachi, Satoshi Kano, Miki Takahara, Takahisa Abe, Akihiro Homma, Hirotoshi Dosaka-Akita
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, Sep. 2020
    English, Scientific journal
  • 上・中・下咽頭癌に対する陽子線治療の初期経験               
    安田 耕一, 湊川 英樹, 出倉 康裕, 対馬 那由多, 鈴木 崇祥, 加納 里志, 鬼丸 力也, 清水 伸一, 本間 明宏, 青山 英史
    頭頸部癌, 46, 2, 161, 161, (一社)日本頭頸部癌学会, Jul. 2020
    Japanese
  • 休日による総治療期間延長に対して1回線量増加の方法を組み合わせて放射線治療を行った早期声門癌の検討               
    出倉 康裕, 安田 耕一, 湊川 英樹, 対馬 那由多, 鈴木 崇祥, 加納 里志, 鬼丸 力也, 本間 明宏, 青山 英史
    頭頸部癌, 46, 2, 179, 179, (一社)日本頭頸部癌学会, Jul. 2020
    Japanese
  • 頭頸部粘膜悪性黒色腫に対する術後陽子線治療30GyE/5回の初期経験               
    湊川 英樹, 安田 耕一, 出倉 康裕, 鈴木 正宣, 中丸 裕爾, 中薗 彬, 鈴木 崇祥, 対馬 那由多, 加納 里志, 鬼丸 力也, 清水 伸一, 本間 明宏, 青山 英史
    頭頸部癌, 46, 2, 188, 188, (一社)日本頭頸部癌学会, Jul. 2020
    Japanese
  • The impact of clinicopathological factors on clinical outcomes in patients with salivary gland adenoid cystic carcinoma: a multi-institutional analysis in Japan
    Daisuke Kawakita, Takayuki Murase, Kaori Ueda, Satoshi Kano, Yuichiro Tada, Kiyoaki Tsukahara, Kenji Okami, Tetsuro Onitsuka, Yasushi Fujimoto, Takuma Matoba, Kazuo Sakurai, Toru Nagao, Nobuhiro Hanai, Ryo Kawata, Naohito Hato, Ken-ichi Nibu, Makoto Urano, Ken-ichi Taguchi, Masato Nakaguro, Kimihide Kusafuka, Hidetaka Yamamoto, Toshitaka Nagao, Hiroshi Inagaki
    International Journal of Clinical Oncology, Springer Science and Business Media LLC, 01 Jul. 2020, [Peer-reviewed]
    Scientific journal
  • Prognostic Implication of Histopathologic Indicators in Salivary Duct Carcinoma: Proposal of a Novel Histologic Risk Stratification Model.
    Masato Nakaguro, Yukiko Sato, Yuichiro Tada, Daisuke Kawakita, Hideaki Hirai, Makoto Urano, Tomotaka Shimura, Kiyoaki Tsukahara, Satoshi Kano, Hiroyuki Ozawa, Kenji Okami, Yuichiro Sato, Chihiro Fushimi, Akira Shimizu, Soichiro Takase, Takuro Okada, Hiroki Sato, Yorihisa Imanishi, Kuninori Otsuka, Yoshihiro Watanabe, Akihiro Sakai, Koji Ebisumoto, Takafumi Togashi, Yushi Ueki, Hisayuki Ota, Natsuki Saigusa, Hideaki Takahashi, Mizuo Ando, Toyoyuki Hanazawa, Toshitaka Nagao
    The American journal of surgical pathology, 44, 4, 526, 535, Apr. 2020, [Peer-reviewed], [International Magazine]
    English, Scientific journal, Salivary duct carcinoma (SDC) is a rare, aggressive malignancy that histologically resembles high-grade mammary duct carcinoma. Because of the rarity of this entity, data verifying the association between histologic features and patient survival are limited. We conducted a comprehensive histologic review of 151 SDC cases and performed an analysis of the association between various histomorphologic parameters and the clinical outcome with the aim of developing a histologic risk stratification model that predicts the prognosis of SDC patients. A multivariate analysis revealed that prominent nuclear pleomorphism (overall survival [OS]: P=0.013; progression-free survival [PFS]: P=0.019), ≥30 mitoses/10 HPF (PFS: P=0.013), high tumor budding (OS: P=0.011; PFS: P<0.001), and high poorly differentiated clusters (OS: P<0.001; PFS: P<0.001) were independent prognostic factors. Patients with vascular invasion demonstrated a marginally significant association with shorter PFS (P=0.064) in a multivariate analysis. We proposed a 3-tier histologic risk stratification model based on the total number of positive factors among 4 prognostically relevant parameters (prominent nuclear pleomorphism, ≥30 mitoses/10 HPF, vascular invasion, and high poorly differentiated clusters). The OS and PFS of patients with low-risk (0 to 1 point) (23% of cases), intermediate-risk (2 to 3 points) (54% of cases), and high-risk (4 points) (23% of cases) tumors progressively deteriorated in this order (hazard ratio, 2.13 and 2.28, and 4.99 and 4.50, respectively; Ptrend<0.001). Our histologic risk stratification model could effectively predict patient survival and may be a useful aid to guide clinical decision-making in relation to the management of patients with SDC.
  • The clinicopathological significance of the adipophilin and fatty acid synthase expression in salivary duct carcinoma.
    Hideaki Hirai, Yuichiro Tada, Masato Nakaguro, Daisuke Kawakita, Yukiko Sato, Tomotaka Shimura, Kiyoaki Tsukahara, Satoshi Kano, Hiroyuki Ozawa, Kenji Okami, Yuichiro Sato, Chihiro Fushimi, Akira Shimizu, Isaku Okamoto, Soichiro Takase, Takuro Okada, Hiroki Sato, Yorihisa Imanishi, Kuninori Otsuka, Yoshihiro Watanabe, Akihiro Sakai, Koji Ebisumoto, Takafumi Togashi, Yushi Ueki, Hisayuki Ota, Natsuki Saigusa, Hideaki Takahashi, Mizuo Ando, Makoto Urano, Toyoyuki Hanazawa, Toshitaka Nagao
    Virchows Archiv : an international journal of pathology, 477, 2, 291, 299, 26 Feb. 2020, [Peer-reviewed], [International Magazine]
    English, Scientific journal, Salivary duct carcinoma (SDC) is an aggressive, uncommon tumor histologically comparable to high-grade mammary ductal carcinoma. SDCs are usually androgen receptor (AR)-positive and often HER2-positive. Recently, therapies targeting these molecules for SDC have attracted attention. Lipid metabolism changes have been described in association with biological behavior in various cancers, although no such relationship has yet been reported for SDC. We therefore analyzed the clinicopathological relevance of the immunohistochemical expression of adipophilin (ADP) and fatty acid synthase (FASN), representative lipid metabolism-related proteins, in 147 SDCs. ADP and FASN were variably immunoreactive in most SDCs (both 99.3%), and the ADP and FASN expression was negatively correlated (P = 0.014). ADP-positive (≥ 5%) SDCs more frequently exhibited a prominent nuclear pleomorphism and high-Ki-67 labeling index than those ADP-negative (P = 0.013 and 0.011, respectively). In contrast, a high FASN score, calculated by the staining proportion and intensity, (≥ 120) was correlated with the high expression of AR and FOXA1 (P < 0.001 and = 0.003, respectively). The ADP and FASN expression differed significantly among the subtypes based on biomarker immunoprofiling, as assessed by the AR, HER2, and Ki-67 status (P = 0.017 and 0.003, respectively). A multivariate analysis showed that ADP-positive expression was associated with a shorter overall and progression-free survival (P = 0.018 and 0.003, respectively). ADP was associated with an aggressive histopathology and unfavorable prognosis, and FASN may biologically interact with the AR signaling pathway in SDC. ADP may, therefore, be a new prognostic indicator and therapeutic target in SDC.
  • HER2陽性再発・転移唾液腺癌患者に対するトラスツズマブ・ドセタキセル併用療法の第II相試験               
    木下 一郎, 加納 里志, 清田 尚臣, 多田 雄一郎, 伊地知 圭, 山崎 知子, 西本 尚樹, 畑中 豊, 松野 吉弘, 秋田 弘俊
    日本内科学会雑誌, 109, Suppl., 230, 230, (一社)日本内科学会, Feb. 2020
    Japanese
  • Central pathology review of salivary gland adenoid cystic carcinoma.
    Kaori Ueda, Takayuki Murase, Toshitaka Nagao, Kimihide Kusafuka, Makoto Urano, Hidetaka Yamamoto, Masato Nakaguro, Ken-Ichi Taguchi, Ayako Masaki, Hideaki Hirai, Daisuke Kawakita, Kiyoaki Tsukahara, Naohito Hato, Toru Nagao, Yasushi Fujimoto, Kazuo Sakurai, Nobuhiro Hanai, Satoshi Kano, Tetsuro Onitsuka, Kenji Okami, Ken-Ichi Nibu, Yuichiro Tada, Ryo Kawata, Hiroshi Inagaki
    Head & neck, 42, 8, 1721, 1727, 23 Jan. 2020, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: To assess the role of a central pathology review in the diagnosis of salivary gland adenoid cystic carcinoma (AdCC). METHODS: Surgically resected salivary gland tumors diagnosed as AdCC (n = 219) in 15 reference hospitals in Japan were subjected to a retrospective pathological re-evaluation. RESULTS: After the review, the AdCC diagnosis was revised in 21/219 cases (9.6%). The six benign tumors (2.7%) comprised five basal cell adenomas and one pleomorphic adenoma, and among these six patients, three received postoperative radiotherapy. The remaining 15 malignant tumors (6.8%) comprised nine basal cell adenocarcinomas and six other carcinomas. All revised basal cell adenoma/adenocarcinoma cases were of rare cribriform variants. CONCLUSIONS: A significant proportion of AdCC pathology reports were revised after the central pathology review. It should be emphasized that the greatest attention should be paid in differentiating AdCC from cribriform variant basal cell adenoma/adenocarcinoma, which is very rare in salivary gland tumors.
  • Analysis of semicircular canal function as evaluated by video Head Impulse Test in patients with vestibular schwannoma.
    Keishi Fujiwara, Shinya Morita, Atsushi Fukuda, Hiroki Akamatsu, Hiroko Yanagi, Kimiko Hoshino, Yuji Nakamaru, Satoshi Kano, Akihiro Homma
    Journal of vestibular research : equilibrium & orientation, 30, 2, 101, 108, 2020, [International Magazine]
    English, Scientific journal, OBJECTIVE: The aim of the present study was to investigate the factors influencing semicircular canal function as evaluated by video Head Impulse Test (vHIT) in patients with vestibular schwannoma. METHODS: Twenty-four patients with untreated vestibular schwannoma underwent vHIT examination. The correlations between semicircular canal function and factors including age, tumor size, disease duration and hearing loss were evaluated. RESULTS: The functions of all three semicircular canals on the affected side evaluated by vHIT were significantly lower than those on the unaffected side. Although there were no significant correlations between semicircular canal function and age, tumor size or disease duration, a negative significant correlation between vestibulo-ocular reflex (VOR) gain as evaluated by vHIT and hearing loss was observed. CONCLUSIONS: From the results of the relationship between hearing loss and VOR gain, the damage to the audio and vestibular systems in patients with VS may be correlated. As it has been suggested that tumor size was not a significant factor in the VOR gain evaluated by vHIT, multifactorial causes rather than the simple compression of the vestibular nerves alone may be related to the dysfunction of the semicircular canals in patients with vestibular schwannoma.
  • Enhanced Angiogenesis in Salivary Duct Carcinoma Ex-Pleomorphic Adenoma.
    Takayoshi Suzuki, Satoshi Kano, Masanobu Suzuki, Shinichiro Yasukawa, Takatsugu Mizumachi, Nayuta Tsushima, Kanako C Hatanaka, Yutaka Hatanaka, Yoshihiro Matsuno, Akihiro Homma
    Frontiers in oncology, 10, 603717, 603717, 2020, [International Magazine]
    English, Scientific journal, Salivary duct carcinoma (SDC) is morphologically similar to breast cancer, with HER2-overexpression reported. With regard to the pattern of disease onset, SDC can arise from de novo or carcinoma ex-pleomorphic adenoma (Ca-ex-PA). Recently, multiple molecular profiles of SDC as well as breast cancer have been reported, with significant differences in HER2 expression between Ca-ex-PA and de novo. We assessed the differences in gene expression between onset classifications. We conducted immunohistochemical analysis and HER2-DISH for 23 patients and classified SDCs into three subtypes as follows: "HER2-positive" (HER2+/any AR), "Luminal-AR" (HER2-/AR+), and "Basal-like" (HER2-/AR-). We assessed the expression levels of 84 functional genes for 19 patients by using a qRT-PCR array. Ten cases were classified as HER2-positive, seven cases as Luminal-AR, and six cases as Basal-like. The gene expression pattern was generally consistent with the corresponding immunostaining classification. The expression levels of VEGFA, ERBB2(HER2), IGF1R, RB1, and XBP1 were higher, while those of SLIT2 and PTEN were lower in Ca-ex-PA than in de novo. The functions of those genes were concentrated in angiogenesis and AKT/PI3K signaling pathway (Fisher's test: p-value = 0.025 and 0.004, respectively). Multiple machine learning methods, OPLS-DA, LASSO, and RandomForest, also show that VEGFA can be a candidate for the characteristic differences between Ca-ex-PA and de novo. In conclusion, the AKT/PI3K signaling pathway leading to angiogenesis was hyper-activated in all SDCs, particularly in those classified into the Ca-ex-PAs. VEGFA was over-expressed significantly in the Ca-ex-PA, which can be a crucial factor in the malignant conversion to SDC.
  • 唾液腺導管癌における脂質関連蛋白発現の臨床病理学的意義               
    平井 秀明, 多田 雄一郎, 中黒 匡人, 川北 大介, 佐藤 由紀子, 志村 智隆, 塚原 清彰, 加納 里志, 小澤 宏之, 大上 研二, 佐藤 雄一郎, 伏見 千宙, 清水 顕, 高瀬 総一郎, 岡田 拓朗, 佐藤 宏樹, 今西 順久, 大塚 邦憲, 渡部 佳弘, 酒井 昭博, 戎本 浩史, 富樫 孝文, 植木 雄志, 太田 久幸, 三枝 奈津季, 高橋 秀聡, 安藤 瑞生, 浦野 誠, 花澤 豊行, 長尾 俊孝
    日本唾液腺学会誌, 60, 24, 25, 日本唾液腺学会, Nov. 2019, [Peer-reviewed]
    Japanese
  • CCRTを施行した進行頭頸部癌患者に対する予防的胃瘻増設の有用性の検討               
    加納 里志, 対馬 那由多, 鈴木 崇祥, 浜田 誠二郎, 横川 泰三, 本間 明宏
    日本癌治療学会学術集会抄録集, 57回, P4, 4, (一社)日本癌治療学会, Oct. 2019
    English
  • 当科における局所進行外耳道扁平上皮癌の治療成績の検討
    加納 里志, 森田 真也, 中丸 裕爾, 水町 貴諭, 対馬 那由多, 鈴木 崇祥, 中薗 彬, 福田 篤, 安田 耕一, 鬼丸 力也, 白土 博樹, 本間 明宏
    頭頸部癌, 45, 3, 300, 304, (一社)日本頭頸部癌学会, Oct. 2019
    Japanese
  • Machine-Learning-Based Prediction of Treatment Outcomes Using MR Imaging-Derived Quantitative Tumor Information in Patients with Sinonasal Squamous Cell Carcinomas: A Preliminary Study.
    Noriyuki Fujima, Yukie Shimizu, Daisuke Yoshida, Satoshi Kano, Takatsugu Mizumachi, Akihiro Homma, Koichi Yasuda, Rikiya Onimaru, Osamu Sakai, Kohsuke Kudo, Hiroki Shirato
    Cancers, 11, 6, 10 Jun. 2019, [Peer-reviewed], [International Magazine]
    English, Scientific journal, The purpose of this study was to determine the predictive power for treatment outcome of a machine-learning algorithm combining magnetic resonance imaging (MRI)-derived data in patients with sinonasal squamous cell carcinomas (SCCs). Thirty-six primary lesions in 36 patients were evaluated. Quantitative morphological parameters and intratumoral characteristics from T2-weighted images, tumor perfusion parameters from arterial spin labeling (ASL) and tumor diffusion parameters of five diffusion models from multi-b-value diffusion-weighted imaging (DWI) were obtained. Machine learning by a non-linear support vector machine (SVM) was used to construct the best diagnostic algorithm for the prediction of local control and failure. The diagnostic accuracy was evaluated using a 9-fold cross-validation scheme, dividing patients into training and validation sets. Classification criteria for the division of local control and failure in nine training sets could be constructed with a mean sensitivity of 0.98, specificity of 0.91, positive predictive value (PPV) of 0.94, negative predictive value (NPV) of 0.97, and accuracy of 0.96. The nine validation data sets showed a mean sensitivity of 1.0, specificity of 0.82, PPV of 0.86, NPV of 1.0, and accuracy of 0.92. In conclusion, a machine-learning algorithm using various MR imaging-derived data can be helpful for the prediction of treatment outcomes in patients with sinonasal SCCs.
  • 舌扁平上皮癌における改訂UICC TNM分類第8版の有用性の検討               
    加納 里志, 対馬 那由多, 水町 貴諭, 鈴木 崇祥, 浜田 誠二郎, 本間 明宏
    頭頸部癌, 45, 2, 157, 157, (一社)日本頭頸部癌学会, May 2019
    Japanese
  • 多形腺腫由来型唾液腺導管癌に特徴的な遺伝子発現の探索               
    鈴木 崇洋, 加納 里志, 浜田 誠二郎, 対馬 那由多, 水町 貴諭, 本間 明宏
    頭頸部癌, 45, 2, 221, 221, (一社)日本頭頸部癌学会, May 2019
    Japanese
  • 強度変調X線治療および強度変調陽子線治療における皮膚炎と皮膚線量に関する検討               
    安田 耕一, 湊川 英樹, 出倉 康裕, 対馬 那由多, 鈴木 崇祥, 加納 里志, 水町 貴諭, 鬼丸 力也, 清水 伸一, 本間 明宏, 白土 博樹
    頭頸部癌, 45, 2, 134, 134, (一社)日本頭頸部癌学会, May 2019
    Japanese
  • 外耳道癌における強度変調陽子線治療と強度変調X線治療との線量分布の比較               
    出倉 康裕, 安田 耕一, 湊川 英樹, 対馬 那由多, 鈴木 崇祥, 加納 里志, 水町 貴諭, 鬼丸 力也, 清水 伸一, 本間 明宏, 白土 博樹
    頭頸部癌, 45, 2, 138, 138, (一社)日本頭頸部癌学会, May 2019
    Japanese
  • 頭頸部癌化学放射線療法におけるEPA高配合栄養機能食品(プロシュア)の有用性の検討
    水町 貴諭, 加納 里志, 本間 明宏, 赤澤 美樹子, 長谷川 千春, 城石 陽子, 岡本 千秋, 熊谷 聡美, 西村 雅勝, 高崎 裕代, 武田 宏司, 安田 耕一, 湊川 英樹, 出倉 康裕, 鬼丸 力也, 白土 博樹, 福田 諭
    癌と化学療法, 46, 4, 685, 689, (株)癌と化学療法社, Apr. 2019
    Japanese
  • A nutritional supplement with a high blend ratio of ω-3 fatty acids (prosure®) reduces severe oral mucositis and body weight loss for head and neck cancer patients treated with chemoradiotherapy
    Takatsugu Mizumachi, Satoshi Kano, Akihiro Homma, Mikiko Akazawa, Chiharu Hasegawa, Yoko Shiroishi, Chiaki Okamoto, Satomi Kumagai, Masaharu Nishimura, Hiroyo Takasaki, Hiroshi Takeda, Koichi Yasuda, Hideki Minatogawa, Yasuhiro Dekura, Rikiya Onimaru, Hiroki Shirato, Satoshi Fukuda
    Japanese Journal of Cancer and Chemotherapy, 46, 4, 685, 689, Apr. 2019, [Peer-reviewed]
    Scientific journal
  • The utility of MRI histogram and texture analysis for the prediction of histological diagnosis in head and neck malignancies
    Fujima Noriyuki, Homma Akihiro, Harada Taisuke, Shimizu Yukie, Tha Khin Khin, Kano Satoshi, Mizumachi Takatsugu, Li Ruijiang, Kudo Kohsuke, Shirato Hiroki
    CANCER IMAGING, 19, 04 Feb. 2019, [Peer-reviewed]
  • The utility of MRI histogram and texture analysis for the prediction of histological diagnosis in head and neck malignancies.
    Noriyuki Fujima, Akihiro Homma, Taisuke Harada, Yukie Shimizu, Khin Khin Tha, Satoshi Kano, Takatsugu Mizumachi, Ruijiang Li, Kohsuke Kudo, Hiroki Shirato
    Cancer imaging : the official publication of the International Cancer Imaging Society, 19, 1, 5, 5, 04 Feb. 2019, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: To assess the utility of histogram and texture analysis of magnetic resonance (MR) fat-suppressed T2-weighted imaging (Fs-T2WI) for the prediction of histological diagnosis of head and neck squamous cell carcinoma (SCC) and malignant lymphoma (ML). METHODS: The cases of 57 patients with SCC (45 well/moderately and 12 poorly differentiated SCC) and 10 patients with ML were retrospectively analyzed. Quantitative parameters with histogram features (relative mean signal, coefficient of variation, kurtosis and skewness) and gray-level co-occurrence matrix (GLCM) features (contrast, correlation, energy and homogeneity) were calculated using Fs-T2WI data with a manual tumor region of interest (ROI). RESULTS: The following significantly different values were obtained for the total SCC versus ML groups: relative mean signal (3.65 ± 0.86 vs. 2.61 ± 0.49), contrast (72.9 ± 16.2 vs. 49.3 ± 8.7) and homogeneity (2.22 ± 0.25 × 10- 1 vs. 2.53 ± 0.12 × 10- 1). In the comparison of the SCC histological grades, the relative mean signal and contrast were significantly lower in the poorly differentiated SCC (2.89 ± 0.63, 56.2 ± 12.9) compared to the well/moderately SCC (3.85 ± 0.81, 77.5 ± 13.9). The homogeneity in poorly differentiated SCC (2.56 ± 0.15 × 10- 1) was higher than that of the well/moderately SCC (2.1 ± 0.18 × 10- 1). CONCLUSIONS: Parameters obtained by histogram and texture analysis of Fs-T2WI may be useful for noninvasive prediction of histological type and grade in head and neck malignancy.
  • Treatment outcomes of local advanced external auditory canal squamous cell carcinomas
    Satoshi Kano, Shinya Morita, Yuji Nakamaru, Takatsugu Mizumachi, Nayuta Tsushima, Takayoshi Suzuki, Akira Nakazono, Atsushi Fukuda, Koichi Yasuda, Rikiya Onimaru, Hiroki Shirato, Akihiro Homma
    Japanese Journal of Head and Neck Cancer, 45, 3, 300, 304, 2019, [Peer-reviewed]
    Scientific journal
  • The high expression of FOXA1 is correlated with a favourable prognosis in salivary duct carcinomas: a study of 142 cases.
    Makoto Urano, Hideaki Hirai, Yuichiro Tada, Daisuke Kawakita, Tomotaka Shimura, Kiyoaki Tsukahara, Satoshi Kano, Hiroyuki Ozawa, Kenji Okami, Yuichiro Sato, Chihiro Fushimi, Akira Shimizu, Soichiro Takase, Takuro Okada, Hiroki Sato, Yorihisa Imanishi, Kuninori Otsuka, Yoshihiro Watanabe, Akihiro Sakai, Koji Ebisumoto, Takafumi Togashi, Yushi Ueki, Hisayuki Ota, Yukiko Sato, Natsuki Saigusa, Masato Nakaguro, Toyoyuki Hanazawa, Toshitaka Nagao
    Histopathology, 73, 6, 943, 952, Dec. 2018, [Peer-reviewed], [International Magazine]
    English, Scientific journal, AIMS: Salivary duct carcinoma (SDC) is an uncommon, aggressive tumour that, histologically, resembles high-grade mammary ductal carcinoma, and is characterised by the expression of androgen receptor (AR). The androgen signalling pathway, a potential therapeutic target, can be regulated by FOXA1. This study aimed to evaluate the clinicopathological implications of FOXA1 in SDC. METHODS AND RESULTS: We examined the relationship between the immunoexpression of FOXA1 and FOXA1 mutations and clinicopathological factors, including the biomarker status and clinical outcome, in 142 SDCs. FOXA1 was expressed in 128 SDCs (90.1%); the immunoexpression was heterogeneous. SDCs with a higher FOXA1 labelling index (LI) (≥20%) more frequently showed less advanced tumors on T classification (P = 0.002). FOXA1 LI was correlated positively with the AR expression value (r = 0.430, P < 0.001). PI3K and p-mTOR positivity, and intact-PTEN, were associated with a higher FOXA1 LI. Twenty-two of 121 SDCs (18.2%) harboured FOXA1 gene mutations at the flanking regions in and around the forkhead DNA binding domain; however, the given gene mutation and the expression of FOXA1 were not significantly correlated. A multivariate analysis revealed that SDCs with a higher FOXA1 LI were associated with longer overall survival and progression-free survival (P = 0.029 and 0.016, respectively). CONCLUSIONS: In SDC, FOXA1, which may biologically interact with the AR and PI3K signalling pathways, is a putative biomarker that may be associated with a favourable prognosis. Further studies are needed to apply the findings to the development of targeted personalised therapy for patients with SDC.
  • Integrating quantitative morphological and intratumoural textural characteristics in FDG-PET for the prediction of prognosis in pharynx squamous cell carcinoma patients.
    N Fujima, K Hirata, T Shiga, R Li, K Yasuda, R Onimaru, K Tsuchiya, S Kano, T Mizumachi, A Homma, K Kudo, H Shirato
    Clinical radiology, 73, 12, 1059.e1-1059.e8, Dec. 2018, [Peer-reviewed], [International Magazine]
    English, Scientific journal, AIM: To assess potential prognostic factors in pharynx squamous cell carcinoma (SCC) patients by quantitative morphological and intratumoural characteristics obtained by 2-[18F]-fluoro-2-deoxy-d-glucose positron-emission tomography/computed tomography (FDG-PET/CT). MATERIALS AND METHODS: The cases of 54 patients with pharynx SCC who underwent chemoradiation therapy were analysed retrospectively. Using their FDG-PET data, the quantitative morphological and intratumoural characteristics of 14 parameters were calculated. The progression-free survival (PFS) and overall survival (OS) information was obtained from patient medical records. Univariate and multivariate analyses were performed to assess the 14 quantitative parameters as well as the T-stage, N-stage, and tumour location data for their relation to PFS and OS. When an independent predictor was suggested in the multivariate analysis, the parameter was further assessed using the Kaplan-Meier method. RESULTS: In the assessment of PFS, the univariate and multivariate analyses indicated the following as independent predictors: the texture parameter of homogeneity and the morphological parameter of sphericity. In the Kaplan-Meier analysis, the PFS rate was significantly improved in the patients who had both a higher value of homogeneity (p=0.01) and a higher value of sphericity (p=0.002). With the combined use of homogeneity and sphericity, the patients with different PFS rates could be divided more clearly. CONCLUSION: The quantitative parameters of homogeneity and sphericity obtained by FDG-PET can be useful for the prediction of the PFS of pharynx SCC patients, especially when used in combination.
  • 喉頭癌cT3の喉頭温存治療(CRT vs RADPLAT) 喉頭癌に対する超選択的動注と放射線同時併用療法
    本間 明宏, 加納 里志, 水町 貴諭, 中薗 彬, 鈴木 崇祥, 坂下 智博, 福田 諭, 鬼丸 力也, 安田 耕一, 湊川 英樹, 出倉 康裕, 土屋 和彦, 白土 博樹
    日本気管食道科学会会報, 69, 5, 319, 320, (NPO)日本気管食道科学会, Oct. 2018
    Japanese
  • Semi-quantitative analysis of pre-treatment morphological and intratumoral characteristics using 18F-fluorodeoxyglucose positron-emission tomography as predictors of treatment outcome in nasal and paranasal squamous cell carcinoma.
    Noriyuki Fujima, Kenji Hirata, Tohru Shiga, Koichi Yasuda, Rikiya Onimaru, Kazuhiko Tsuchiya, Satoshi Kano, Takatsugu Mizumachi, Akihiro Homma, Kohsuke Kudo, Hiroki Shirato
    Quantitative imaging in medicine and surgery, 8, 8, 788, 795, Sep. 2018, [Peer-reviewed], [International Magazine]
    English, Scientific journal, Background: To investigate the utility of quantitative morphological and intratumoral characteristics obtained by 18F-fluorodeoxyglucose positron-emission tomography/computed tomography (FDG-PET/CT) for the prediction of treatment outcome in patients with nasal or paranasal cavity squamous cell carcinoma (SCC). Methods: Twenty-four patients with nasal or paranasal cavity SCC who received curative non-surgical therapy (a combination of super-selective arterial cisplatin infusion and radiotherapy) were retrospectively analyzed. From pre-treatment FDG-PET data, a total of 13 parameters of quantitative morphological characteristics (tumor volume, surface area and sphericity), intratumoral characteristics (the maximum and mean standard uptake value, three intratumoral histogram and four textural parameters) and total lesion glycolysis (TLG) were respectively calculated. Information regarding the treatment outcome was determined from the histological diagnosis or clinical follow-up. Each of the 13 quantitative parameters as well as T- and N-stage was assessed for its relation to treatment outcome of local control or failure. Results: In univariate analysis, significant differences in surface area and sphericity between the local control and failure groups were observed. The receiver operating characteristic (ROC) curve analysis showed that sphericity had the highest accuracy of 0.88. In the multivariate analysis, sphericity was revealed as an independent predictor of the local control or failure. Conclusions: The quantitative parameters of sphericity are useful to predict the treatment outcome in patients with nasal or paranasal SCC.
  • Comparison of the University of Pittsburgh staging system and the eighth edition of the American Joint Committee on Cancer TNM classification for the prognostic evaluation of external auditory canal cancer.
    Morita S, Mizumachi T, Nakamaru Y, Sakashita T, Kano S, Hoshino K, Fukuda A, Fujiwara K, Homma A
    International journal of clinical oncology, 23, 6, 1029, 1037, Jul. 2018, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, BACKGROUND: The purpose was to compare survival differences between patients with external auditory canal (EAC) cancer treated according to the University of Pittsburgh modified TNM staging system and those treated in accordance with the 8th edition of the American Joint Committee on Cancer (AJCC) staging manual on the TNM staging system for cutaneous cancers of the head and neck. METHODS: We performed a retrospective, single-institution review of 60 patients with EAC cancer treated with curative intent between September 2002 and March 2018. Survival outcomes were measured on the basis of the two staging systems. RESULTS: The C-index values for the overall survival (OS) rate revealed that the University of Pittsburgh staging system had higher prognostic accuracy than the 8th edition of the AJCC staging system. Univariable and multivariable analysis showed that T classification according to the University of Pittsburgh staging system was an independent predictor of the OS rate (hazard ratio 5.25; 95% confidence interval 1.38-24.9; P = 0.015). Meanwhile, the AJCC staging system could not differentiate T2 from T3-4 cancers. CONCLUSION: The University of Pittsburgh staging system for patients with EAC cancer is a valuable tool for use in clinical decision-making and predicting survival outcome.
  • Genetic mutation analysis of the malignant transformation of sinonasal inverted papilloma by targeted amplicon sequencing
    Shinichiro Yasukawa, Satoshi Kano, Hiromitsu Hatakeyama, Yuji Nakamaru, Dai Takagi, Takatsugu Mizumachi, Masanobu Suzuki, Takayoshi Suzuki, Akira Nakazono, Shinya Tanaka, Hiroshi Nishihara, Akihiro Homma
    International Journal of Clinical Oncology, 23, 5, 1, 9, Springer Tokyo, 19 May 2018, [Peer-reviewed]
    English, Scientific journal
  • 唾液腺導管癌における免疫染色およびRT-PCR法を用いた分子生物学的プロファイルの検討               
    鈴木 崇祥, 加納 里志, 畑中 佳奈子, 鈴木 正宣, 安川 真一郎, 中薗 彬, 水町 貴諭, 畑中 豊, 松野 吉宏, 本間 明宏
    頭頸部癌, 44, 2, 179, 179, (一社)日本頭頸部癌学会, May 2018
    Japanese
  • 当科における局所進行外耳道扁平上皮癌の治療成績の検討               
    加納 里志, 森田 真也, 中丸 裕爾, 水町 貴諭, 中薗 彬, 福田 篤, 安田 耕一, 鬼丸 力也, 白土 博樹, 本間 明宏
    頭頸部癌, 44, 2, 181, 181, (一社)日本頭頸部癌学会, May 2018
    Japanese
  • 当科における局所進行外耳道扁平上皮癌の治療成績の検討               
    加納 里志, 森田 真也, 中丸 裕爾, 水町 貴諭, 中薗 彬, 福田 篤, 安田 耕一, 鬼丸 力也, 白土 博樹, 本間 明宏
    頭頸部癌, 44, 2, 181, 181, (一社)日本頭頸部癌学会, May 2018
    Japanese
  • 唾液腺導管癌における免疫染色およびRT-PCR法を用いた分子生物学的プロファイルの検討               
    鈴木 崇祥, 加納 里志, 畑中 佳奈子, 鈴木 正宣, 安川 真一郎, 中薗 彬, 水町 貴諭, 畑中 豊, 松野 吉宏, 本間 明宏
    頭頸部癌, 44, 2, 179, 179, (一社)日本頭頸部癌学会, May 2018
    Japanese
  • Validation of the 8th edition of the AJCC/UICC TNM staging system for tongue squamous cell carcinoma
    Satoshi Kano, Tomohiro Sakashita, Nayuta Tsushima, Takatsugu Mizumachi, Akira Nakazono, Takayoshi Suzuki, Shinichiro Yasukawa, Akihiro Homma
    International Journal of Clinical Oncology, 23, 5, 1, 7, Springer Tokyo, 19 Apr. 2018, [Peer-reviewed]
    English, Scientific journal
  • 鼻副鼻腔内反性乳頭腫の悪性転化に関与する遺伝子変異の解析
    安川 真一郎, 加納 里志, 畠山 博充, 中丸 裕爾, 高木 大, 水町 貴諭, 鈴木 正宣, 鈴木 崇祥, 中薗 彬, 本間 明宏
    日本耳鼻咽喉科学会会報, 121, 4, 539, 539, (一社)日本耳鼻咽喉科学会, Apr. 2018
    Japanese
  • 唾液腺導管癌における遺伝子発現解析および発生様式間の比較検討
    鈴木 崇祥, 加納 里志, 鈴木 正宣, 安川 真一郎, 中薗 彬, 水町 貴諭, 本間 明宏
    日本耳鼻咽喉科学会会報, 121, 4, 541, 541, (一社)日本耳鼻咽喉科学会, Apr. 2018
    Japanese
  • 当院における嗅神経芽細胞腫の治療方針と成績
    中丸 裕爾, 高木 大, 鈴木 正宣, 加納 里志, 水町 貴諭, 中薗 彬, 本間 明宏
    日本耳鼻咽喉科学会会報, 121, 4, 567, 567, (一社)日本耳鼻咽喉科学会, Apr. 2018
    Japanese
  • 舌扁平上皮癌における新しいTNM分類の有用性の検討
    加納 里志, 水町 貴諭, 対馬 那由多, 鈴木 崇祥, 中薗 彬, 安川 真一郎, 本間 明宏
    日本耳鼻咽喉科学会会報, 121, 4, 578, 578, (一社)日本耳鼻咽喉科学会, Apr. 2018
    Japanese
  • 当院における嗅神経芽細胞腫の治療方針と成績
    中丸 裕爾, 高木 大, 鈴木 正宣, 加納 里志, 水町 貴諭, 中薗 彬, 本間 明宏
    日本耳鼻咽喉科学会会報, 121, 4, 567, 567, (一社)日本耳鼻咽喉科学会, Apr. 2018
    Japanese
  • 唾液腺導管癌における重要な治療標的分子の遺伝子変異と蛋白発現 その予後・組織発生との関連
    志村 智隆, 多田 雄一郎, 川北 大介, 塚原 清彰, 加納 里志, 清水 顕, 今西 順久, 大上 研二, 佐藤 雄一郎, 平井 秀明, 長尾 俊孝, 小林 一女
    日本耳鼻咽喉科学会会報, 121, 4, 542, 542, (一社)日本耳鼻咽喉科学会, Apr. 2018
    Japanese
  • 唾液腺導管癌における遺伝子発現解析および発生様式間の比較検討
    鈴木 崇祥, 加納 里志, 鈴木 正宣, 安川 真一郎, 中薗 彬, 水町 貴諭, 本間 明宏
    日本耳鼻咽喉科学会会報, 121, 4, 541, 541, (一社)日本耳鼻咽喉科学会, Apr. 2018
    Japanese
  • 鼻副鼻腔内反性乳頭腫の悪性転化に関与する遺伝子変異の解析               
    安川 真一郎, 加納 里志, 畠山 博充, 中丸 裕爾, 高木 大, 水町 貴諭, 鈴木 正宣, 鈴木 崇祥, 中薗 彬, 本間 明宏
    日本耳鼻咽喉科学会会報, 121, 4, 539, 539, (一社)日本耳鼻咽喉科学会, Apr. 2018
    Japanese
  • 咽喉頭直達鏡固定システムの試作               
    本間 明宏, 清水 勇一, 畠山 博充, 溝口 兼司, 水町 貴諭, 加納 里志, 坂下 智博, 福田 諭
    耳鼻咽喉科展望, 61, 1, 66, 67, 耳鼻咽喉科展望会, Feb. 2018
    Japanese
  • Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas.
    Tomotaka Shimura, Yuichiro Tada, Hideaki Hirai, Daisuke Kawakita, Satoshi Kano, Kiyoaki Tsukahara, Akira Shimizu, Soichiro Takase, Yorihisa Imanishi, Hiroyuki Ozawa, Kenji Okami, Yuichiro Sato, Yukiko Sato, Chihiro Fushimi, Hideaki Takahashi, Takuro Okada, Hiroki Sato, Kuninori Otsuka, Yoshihiro Watanabe, Akihiro Sakai, Koji Ebisumoto, Takafumi Togashi, Yushi Ueki, Hisayuki Ota, Mizuo Ando, Shinji Kohsaka, Toyoyuki Hanazawa, Hideaki Chazono, Yoshiyuki Kadokura, Hitome Kobayashi, Toshitaka Nagao
    Oncotarget, 9, 2, 1852, 1867, 05 Jan. 2018, [Peer-reviewed], [International Magazine]
    English, Scientific journal, The molecular characteristics of therapeutically-relevant targets and their clinicopathological implications in salivary duct carcinomas (SDCs) are poorly understood. We investigated the gene alterations and the immunoexpression of crucial oncogenic molecules in 151 SDCs. The mutation rates that were identified, in order of frequency, were as follows: TP53, 68%; PIK3CA, 18%; H-RAS, 16%; BRAF, 4%; and AKT1, 1.5%. PIK3CA/H-RAS/BRAF mutations were more common in de novo SDC than in SDC ex-pleomorphic adenoma. Furthermore, these mutations were mutually exclusive for HER2 overexpression/amplification. TP53 mutations were frequently detected in cases with the aberrant p53 expression, and TP53 missense and truncating mutations were associated with p53-extreme positivity and negativity, respectively. DISH analysis revealed no cases of EGFR amplification. The rates of PI3K, p-Akt, and p-mTOR positivity were 34%, 22%, and 66%, respectively; PTEN loss was observed in 47% of the cases. These expressions were correlated according to the signaling axis. Cases with PI3K negativity and PTEN loss appeared to show a lower expression of androgen receptor. In the multivariate analysis, patients with SDC harboring TP53 truncating mutations showed shorter progression-free survival. Conversely, p-Akt positivity was associated with a favorable outcome. This study might provide information that leads to advances in personized therapy for SDC.
  • 舌扁平上皮癌における新しいTNM分類の有用性の検討               
    加納 里志, 中薗 彬, 水町 貴諭, 本間 明宏
    日本癌治療学会学術集会抄録集, 55回, P157, 4, (一社)日本癌治療学会, Oct. 2017
    Japanese
  • 舌扁平上皮癌における新しいTNM分類の有用性の検討               
    加納 里志, 中薗 彬, 水町 貴諭, 本間 明宏
    日本癌治療学会学術集会抄録集, 55回, P157, 4, (一社)日本癌治療学会, Oct. 2017
    Japanese
  • Atypical adenoma of the thyroid diagnosed as anaplastic cancer by cytopathology
    Hiromitsu Hatakeyama, Kimiko Hoshino, Kenji Mizoguchi, Takayoshi Suzuki, Kanako C. Hatanaka, Yukie Yamaya, Satoshi Kano, Takatsugu Mizumachi, Akihiro Homma
    DIAGNOSTIC CYTOPATHOLOGY, 45, 10, 928, 933, Oct. 2017, [Peer-reviewed]
    English, Scientific journal
  • 舌扁平上皮癌における新しいTNM分類の有用性の検討               
    加納 里志, 坂下 智博, 水町 貴諭, 本間 明宏
    口腔・咽頭科, 30, 3, 429, 429, 日本口腔・咽頭科学会, Aug. 2017
    Japanese
  • Confirmation of the eighth edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan
    Takatsugu Mizumachi, Akihiro Homma, Tomohiro Sakashita, Satoshi Kano, Hiromitsu Hatakeyama, Satoshi Fukuda
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 22, 4, 682, 689, Aug. 2017, [Peer-reviewed]
    English, Scientific journal
  • Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification
    Soichiro Takase, Satoshi Kano, Yuichiro Tada, Daisuke Kawakita, Tomotaka Shimura, Hideaki Hirai, Kiyoaki Tsukahara, Akira Shimizu, Yorihisa Imanishi, Hiroyuki Ozawa, Kenji Okami, Yuichiro Sato, Yukiko Sato, Chihiro Fushimi, Takuro Okada, Hiroki Sato, Kuninori Otsuka, Yoshihiro Watanabe, Akihiro Sakai, Koji Ebisumoto, Takafumi Togashi, Yushi Ueki, Hisayuki Ota, Toyoyuki Hanazawa, Hideaki Chazono, Robert Yoshiyuki Osamura, Toshitaka Nagao
    ONCOTARGET, 8, 35, 59023, 59035, Aug. 2017, [Peer-reviewed]
    English, Scientific journal
  • Osteoradionecrosis of the hyoid bone after intra-arterial chemoradiotherapy for oropharyngeal cancer: MR imaging findings
    Hiromitsu Hatakeyama, Noriyuki Fujima, Kazuhiko Tsuchiya, Kenji Mizoguchi, Takatsugu Mizumachi, Tomohiro Sakashita, Satoshi Kano, Akihiro Homma, Satoshi Fukuda
    CANCER IMAGING, 17, Jul. 2017, [Peer-reviewed]
    English, Scientific journal
  • Role of microRNA-296-3p in the malignant transformation of sinonasal inverted papilloma
    Tomohiko Kakizaki, Hiromitsu Hatakeyama, Yuji Nakamaru, Dai Takagi, Takatsugu Mizumachi, Tomohiro Sakashita, Satoshi Kano, Akihiro Homma, Satoshi Fukuda
    ONCOLOGY LETTERS, 14, 1, 987, 992, Jul. 2017, [Peer-reviewed]
    English, Scientific journal
  • Osteoradionecrosis of the hyoid bone after intra-arterial chemoradiotherapy for oropharyngeal cancer: MR imaging findings.
    Hatakeyama H, Fujima N, Tsuchiya K, Mizoguchi K, Mizumachi T, Sakashita T, Kano S, Homma A, Fukuda S
    Cancer imaging : the official publication of the International Cancer Imaging Society, 17, 1, 22, 22, Jul. 2017, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: Osteoradionecrosis (ORN) of the hyoid bone sometimes induces severe front neck infection and can cause laryngeal stenosis and carotid rupture. Although ORN of the hyoid bone is known to be a complication of chemoradiotherapy for head and neck cancer, there has been no basis for its evaluation. Our purpose is to present the clinical and MR imaging features of ORN of the hyoid bone. METHODS: The study group comprised patients with advanced oropharyngeal cancer treated with targeted intra-arterial cisplatin infusion with concomitant radiotherapy. ORN of the hyoid bone was identified on the basis of decreased signal intensity of the bone marrow on T1WI images. Signal intensity on T2WI images was used to distinguish between inflammation and fibrosis. RESULTS: A total of 39 pre-treatment MR images and follow-up MR images were reviewed. ORN of the hyoid bone were detected in 30% of patients after treatment, with 23% of them showing inflammation and 7.7% fibrosis. Two patients developed severe neck infection and received antibiotics and underwent surgical intervention by tracheostomy and resection of the hyoid bone. CONCLUSION: Our MR imaging study showed that ORN of the hyoid bone is not particularly rare in patients with oropharyngeal cancer treated with chemoradiotherapy. Clinicians should evaluate images carefully to prevent the development of severe complication due to infection associated with ORN of the hyoid bone.
  • 北海道大学病院における舌癌治療の現況・選択的動注化学療法の意義               
    坂下 智博, 本間 明宏, 畠山 博充, 加納 里志, 水町 貴諭, 蠣崎 文彦, 対馬 那由多, 福田 諭
    耳鼻咽喉科展望, 60, 補冊1, 50, 51, 耳鼻咽喉科展望会, Jun. 2017
    Japanese
  • 北海道大学病院における喉頭癌治療の現況               
    中薗 彬, 水町 貴諭, 本間 明宏, 畠山 博充, 加納 里志, 古沢 純, 坂下 智博, 鈴木 章之, 福田 諭
    耳鼻咽喉科展望, 60, 補冊1, 8, 9, 耳鼻咽喉科展望会, Jun. 2017
    Japanese
  • 舌扁平上皮癌における腫瘍免疫チェックポイントの解析               
    加納 里志, 鈴木 崇祥, 倉本 倫之介, 坂下 智博, 水町 貴諭, 畠山 博充, 本間 明宏, 福田 諭
    頭頸部癌, 43, 2, 207, 207, 日本頭頸部癌学会, May 2017
    Japanese
  • HPV関連中咽頭癌症例におけるTNM分類改訂に伴う病期分類と生存率の検討
    水町 貴諭, 本間 明宏, 坂下 智博, 加納 里志, 畠山 博充, 福田 諭
    日本耳鼻咽喉科学会会報, 120, 4, 611, 611, (一社)日本耳鼻咽喉科学会, Apr. 2017
    Japanese
  • 唾液腺導管癌ではFOXA1の発現が予後予測因子となる
    平井 秀明, 多田 雄一郎, 川北 大介, 志村 智隆, 塚原 清彰, 加納 里志, 小澤 宏之, 大上 研二, 佐藤 雄一郎, 長尾 俊孝
    日本病理学会会誌, 106, 1, 329, 329, (一社)日本病理学会, Mar. 2017
    Japanese
  • 【頭頸部癌学-診断と治療の最新研究動向-】 頭頸部癌臨床研究の動向 多施設での中咽頭癌の治療成績(手術、放射線)               
    加納 里志, 本間 明宏
    日本臨床, 75, 増刊2 頭頸部癌学, 184, 189, (株)日本臨床社, Feb. 2017
    Japanese
  • Expression of p53, p16, cyclin D1, epidermal growth factor receptor and Notch1 in patients with temporal bone squamous cell carcinoma
    Shinya Morita, Yuji Nakamaru, Akihiro Homma, Shinichiro Yasukawa, Hiromitsu Hatakeyama, Tomohiro Sakashita, Satoshi Kano, Atsushi Fukuda, Satoshi Fukuda
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 22, 1, 181, 189, Feb. 2017, [Peer-reviewed]
    English, Scientific journal
  • Pretreatment lymphocyte-to-monocyte ratio as an independent prognostic factor for head and neck cancer
    Satoshi Kano, Akihiro Homma, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Tomohiro Sakashita, Tomohiko Kakizaki, Satoshi Fukuda
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 39, 2, 247, 253, Feb. 2017, [Peer-reviewed]
    English, Scientific journal
  • Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan
    Daisuke Kawakita, Yuichiro Tada, Yorihisa Imanishi, Shintaro Beppu, Kiyoaki Tsukahara, Satoshi Kano, Hiroyuki Ozawa, Kenji Okami, Yuichiro Sato, Akira Shimizu, Yukiko Sato, Chihiro Fushimi, Soichiro Takase, Takuro Okada, Hiroki Sato, Kuninori Otsuka, Yoshihiro Watanabe, Akihiro Sakai, Koji Ebisumoto, Takafumi Togashi, Yushi Ueki, Hisayuki Ota, Tomotaka Shimura, Toyoyuki Hanazawa, Shingo Murakami, Toshitaka Nagao
    ONCOTARGET, 8, 1, 1083, 1091, Jan. 2017, [Peer-reviewed]
    English, Scientific journal
  • SORORIN and PLK1 as potential therapeutic targets in malignant pleural mesothelioma
    Tatsuya Kato, Daiyoon Lee, Licun Wu, Priya Patel, Ahn Jin Young, Hironobu Wada, Hsin Pei Hu, Hideki Ujiie, Mitsuhito Kaji, Satoshi Kano, Shinichi Matsuge, Hiromitsu Domen, Hiromi Kanno, Yutaka Hatanaka, Kanako C. Hatanaka, Kichizo Kaga, Yoshiro Matsui, Yoshihiro Matsuno, Marc De Perrot, Kazuhiro Yasufuku
    International Journal of Oncology, 49, 6, 2411, 2420, Dec. 2016
    Scientific journal
  • 唾液腺導管癌ではFOXA1の発現が予後予測因子となる
    平井 秀明, 多田 雄一郎, 川北 大介, 志村 智隆, 塚原 清彰, 加納 里志, 小澤 宏之, 大上 研二, 佐藤 雄一郎, 清水 顕, 今西 順久, 長尾 俊孝
    日本唾液腺学会誌, 57, 31, 31, 日本唾液腺学会, Nov. 2016
    Japanese
  • 中咽頭癌に対する集学的治療 中咽頭癌に対する放射線化学療法の検討 多施設による後方視的観察研究
    加納 里志
    耳鼻と臨床, 62, Suppl.1, S9,S28, S16,S28, 耳鼻と臨床会, Nov. 2016
    Japanese
  • The role of prophylactic neck dissection and tumor thickness evaluation for patients with cN0 tongue squamous cell carcinoma
    Nayuta Tsushima, Tomohiro Sakashita, Akihiro Homma, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Tomohiko Kakizaki, Takayoshi Suzuki, Satoshi Fukuda
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 273, 11, 3987, 3992, Nov. 2016, [Peer-reviewed]
    English, Scientific journal
  • Effectiveness of superselective intra-arterial chemoradiotherapy targeting retropharyngeal lymph node metastasis
    Takayoshi Suzuki, Tomohiro Sakashita, Akihiro Homma, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Daisuke Yoshida, Noriyuki Fujima, Rikiya Onimaru, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Fumiyuki Suzuki, Satoshi Fukuda
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 273, 10, 3331, 3336, Oct. 2016, [Peer-reviewed]
    English, Scientific journal
  • 唾液腺導管癌における免疫組織化学的発現解析 多施設共同による152症例の検討
    加納 里志, 高瀬 聡一郎, 多田 雄一郎, 川北 大介, 塚原 清彰, 清水 顕, 今西 順久, 小澤 宏之, 大上 研二, 佐藤 雄一郎, 佐藤 由紀子, 志村 智隆, 花澤 豊行, 長村 義之, 長尾 俊孝
    日本癌治療学会学術集会抄録集, 54回, PS, 3, (一社)日本癌治療学会, Oct. 2016
    Japanese
  • The Outcomes of Surgery and Chemoradiotherapy for Temporal Bone Cancer
    Shinya Morita, Akihiro Homma, Yuji Nakamaru, Tomohiro Sakashita, Hiromitsu Hatakeyama, Satoshi Kano, Atsushi Fukuda, Satoshi Fukuda
    OTOLOGY & NEUROTOLOGY, 37, 8, 1174, 1182, Sep. 2016, [Peer-reviewed]
    English, Scientific journal
  • Kinesin family members KIF11 and KIF23 as potential therapeutic targets in malignant pleural mesothelioma
    Tatsuya Kato, Daiyoon Lee, Licun Wu, Priya Patel, Ahn Jin Young, Hironobu Wada, Hsin Pei Hu, Hideki Ujiie, Mitsuhito Kaji, Satoshi Kano, Shinichi Matsuge, Hiromitsu Domen, Kichizo Kaga, Yoshiro Matsui, Hiromi Kanno, Yutaka Hatanaka, Kanako C. Hatanaka, Yoshihiro Matsuno, Marc De Perrot, Kazuhiro Yasufuku
    International Journal of Oncology, 49, 2, 448, 456, Aug. 2016
    Scientific journal
  • 唾液腺導管癌のバイオマーカー発現の包括的解明
    増淵 達夫, 多田 雄一郎, 高瀬 総一郎, 三浦 弘規, 伏見 千宙, 松木 崇, 川北 大介, 塚原 清彰, 加納 里志, 小澤 宏之, 大上 研二
    国際医療福祉大学学会誌, 21, 抄録号, 82, 82, 国際医療福祉大学学会, Aug. 2016
    Japanese
  • A Retrospective Study of G-Tube Use in Japanese Patients Treated with Concurrent Chemoradiotherapy for Hypopharyngeal Cancer
    Akihiro Homma, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Satoshi Kano, Tomohiro Sakashita, Rinnosuke Kuramoto, Yuji Nakamaru, Rikiya Onimaru, Kazuhiko Tsuchiya, Daisuke Yoshida, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
    PLOS ONE, 11, 8, e0161734, Aug. 2016, [Peer-reviewed]
    English, Scientific journal
  • Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients
    Kuninori Otsuka, Yorihisa Imanishi, Yuichiro Tada, Daisuke Kawakita, Satoshi Kano, Kiyoaki Tsukahara, Akira Shimizu, Hiroyuki Ozawa, Kenji Okami, Akihiro Sakai, Yuichiro Sato, Yushi Ueki, Yukiko Sato, Toyoyuki Hanazawa, Hideaki Chazono, Kaoru Ogawa, Toshitaka Nagao
    ANNALS OF SURGICAL ONCOLOGY, 23, 6, 2038, 2045, Jun. 2016, [Peer-reviewed]
    English, Scientific journal
  • 中咽頭扁平上皮癌に対する化学放射線療法施行症例の臨床的検討               
    水町 貴諭, 坂下 智博, 加納 里志, 畠山 博充, 本間 明宏, 土屋 和彦, 安田 耕一, 鬼丸 力也, 白土 博樹, 福田 諭
    頭頸部癌, 42, 2, 181, 181, (一社)日本頭頸部癌学会, May 2016
    Japanese
  • 化学放射線治療を行った頭頸部扁平上皮癌患者における治療前血中炎症細胞と予後に関する検討               
    加納 里志, 本間 明宏, 畠山 博充, 水町 貴諭, 坂下 智博, 福田 諭
    頭頸部癌, 42, 2, 183, 183, (一社)日本頭頸部癌学会, May 2016
    Japanese
  • 下咽頭癌に対する化学放射線療法後の嚥下障害 欧米の報告との比較               
    本間 明宏, 畠山 博充, 水町 貴諭, 加納 里志, 坂下 智博, 鬼丸 力也, 土屋 和彦, 安田 耕一, 白土 博樹, 福田 諭
    頭頸部癌, 42, 2, 214, 214, (一社)日本頭頸部癌学会, May 2016
    Japanese
  • 頭頸部癌における免疫チェックポイント分子と増殖・刺激因子シグナル伝達経路               
    畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 本間 明宏, 福田 諭
    頭頸部癌, 42, 2, 220, 220, (一社)日本頭頸部癌学会, May 2016
    Japanese
  • 唾液腺導管癌における標的遺伝子変異と免疫組織化学的発現の検討 その臨床病理学的因子との関連               
    志村 智隆, 多田 雄一郎, 川北 大介, 塚原 清彰, 加納 里志, 清水 顕, 高瀬 聡一郎, 今西 順久, 小澤 宏之, 大上 研二, 佐藤 雄一郎, 長尾 俊孝
    頭頸部癌, 42, 2, 174, 174, (一社)日本頭頸部癌学会, May 2016
    Japanese
  • 根治手術を施行した唾液腺導管癌における術前採血マーカーの予後への影響               
    別府 慎太郎, 多田 雄一郎, 川北 大介, 塚原 清彰, 加納 里志, 清水 顕, 今西 順久, 小澤 宏之, 大上 研二, 佐藤 雄一郎, 花澤 豊行, 長尾 俊孝
    頭頸部癌, 42, 2, 174, 174, (一社)日本頭頸部癌学会, May 2016
    Japanese
  • 喉頭腫瘍におけるHPV感染の検討               
    水町 貴諭, 中薗 彬, 坂下 智博, 加納 里志, 畠山 博充, 本間 明宏, 福田 諭
    日本気管食道科学会会報, 67, 2, s61, s61, (NPO)日本気管食道科学会, Apr. 2016
    Japanese
  • 中咽頭癌に合併し多発骨転移との鑑別が困難であった急性リンパ性白血病の一例               
    渡邊 史郎, 真鍋 治, 平田 健司, 菊地 恒矢, 牧野 俊一, 豊永 拓哉, 小林 健太郎, 内山 裕子, 志賀 哲, 加納 里志, 玉木 長良
    核医学, 53, 1, 507, 507, (一社)日本核医学会, Feb. 2016
    Japanese
  • Clinical outcomes of weekly cisplatin chemoradiotherapy for patients with pyriform sinus cancer
    Tomohiro Sakashita, Akihiro Homma, Hiromitsu Hatakeyama, Jun Furusawa, Satoshi Kano, Takatsugu Mizumachi, Satoshi Iizuka, Rikiya Onimaru, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 20, 6, 1081, 1085, Dec. 2015, [Peer-reviewed]
    English, Scientific journal
  • Indications for superselective intra-arterial cisplatin infusion and concomitant radiotherapy in cases of hypopharyngeal cancer
    Jun Furusawa, Akihiro Homma, Rikiya Onimaru, Tomohiro Sakashita, Daisuke Yoshida, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Satoshi Kano, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
    AURIS NASUS LARYNX, 42, 6, 443, 448, Dec. 2015, [Peer-reviewed]
    English, Scientific journal
  • Early and long-term morbidity after minimally invasive total laryngo-pharyngo-esophagectomy with gastric pull-up reconstruction via thoracoscopy, laparoscopy and cervical incision
    Akihiro Homma, Yuji Nakamaru, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Satoshi Kano, Jun Furusawa, Tomohiro Sakashita, Toshiaki Shichinohe, Yuma Ebihara, Satoshi Hirano, Hiroshi Furukawa, Toshihiko Hayashi, Yuhei Yamamoto, Satoshi Fukuda
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 272, 11, 3551, 3556, Nov. 2015, [Peer-reviewed]
    English, Scientific journal
  • 唾液腺導管癌における標的遺伝子変異と免疫組織化学的発現の検討 その臨床病理学的因子との関連
    志村 智隆, 多田 雄一郎, 川北 大介, 塚原 清彰, 加納 里志, 清水 顕, 今西 順久, 小澤 宏之, 大上 研二, 佐藤 雄一郎, 長尾 俊孝
    日本唾液腺学会誌, 56, 25, 25, 日本唾液腺学会, Nov. 2015
    Japanese
  • 唾液腺導管癌におけるHER2下流シグナルの解析               
    加納 里志, 本間 明宏, 畠山 博充, 水町 貴諭, 坂下 智博, 鈴木 崇祥, 福田 諭
    日本唾液腺学会誌, 56, 34, 34, 日本唾液腺学会, Nov. 2015
    Japanese
  • 唾液腺導管癌の臨床成績と予後因子 多施設共同による141例の検討
    大塚 邦憲, 今西 順久, 多田 雄一郎, 川北 大介, 花澤 豊行, 茶薗 英明, 加納 里志, 清水 顕, 塚原 清彰, 大上 研二, 酒井 昭博, 佐藤 雄一郎, 植木 雄志, 佐藤 由紀子, 小澤 宏之, 小川 郁, 長尾 俊孝
    日本唾液腺学会誌, 56, 35, 35, 日本唾液腺学会, Nov. 2015
    Japanese
  • Management for squamous cell carcinoma of the nasal cavity and ethmoid sinus: A single institution experience
    Akihiro Homma, Yuji Nakamaru, Tomohiro Sakashita, Rikiya Onimaru, Shunsuke Terasaka, Kazuhiko Tsuchiya, Daisuke Yoshida, Koichi Yasuda, Hiromitsu Hatakeyama, Jun Furusawa, Takatsugu Mizumachi, Satoshi Kano, Hiroki Shirato, Satoshi Fukuda
    AURIS NASUS LARYNX, 42, 5, 377, 381, Oct. 2015, [Peer-reviewed]
    English, Scientific journal
  • 耳下腺原発唾液腺導管癌の検討
    蠣崎 文彦, 加納 里志, 折舘 伸彦, 本間 明宏, 鈴木 清護, 畠山 博充, 水町 貴諭, 坂下 智博, 福田 諭
    耳鼻咽喉科展望, 58, 補冊1, 12, 13, 耳鼻咽喉科展望会, Sep. 2015
    Japanese
  • 北海道大学における原発不明頸部リンパ節転移癌の解析
    加納 里志, 本間 明宏, 畠山 博充, 水町 貴諭, 古沢 純, 坂下 智博, 福田 諭
    耳鼻咽喉科展望, 58, 補冊1, 52, 53, 耳鼻咽喉科展望会, Sep. 2015
    Japanese
  • 頭頸部・口腔がん治療の未来を展望する 頭頸部癌ゲノム・プロテオーム解析からの個別化分子標的治療へ               
    畠山 博充, 本間 明宏, 坂下 智博, 水町 貴諭, 加納 里志, 蠣崎 文彦, 福田 諭
    日本癌治療学会誌, 50, 3, 323, 323, (一社)日本癌治療学会, Sep. 2015
    Japanese
  • 頭頸部扁平上皮癌患者における治療前血中炎症細胞と予後に関する検討               
    加納 里志, 本間 明宏, 畠山 博充, 水町 貴諭, 坂下 智博, 福田 諭
    日本癌治療学会誌, 50, 3, 2350, 2350, (一社)日本癌治療学会, Sep. 2015
    Japanese
  • 耳鼻咽喉科領域疾患に関与するユビキチン化タンパク質修飾
    鈴木 正宣, 渡部 昌, 中丸 裕爾, 高木 大, 加納 里志, 本間 あや, 畠山 鎮次, 福田 諭
    耳鼻咽喉科免疫アレルギー, 33, 3, 185, 192, 日本耳鼻咽喉科免疫アレルギー学会, Sep. 2015
    Japanese
  • 多施設共同による唾液腺導管癌の臨床的、病理組織学的、免疫組織化学的研究               
    多田 雄一郎, 加納 里志, 清水 顕, 塚原 清彰, 今西 順久, 大上 研二, 佐藤 雄一郎, 花澤 豊行, 佐藤 由紀子, 三浦 弘規, 増淵 達夫, 伏見 千宙, 長尾 俊孝
    国際医療福祉大学学会誌, 20, 抄録号, 57, 57, 国際医療福祉大学学会, Aug. 2015
    Japanese
  • Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: A single-institution retrospective study in Japan
    Tomohiro Sakashita, Akihiro Homma, Hiromitsu Hatakeyama, Jun Furusawa, Satoshi Kano, Takatsugu Mizumachi, Satoshi Iizuka, Rikiya Onimaru, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
    ACTA OTO-LARYNGOLOGICA, 135, 8, 853, 858, Aug. 2015, [Peer-reviewed]
    English, Scientific journal
  • Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma
    Takatsugu Mizumachi, Akihiro Homma, Tomohiko Kakizaki, Tomohiro Sakashita, Satoshi Kano, Hiromitsu Hatakeyama, Kazuhiko Tsuchiya, Koichi Yasuda, Rikiya Onimaru, Hiroki Shirato, Jun Taguchi, Yasushi Shimizu, Ichiro Kinoshita, Hirotoshi Akita, Satoshi Fukuda
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 20, 3, 431, 437, Jun. 2015, [Peer-reviewed]
    English, Scientific journal
  • 唾液腺導管癌における免疫組織化学的バイオマーカーの予後因子としての意義 多施設共同研究による検討               
    高瀬 聡一郎, 多田 雄一郎, 川北 大介, 加納 里志, 清水 顕, 小澤 宏之, 塚原 清彰, 大上 研二, 佐藤 雄一郎, 長尾 俊孝
    頭頸部癌, 41, 2, 193, 193, (一社)日本頭頸部癌学会, May 2015
    Japanese
  • 唾液腺癌を対象としたHER2タンパク過剰発現および遺伝子増幅検査法の臨床的バリデーションに関する検討               
    加納 里志, 畑中 豊, 松野 吉宏, 本間 明宏, 秋田 弘俊, 福田 諭
    頭頸部癌, 41, 2, 257, 257, (一社)日本頭頸部癌学会, May 2015
    Japanese
  • 喉頭癌T1症例の臨床的検討
    水町 貴諭, 中薗 彬, 溝口 兼司, 坂下 智博, 加納 里志, 畠山 博充, 本間 明宏, 福田 諭
    日本耳鼻咽喉科学会会報, 118, 4, 504, 504, (一社)日本耳鼻咽喉科学会, Apr. 2015
    Japanese
  • 多施設共同による唾液腺導管癌の後方視的観察研究 生存率および予後因子に関する検討
    大塚 邦憲, 多田 雄一郎, 川北 大介, 花澤 豊行, 加納 里志, 清水 顕, 今西 順久, 小澤 宏之, 塚原 清彰, 大上 研二, 佐藤 雄一郎, 長尾 俊孝, 小川 郁
    日本耳鼻咽喉科学会会報, 118, 4, 526, 526, (一社)日本耳鼻咽喉科学会, Apr. 2015
    Japanese
  • 頭頸部癌化学放射線療法におけるEPA高配合栄養機能食品(プロシュア)の有用性の検討               
    水町 貴諭, 中薗 彬, 坂下 智博, 加納 里志, 畠山 博充, 本間 明宏, 福田 諭
    日本気管食道科学会会報, 66, 2, s20, s20, (NPO)日本気管食道科学会, Apr. 2015
    Japanese
  • 喉頭に生じたInflammatory Myofibroblastic Tumorの一例               
    横川 泰三, 加納 里志, 溝口 兼司, 畠山 博充, 本間 明宏, 福田 諭
    日本気管食道科学会会報, 66, 2, s64, s64, (NPO)日本気管食道科学会, Apr. 2015
    Japanese
  • Lymph node metastasis in the suprasternal space from thyroid papillary cancer
    Homma Akihiro, Hatakeyama Hiromitsu, Mizumachi Takatsugu, Furusawa Jun, Kano Satoshi, Sakashita Tomohiro, Fukuda Satoshi
    International Cancer Conference Journal, 4, 1, 57, 60, Springer, Jan. 2015
    English, The suprasternal space is a narrow space between the superficial and deep layers of the investing layers of the deep cervical fascia above the manubrium of the sternum. The suprasternal space has been paid littleattention as a space with the potential for lymph nodemetastasis from both thyroid cancer and head and neckcancer. We experienced 2 patients who were found to have a lymph node in the suprasternal space preoperatively. Both of them had well-differentiated thyroid papillary carcinomas and level III and IV lymph node metastases as well as metastasis in the suprasternal space. We have not previously dissected the suprasternal space prophylactically in other patients with thyroid papillary cancer, but no patient has developed metastasis in this space to date. Thesuprasternal space is not usually dissected in atients with thyroid cancer. However, suprasternal space metastasis has been reported to occur occasionally in patients with lymph node metastases in levels III and IV. We consider that dissection of the suprasternal space, which is not routinely performed, should be done when preoperative examination suggests lymph node metastasis in the suprasternal space as dissection of this space is less invasive, easy to achieve, and is not time consuming. Greater attention should be paidto the suprasternal space as an area with the otential for lymph node metastasis from thyroid cancer.
  • The efficacy of superselective intra-arterial infusion with concomitant radiotherapy for adenoid cystic carcinoma of the head and neck
    Akihiro Homma, Tomohiro Sakashita, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Yuji Nakamaru, Daisuke Yoshida, Rikiya Onimaru, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
    ACTA OTO-LARYNGOLOGICA, 135, 9, 950, 954, 2015, [Peer-reviewed]
    English, Scientific journal
  • Epithelial-mesenchymal transition in human papillomavirus-positive and -negative oropharyngeal squamous cell carcinoma
    Hiromitsu Hatakeyama, Takatsugu Mizumachi, Tomohiro Sakashita, Satoshi Kano, Akihiro Homma, Satoshi Fukuda
    ONCOLOGY REPORTS, 32, 6, 2673, 2679, Dec. 2014, [Peer-reviewed]
    English, Scientific journal
  • A clinical study of cases diagnosed as being oropharyngeal carcinoma after cervical mass extirpation/biopsy
    Takatsugu Mizumachi, Satoshi Kano, Tomohiro Sakashita, Hiromitsu Hatakeyama, Akihiro Homma, Satoshi Fukuda
    Journal of Otolaryngology of Japan, 117, 12, 1463, 1470, Oto-Rhino-Laryngological Society of Japan Inc., 01 Dec. 2014, [Peer-reviewed]
    Japanese, Scientific journal
  • Effect of local extension sites on survival in locally advanced maxillary sinus cancer
    Satoshi Kano, Ryuichi Hayashi, Akihiro Homma, Kazuto Matsuura, Kengo Kato, Kazuyoshi Kawabata, Nobuya Monden, Yasuhisa Hasegawa, Tetsuro Onitsuka, Yasushi Fujimoto, Shigemichi Iwae, Kenji Okami, Takashi Matsuzuka, Kunitoshi Yoshino, Masato Fujii
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 36, 11, 1567, 1572, Nov. 2014, [Peer-reviewed]
    English, Scientific journal
  • 唾液腺導管癌における免疫組織化学的バイオマーカーの予後因子としての意義 多施設共同研究による147例の検討
    高瀬 聡一郎, 多田 雄一郎, 川北 大介, 加納 里志, 清水 顕, 小澤 宏之, 塚原 清彰, 大上 研二, 佐藤 雄一郎, 長尾 俊孝
    日本唾液腺学会誌, 55, 26, 26, 日本唾液腺学会, Nov. 2014
    Japanese
  • Analysis of human papillomavirus in metastatic lymph nodes from unknown primary head and neck carcinomas
    Satoshi Kano, Akihiro Homma, Seigo Suzuki, Hiromitsu Hatakeyama, Jyun Furusawa, Takatsugu Mizumachi, Tomohiro Sakashita, Nobuhiko Oridate, Satoshi Fukuda
    Japanese Journal of Head and Neck Cancer, 40, 3, 344, 348, Japan Society for Head and Neck Cancer, 31 Oct. 2014
    Japanese, Scientific journal
  • The incidence of late neck recurrence in N0 maxillary sinus squamous cell carcinomas after superselective intra-arterial chemoradiotherapy without prophylactic neck irradiation
    Tomohiro Sakashita, Akihiro Homma, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Jun Furusawa, Daisuke Yoshida, Noriyuki Fujima, Rikiya Onimaru, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 271, 10, 2767, 2770, Oct. 2014, [Peer-reviewed]
    English, Scientific journal
  • 術前細胞診にて悪性が確定しなかった甲状腺結節におけるエコー陽性所見の数と悪性リスクの関係について               
    坂下 智博, 本間 明宏, 畠山 博充, 水町 貴諭, 加納 里志, 古沢 純, 飯塚 さとし, 干野 季美子, 畑中 佳奈子, 福田 諭
    日本内分泌・甲状腺外科学会雑誌, 31, Suppl.2, S234, S234, 日本内分泌外科学会・日本甲状腺外科学会, Sep. 2014
    Japanese
  • 再発転移唾液腺導管癌に対する新しい個別化治療戦略の構築               
    多田 雄一郎, 三浦 弘規, 増淵 達夫, 伏見 千宙, 長村 義之, 長尾 俊孝, 大上 研二, 花澤 豊行, 佐藤 雄一郎, 今西 順久, 清水 顕, 加納 里志
    国際医療福祉大学学会誌, 19, 抄録号, 71, 71, 国際医療福祉大学学会, Aug. 2014
    Japanese
  • 多施設共同による多形腺腫由来癌の病態組織型と臨床像の比較検討研究               
    伏見 千宙, 多田 雄一郎, 三浦 弘規, 増淵 達夫, 長村 義之, 長尾 俊孝, 大上 研二, 花澤 豊行, 佐藤 雄一郎, 今西 順久, 清水 顕, 加納 里志
    国際医療福祉大学学会誌, 19, 抄録号, 74, 74, 国際医療福祉大学学会, Aug. 2014
    Japanese
  • 癌予測に有用なエコー所見に関する検討 術前細胞診で癌が確定しなかった症例を対象に
    坂下 智博, 本間 明宏, 畠山 博充, 水町 貴諭, 加納 里志, 古沢 純, 飯塚 さとし, 畑中 佳奈子, 福田 諭
    日本内分泌・甲状腺外科学会雑誌, 31, 2, 130, 133, 日本内分泌外科学会・日本甲状腺外科学会, Jun. 2014
    Japanese
  • 局所進行頭頸部癌に対する導入化学療法後のweekly CDDP併用化学放射線療法の安全性と有用性の検討               
    水町 貴諭, 本間 明宏, 坂下 智博, 加納 里志, 畠山 博充, 清水 康, 秋田 弘俊, 土屋 和彦, 安田 耕一, 鬼丸 力也, 白土 博樹, 福田 諭
    頭頸部癌, 40, 2, 177, 177, (一社)日本頭頸部癌学会, May 2014
    Japanese
  • セツキシマブ投与におけるEGFRリガンド発現変化と効果               
    畠山 博充, 坂下 智博, 水町 貴諭, 加納 里志, 本間 明宏, 福田 諭, 古沢 純
    頭頸部癌, 40, 2, 187, 187, (一社)日本頭頸部癌学会, May 2014
    Japanese
  • 唾液腺導管癌におけるHER2下流シグナルの解析               
    加納 里志, 本間 明宏, 畠山 博充, 古沢 純, 水町 貴諭, 坂下 智博, 福田 諭
    頭頸部癌, 40, 2, 191, 191, (一社)日本頭頸部癌学会, May 2014
    Japanese
  • 下咽頭癌に対するRADPLATとweekly CDDP併用化学放射線治療の比較検討               
    古沢 純, 本間 明宏, 坂下 智博, 畠山 博充, 加納 里志, 水町 貴諭, 土屋 和彦, 吉田 大介, 安田 耕一, 白土 博樹, 福田 諭
    頭頸部癌, 40, 2, 198, 198, (一社)日本頭頸部癌学会, May 2014
    Japanese
  • Salvage operations for patients with persistent or recurrent cancer of the maxillary sinus after superselective intra-arterial infusion of cisplatin with concurrent radiotherapy
    Tomohiro Sakashita, Akihiro Homma, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Jun Furusawa, Daisuke Yoshida, Noriyuki Fujima, Rikiya Onimaru, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Fumiyuki Suzuki, Satoshi Fukuda
    BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 52, 4, 323, 328, Apr. 2014, [Peer-reviewed]
    English, Scientific journal
  • 多施設共同による唾液腺導管癌の後方視的観察研究 救済治療の課題と今後の展望
    加納 里志, 多田 雄一郎, 花澤 豊行, 今西 順久, 清水 顕, 大上 研二, 佐藤 雄一郎, 長尾 俊孝
    日本耳鼻咽喉科学会会報, 117, 4, 571, 571, (一社)日本耳鼻咽喉科学会, Apr. 2014
    Japanese
  • Burns spaceに転移を来した甲状腺乳頭癌の2例               
    本間 明宏, 畠山 博充, 水町 貴諭, 古沢 純, 加納 里志, 坂下 智博, 福田 諭
    日本耳鼻咽喉科学会会報, 117, 4, 605, 605, (一社)日本耳鼻咽喉科学会, Apr. 2014
    Japanese
  • Secondary voice prosthesis placement using a curved rigid esophagoscope               
    Takatsugu Mizumachi, Akihiro Homma, Tomohiro Sakashita, Satoshi Kano, Hiromitsu Hatakeyama, Seigo Suzuki, Nobuhiko Oridate, Satoshi Fukuda
    Oto-Rhino-Laryngology Tokyo, 56, 5, 334, 337, 2014
    Japanese, Scientific journal
  • Salvage operations for patients with persistent or recurrent cancer of the maxillary sinus after superselective intra-arterial infusion of cisplatin with concurrent radiotherapy
    Sakashita T, Homma A, Hatakeyama H, Kano S, Mizumachi T, Furusawa J, Yoshida D, Fujima N, Onimaru R, Tsuchiya K, Yasuda K, Shirato H, Suzuki F, Fukuda S
    Br J Oral Maxillofac Surg, 52, 4, 323, 8, 2014, [Peer-reviewed]
  • The potential diagnostic role of the number of ultrasonographic characteristics for patients with thyroid nodules evaluated as bethesda I-v.
    Tomohiro Sakashita, Akihiro Homma, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Satoshi Kano, Jun Furusawa, Satoshi Iizuka, Kimiko Hoshino, Kanako C Hatanaka, Koji Oba, Satoshi Fukuda
    Frontiers in oncology, 4, 261, 261, 2014, [Peer-reviewed], [International Magazine]
    English, Scientific journal, OBJECTIVE: Fine-needle aspiration cytology (FNAC) is considered to be the most reliable method of examination for thyroid nodules. However, when thyroid nodules are evaluated as Bethesda I-V, the role of ultrasonography is considered to be enhanced. We investigated the association between a number of ultrasonographic (US) characteristics and the risk of thyroid malignancy, and assessed the optimal compromise on the number of US characteristics for predicting thyroid malignancy. METHODS: Seventy-three patients, whose thyroid nodules were evaluated as Bethesda I-V by FNAC prior to surgery, were treated surgically. A number of US characteristics, such as microcalcification, irregular margins, hypoechogenicity, a taller-than-wide shape, and the absence of halo sign, were assessed before surgery. The optimal compromise on the number of US characteristics was analyzed using a receiver operating characteristics (ROC) curve. The area under the ROC curve (AUC) represents the overall discriminatory ability of a test. RESULTS: The risk of malignancy was 11.8% in patients without any US characteristics, 44.4% in those with one characteristic, 61.5% in those with two characteristics, 75% in those with three characteristics, 90% in those with four characteristics, and 100% in those with five characteristics. The AUC was favorable (0.81599). At least two US characteristics were revealed to be the optimal compromise on the number of US characteristics based on the ROC curve. CONCLUSION: We proved the role of the number of US characteristics in predicting thyroid malignancy. It was thought that a surgical approach should be considered for patients with at least two US characteristics.
  • Concomitant weekly cisplatin and radiotherapy for oropharyngeal squamous cell carcinoma
    Takatsugu Mizumachi, Akihiro Homma, Tomohiro Sakashita, Satoshi Kano, Hiromitsu Hatakeyama, Kazuhiko Tsuchiya, Kouichi Yasuda, Rikiya Onimaru, Hiroki Shirato, Satoshi Fukuda
    Japanese Journal of Head and Neck Cancer, 40, 1, 66, 70, (一社)日本頭頸部癌学会, 2014
    Japanese, Scientific journal
  • がん免疫療法
    西村 剛志, 加納 里志, 佐久間 直子, 佐野 大佑, 小松 正規, 折舘 伸彦
    耳鼻咽喉科免疫アレルギー, 31, 4, 237, 246, 日本耳鼻咽喉科免疫アレルギー学会, Dec. 2013
    Japanese
  • Combined analysis of HPV status and pl6 expression in patients with oropharyngeal squamous cell carcinoma
    Takatsugu Mizumachi, Hiromitsu Hatakeyama, Satoshi Kano, Tomohiro Sakashita, Seigo Suzuki, Akihiro Homma, Nobuhiko Oridate, Satoshi Fukuda
    Japanese Journal of Head and Neck Cancer, 39, 3, 334, 338, Japan Society for Head and Neck Cancer, 28 Oct. 2013
    Japanese, Scientific journal
  • Salvage surgery for recurrent oropharyngeal cancer after chemoradiotherapy
    Satoshi Kano, Akihiro Homma, Ryuichi Hayashi, Kazuyoshi Kawabata, Kunitoshi Yoshino, Shigemichi Iwae, Yasuhisa Hasegawa, Kenichi Nibu, Takakuni Kato, Kiyoto Shiga, Kazuto Matsuura, Nobuya Monden, Masato Fujii
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 18, 5, 817, 823, Oct. 2013, [Peer-reviewed]
    English, Scientific journal
  • Improved survival of Japanese patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma
    Takatsugu Mizumachi, Satoshi Kano, Tomohiro Sakashita, Hiromitsu Hatakeyama, Seigo Suzuki, Akihiro Homma, Nobuhiko Oridate, Satoshi Fukuda
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 18, 5, 824, 828, Oct. 2013, [Peer-reviewed]
    English, Scientific journal
  • 当科における二期的気管食道瘻形成術 彎曲型食道直達鏡の試作
    水町 貴諭, 本間 明宏, 坂下 智博, 加納 里志, 畠山 博充, 鈴木 清護, 折舘 伸彦, 福田 諭
    耳鼻咽喉科展望, 56, 5, 334, 337, 耳鼻咽喉科展望会, Oct. 2013
    Japanese
  • Prognostic value of cyclin D1 expression in tumor-free surgical margins in head and neck squamous cell carcinomas
    Tomohiro Sakashita, Akihiro Homma, Seigo Suzuki, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Nobuhiko Oridate, Satoshi Fukuda
    ACTA OTO-LARYNGOLOGICA, 133, 9, 984, 991, Sep. 2013, [Peer-reviewed]
    English, Scientific journal
  • 中咽頭癌に対する放射線化学療法の検討 多施設による後方視的観察研究               
    加納 里志, 本間 明宏, 林 隆一, 川端 一喜, 吉野 邦俊, 岩江 信法, 長谷川 泰久, 丹生 健一, 加藤 孝邦, 志賀 清人, 松浦 一登, 門田 伸也, 藤井 正人
    日本癌治療学会誌, 48, 3, 1248, 1248, (一社)日本癌治療学会, Sep. 2013
    Japanese
  • 多施設共同による唾液腺導管癌の後方視的観察研究               
    多田 雄一郎, 鎌田 信悦, 長村 義之, 三浦 弘規, 増淵 達夫, 伏見 千宙, 丸屋 信一郎, 長尾 俊孝, 大上 研二, 花澤 豊行, 佐藤 雄一郎, 今西 順久, 清水 顕, 加納 里志
    国際医療福祉大学学会誌, 18, 抄録号, 77, 77, 国際医療福祉大学学会, Aug. 2013
    Japanese
  • 中咽頭癌症例におけるHPV感染と転移リンパ節の検討
    水町 貴諭, 加納 里志, 本間 明宏, 折舘 伸彦, 福田 諭
    口腔・咽頭科, 26, 2, 161, 166, 日本口腔・咽頭科学会, Jun. 2013
    Japanese
  • 北海道大学病院における鼻副鼻腔癌の治療成績 上顎洞原発扁平上皮癌を中心に
    本間 明宏, 折舘 伸彦, 鈴木 清護, 畠山 博充, 加納 里志, 古沢 純, 水町 貴諭, 坂下 智博, 鈴木 章之, 瀧 重成, 稲村 直哉, 福田 諭
    耳鼻咽喉科展望, 56, 補冊2, 130, 131, 耳鼻咽喉科展望会, May 2013
    Japanese
  • 北海道大学病院における上咽頭癌の治療 10年間(2000〜2010)のまとめ
    土屋 和彦, 安田 耕一, 西川 由記子, 木下 留美子, 鬼丸 力也, 原田 慶一, 井上 哲也, 加藤 徳雄, 清水 伸一, 白土 博樹, 西岡 健, 鈴木 恵士郎, 田口 大志, 長谷川 雅一, 折舘 伸彦, 本間 明宏, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 福田 諭, 竹内 啓, 田口 純
    耳鼻咽喉科展望, 56, 補冊2, 174, 175, 耳鼻咽喉科展望会, May 2013
    Japanese
  • 化学放射線療法の現状と役割 動注化学療法による化学放射線療法 上顎洞癌を中心に               
    本間 明宏, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 吉田 大介, 鬼丸 力也, 土屋 和彦, 安田 耕一, 白土 博樹, 藤井 正人, 福田 諭
    頭頸部癌, 39, 2, 134, 134, (一社)日本頭頸部癌学会, May 2013
    Japanese
  • 多施設共同による唾液腺導管癌の後方視的観察研究 導管癌および多形腺腫由来導管癌の臨床像               
    清水 顕, 伊藤 博之, 高瀬 聡一郎, 鈴木 衞, 長尾 俊孝, 今西 順久, 大塚 邦憲, 多田 雄一郎, 加納 里志, 花澤 豊行, 茶園 英明
    頭頸部癌, 39, 2, 137, 137, (一社)日本頭頸部癌学会, May 2013
    Japanese
  • HPV陽性中咽頭癌に対するweekly CDDP併用化学放射線治療の臨床的検討               
    水町 貴諭, 本間 明宏, 坂下 智博, 加納 里志, 畠山 博充, 福田 諭
    頭頸部癌, 39, 2, 139, 139, (一社)日本頭頸部癌学会, May 2013
    Japanese
  • HPV陽・陰性中咽頭扁平上皮癌の上皮間葉移行における特性               
    畠山 博充, 水町 貴諭, 坂下 智博, 加納 里志, 本間 明宏, 福田 諭
    頭頸部癌, 39, 2, 188, 188, (一社)日本頭頸部癌学会, May 2013
    Japanese
  • 上顎洞原発扁平上皮癌T4症例の進展部位別予後解析 多施設後ろ向き観察研究               
    加納 里志, 林 隆一, 本間 明宏, 松浦 一登, 加藤 健吾, 川端 一喜, 松塚 崇, 大上 研二, 岩江 信法, 藤井 正人
    頭頸部癌, 39, 2, 201, 201, (一社)日本頭頸部癌学会, May 2013
    Japanese
  • 上顎洞扁平上皮癌に対する超選択的動注併用放射線治療後の救済手術に関する検討               
    坂下 智博, 本間 明宏, 鈴木 章之, 畠山 博充, 加納 里志, 水町 貴諭, 古沢 純, 福田 諭
    頭頸部癌, 39, 2, 202, 202, (一社)日本頭頸部癌学会, May 2013
    Japanese
  • 両側に生じたHPV陽性舌根癌症例               
    水町 貴諭, 坂下 智博, 加納 里志, 畠山 博充, 本間 明宏, 福田 諭
    頭頸部癌, 39, 2, 228, 228, (一社)日本頭頸部癌学会, May 2013
    Japanese
  • 甲状腺未分化癌・低分化癌症例における分化機構についての免疫組織学的検討               
    干野 季美子, 畠山 博充, 坂下 智博, 加納 里志, 水町 貴諭, 本間 明宏, 畑中 佳奈子, 福田 諭
    頭頸部癌, 39, 2, 244, 244, (一社)日本頭頸部癌学会, May 2013
    Japanese
  • Regional control after concomitant chemoradiotherapy without planned neck dissection in node-positive head and neck squamous cell carcinomas
    Tomohiro Sakashita, Akihiro Homma, Nobuhiko Oridate, Seigo Suzuki, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Rikiya Onimaru, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
    AURIS NASUS LARYNX, 40, 2, 211, 215, Apr. 2013, [Peer-reviewed]
    English, Scientific journal
  • 頭頸部癌化学放射線療法における小野寺栄養指数の意義               
    折舘 伸彦, 倉本 倫之介, 本間 明宏, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 蠣崎 文彦, 福田 諭
    日本気管食道科学会会報, 64, 2, s55, s55, (NPO)日本気管食道科学会, Apr. 2013
    Japanese
  • 当科における導入化学療法後の放射線化学療法例の検討               
    蠣崎 文彦, 本間 明宏, 折舘 伸彦, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 福田 諭
    日本耳鼻咽喉科学会会報, 116, 4, 524, 524, (一社)日本耳鼻咽喉科学会, Apr. 2013
    Japanese
  • 喉頭癌T3症例の治療成績の検討
    水町 貴諭, 折舘 伸彦, 本間 明宏, 坂下 智博, 加納 里志, 畠山 博充, 鈴木 清護, 福田 諭
    頭頸部外科, 22, 3, 317, 321, (NPO)日本頭頸部外科学会, Feb. 2013
    Japanese
  • Superselective intra-arterial cisplatin infusion and concomitant radiotherapy for maxillary sinus cancer
    Homma A, Sakashita T, Yoshida D, Onimaru R, Tsuchiya K, Suzuki F, Yasuda K, Hatakeyama H, Furusawa J, Mizumachi T, Kano S, Inamura N, Taki S, Shirato H, Fukuda S
    Br J Cancer, 109, 12, 2980, 6, Nature publishing group, 2013, [Peer-reviewed]
    English, Background: The purpose of this study was to evaluate the efficacy of superselective cisplatin infusion with concomitant radiotherapy (RADPLAT) for previously untreated patients with the squamous cell carcinoma of maxillary sinus (SCC-MS). Methods: Between 1999 and 2010, 54 patients were given superselective intra-arterial infusions of cisplatin (100-120mgm(-2) per week) with simultaneous intra-venous infusions of thiosulfate to neutralise cisplatin toxicity and conventional radiotherapy (65-70 Gy). Results: One patient (1.9%) was diagnosed with T2, 14 (25.9%) with T3, 27 (50%) with T4a, and 12 (22.2%) with T4b disease. Lymph-node involvement was present in 12 patients (22.2%). During the median follow-up period of 6.4 years, the 5-year local progression-free and overall survival rates were 65.8 and 67.9% for all patients, respectively. No patient died as a result of treatment toxicity or experienced a cerebrovascular accident. Osteonecrosis (n-5), brain necrosis (n-1), and ocular/ visual problems (n = 14) were observed as late adverse reactions. Conclusion: We have shown excellent overall survival and local progression-free rate in SCC-MS patients treated by RADPLAT with acceptable rates of acute and late toxicity. A multi-institutional trial is needed to prove that this strategy is a feasible and effective approach for the treatment of SCC-MS.
  • Matched-Pair Analysis in Patients with Advanced Oropharyngeal Cancer: Surgery versus Concurrent Chemoradiotherapy
    Satoshi Kano, Akihiro Homma, Ryuichi Hayashi, Kazuyoshi Kawabata, Kunitoshi Yoshino, Shigemichi Iwae, Yasuhisa Hasegawa, Kenichi Nibu, Takakuni Kato, Kiyoto Shiga, Kazuto Matsuura, Nobuya Monden, Masato Fujii
    ONCOLOGY, 84, 5, 290, 298, 2013, [Peer-reviewed]
    English, Scientific journal
  • The current status of treatment for oropharyngeal cancer in Japan - A multi-institutional retrospective observation study
    Akihiro Homma, Ryuichi Hayashi, Kazuyoshi Kawabata, Kunitoshi Yoshino, Shigemichi Iwae, Yasuhisa Hasegawa, Satoshi Kano, Kenichi Nibu, Takakuni Kato, Kiyoto Shiga, Kazuto Matsuura, Nobuya Monden, Masato Fujii
    Japanese Journal of Head and Neck Cancer, 39, 4, 449, 455, Japan Society for Head and Neck Cancer, 2013
    Japanese, Scientific journal
  • 切除可能T3、T4上顎洞扁平上皮癌における手術の位置付け 当院における治療戦略
    本間 明宏, 折舘 伸彦, 鈴木 清護, 鈴木 章之, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 吉田 大介, 鬼丸 力也, 土屋 和彦, 安田 耕一, 白土 博樹, 福田 諭
    耳鼻と臨床, 58, Suppl.1, S52, S56, 耳鼻と臨床会, Nov. 2012
    Japanese
  • 唾液腺導管癌の免疫組織化学・分子病理学的検討 多施設共同研究               
    増淵 達夫, 多田 雄一郎, 長村 義之, 丸屋 信一郎, 佐藤 由紀子, 加納 里志, 長尾 俊孝
    日本唾液腺学会誌, 53, 28, 28, 日本唾液腺学会, Nov. 2012
    Japanese
  • An analysis of sentinel lymph node distribution for ealry tongue cancer               
    Tomohiro Sakashita, Akihiro Homma, Nobuhiko Oridate, Seigo Suzuki, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Satoshi Fukuda
    Oto-Rhino-Laryngology Tokyo, 55, 5, 100, 104, Oct. 2012
    Japanese, Scientific journal
  • Combined modality therapy for laryngeal cancer with superselective intra-arterial cisplatin infusion and concomitant radiotherapy
    Shigenari Taki, Akihiro Homma, Fumiyuki Suzuki, Nobuhiko Oridate, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Satoshi Kano, Jun Furusawa, Tomohiro Sakashita, Naoya Inamura, Daisuke Yoshida, Rikiya Onimaru, Hiroki Shirato, Satoshi Fukuda
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 17, 5, 441, 446, Oct. 2012, [Peer-reviewed]
    English, Scientific journal
  • Platinum concentration in sentinel lymph nodes after preoperative intra-arterial cisplatin chemotherapy targeting primary tongue cancer
    Tomohiro Sakashita, Akihiro Homma, Nobuhiko Oridate, Seigo Suzuki, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Daisuke Yoshida, Noriyuki Fujima, Satoshi Fukuda
    ACTA OTO-LARYNGOLOGICA, 132, 10, 1121, 1125, Oct. 2012, [Peer-reviewed]
    English, Scientific journal
  • 頭頸部癌化学放射線療法における経管栄養の役割に関する検討               
    倉本 倫之介, 折舘 伸彦, 本間 明宏, 及川 敬太, 藤田 香, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 福田 諭
    嚥下医学, 1, 2, 359, 363, 日本嚥下医学会, Oct. 2012
    Japanese
  • 早期舌癌におけるセンチネルリンパ節の領域分布に関する検討
    坂下 智博, 本間 明宏, 折舘 伸彦, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 福田 諭
    耳鼻咽喉科展望, 55, 5, 364, 368, 耳鼻咽喉科展望会, Oct. 2012
    Japanese
  • 照射後の異時重複下咽頭癌に対するESD後に反復感染をきたし喉頭全摘に至った1症例
    加納 里志, 折舘 伸彦, 福田 諭
    日本気管食道科学会会報, 63, 4, 331, 336, (NPO)日本気管食道科学会, Aug. 2012
    Japanese
  • HPV陽性中咽頭癌の転移リンパ節の臨床像               
    水町 貴諭, 加納 里志, 本間 明宏, 折舘 伸彦, 福田 諭
    口腔・咽頭科, 25, 3, 295, 295, 日本口腔・咽頭科学会, Aug. 2012
    Japanese
  • 舌根癌における放射線同時併用超選択的動注化学療法
    加納 里志, 本間 明宏, 折舘 伸彦, 鈴木 章之, 畠山 博充, 水町 貴諭, 古沢 純, 坂下 智博, 吉田 大介, 鬼丸 力也, 白戸 博樹, 福田 諭
    北海道醫學雜誌 = Acta medica Hokkaidonensia, 87, 4, 208, 208, 01 Aug. 2012
    Japanese
  • PET-CT検査にてはじめて原因が特定しえた喉頭麻痺の2症例               
    折舘 伸彦, 溝口 兼司, 加納 里志, 本間 明宏, 福田 諭
    耳鼻咽喉科臨床 補冊, 補冊133, 110, 110, 耳鼻咽喉科臨床学会, Jul. 2012
    Japanese
  • Evaluation of nodal response after intra-arterial chemoradiation for node-positive head and neck cancer
    Tomohiro Sakashita, Akihiro Homma, Nobuhiko Oridate, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Satoshi Fukuda
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 269, 6, 1671, 1676, Jun. 2012, [Peer-reviewed]
    English, Scientific journal
  • 中咽頭扁平上皮癌症例におけるHPV感染とp16の発現に関する検討               
    水町 貴諭, 鈴木 清護, 畠山 博充, 加納 里志, 坂下 智博, 本間 明宏, 折舘 伸彦, 福田 諭
    頭頸部癌, 38, 2, 161, 161, (一社)日本頭頸部癌学会, May 2012
    Japanese
  • 原発不明頸部リンパ節転移におけるp16とヒト乳頭腫ウイルスの解析               
    加納 里志, 折舘 伸彦, 本間 明宏, 鈴木 清護, 畠山 博充, 水町 貴諭, 坂下 智博, 福田 諭
    頭頸部癌, 38, 2, 162, 162, (一社)日本頭頸部癌学会, May 2012
    Japanese
  • 頭頸部扁平上皮癌根治切除症例の切除断端における免疫組織学的予後因子の検討               
    坂下 智博, 折舘 伸彦, 本間 明宏, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 福田 諭
    頭頸部癌, 38, 2, 182, 182, (一社)日本頭頸部癌学会, May 2012
    Japanese
  • 中咽頭癌に対する治療の現状(第2報) 多施設による後ろ向き観察研究               
    林 隆一, 川端 一嘉, 吉野 邦俊, 岩江 信法, 長谷川 泰久, 加納 里志, 丹生 健一, 加藤 孝邦, 志賀 清人, 本間 明宏, 藤井 正人
    頭頸部癌, 38, 2, 205, 205, (一社)日本頭頸部癌学会, May 2012
    Japanese
  • 多施設共同による唾液腺導管癌の後方視的観察研究 免疫組織学的・分子病理学的検討               
    多田 雄一郎, 花澤 豊行, 今西 順久, 佐藤 雄一郎, 金澤 丈治, 福島 啓文, 清水 顕, 加納 里志, 矢島 陽子, 大上 研二, 長尾 俊孝
    頭頸部癌, 38, 2, 209, 209, (一社)日本頭頸部癌学会, May 2012
    Japanese
  • 多施設共同による唾液腺導管癌の後方視的観察研究 術前病理組織学的診断における検査法と診断率の現状               
    茶薗 英明, 多田 雄一郎, 今西 順久, 佐藤 雄一郎, 金澤 丈治, 福島 啓文, 清水 顕, 加納 里志, 矢島 陽子, 大上 研二, 大塚 邦憲, 花澤 豊行, 長尾 俊孝
    頭頸部癌, 38, 2, 210, 210, (一社)日本頭頸部癌学会, May 2012
    Japanese
  • 多施設共同による唾液腺導管癌の後方視的観察研究 生存率および予後因子に関する検討               
    大塚 邦憲, 多田 雄一郎, 今西 順久, 花澤 豊行, 佐藤 雄一郎, 金澤 丈治, 福島 啓文, 清水 顕, 加納 里志, 矢島 陽子, 大上 研二, 長尾 俊孝
    頭頸部癌, 38, 2, 210, 210, (一社)日本頭頸部癌学会, May 2012
    Japanese
  • 頭頸部癌化学放射線療法における経管栄養の役割に関する検討               
    折舘 伸彦, 倉本 倫之介, 本間 明宏, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 及川 敬太, 福田 諭
    頭頸部癌, 38, 2, 210, 210, (一社)日本頭頸部癌学会, May 2012
    Japanese
  • 照射後の異時重複下咽頭癌に対するESD後に反復感染をきたし喉頭全摘に至った一症例
    加納 里志, 折舘 伸彦, 福田 諭
    日本気管食道科学会会報, 63, 2, s87, s87, (NPO)日本気管食道科学会, Apr. 2012
    Japanese
  • 女性喉頭癌症例におけるHPV感染の検討
    水町 貴諭, 加納 里志, 畠山 博充, 坂下 智博, 鈴木 清護, 本間 明宏, 折舘 伸彦, 福田 諭
    日本耳鼻咽喉科学会会報, 115, 4, 466, 466, (一社)日本耳鼻咽喉科学会, Apr. 2012
    Japanese
  • Weekly CDDP同時併用放射線療法後の頸部郭清・頸部制御率
    坂下 智博, 本間 明宏, 折舘 伸彦, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 福田 諭
    日本耳鼻咽喉科学会会報, 115, 4, 519, 519, (一社)日本耳鼻咽喉科学会, Apr. 2012
    Japanese
  • 舌根部癌に対する喉頭機能温存治療 中咽頭前壁原発扁平上皮癌に対する超選択的動注化学療法と照射の同時併用療法               
    本間 明宏, 坂下 智博, 折舘 伸彦, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 福田 諭
    日本気管食道科学会会報, 63, 1, 77, 78, (NPO)日本気管食道科学会, Feb. 2012
    Japanese
  • HER2 expression in salivary duct carcinoma
    SUZUKI Takayoshi, KANO Satoshi, ORIDATE Nobuhiko, HONMA Akihiro, SUZUKI Seigo, HATAKEYAMA Hiromitsu, MIZUMACHI Takatsugu, FURUSAWA Jun, SAKASHITA Tomohiro, FUKUDA Satoshi
    JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY, 21, 2, 195, 201, 特定非営利活動法人 日本頭頸部外科学会, 30 Oct. 2011
    Japanese, Salivary duct carcinoma histologically resembles an invasive mammary ductal carcinoma and is a malignant tumor with a poor prognosis. The rarity of this carcinoma has resulted in a lack of consensus on its chemotherapy regimen. In recent years, HER2 overexpression has been reported in not only breast cancer but also salivary duct carcinoma, so we performed an immunostaining on the surgical specimens of salivary duct carcinoma and analyzed the relationship between HER2 expression and the clinical background. As a result, 3 cases were found to be HER2-positive. In salivary gland carcinomas, t...
  • TRIM32 promotes neural differentiation through retinoic acid receptor-mediated transcription
    Tomonobu Sato, Fumihiko Okumura, Satoshi Kano, Takeshi Kondo, Tadashi Ariga, Shigetsugu Hatakeyama
    JOURNAL OF CELL SCIENCE, 124, 20, 3492, 3502, Oct. 2011, [Peer-reviewed]
    English, Scientific journal
  • 機能温存をめざした下咽頭癌の治療 下咽頭癌に対する超選択的動注化学療法と照射の同時併用療法の有用性               
    本間 明宏, 加納 里志, 水町 貴諭, 福田 諭
    口腔・咽頭科, 24, 3, 229, 229, 日本口腔・咽頭科学会, Aug. 2011
    Japanese
  • HPV感染による中咽頭癌治療の層別化戦略               
    水町 貴諭, 加納 里志, 本間 明宏, 折舘 伸彦, 福田 諭
    口腔・咽頭科, 24, 3, 353, 353, 日本口腔・咽頭科学会, Aug. 2011
    Japanese
  • Concomitant Weekly Cisplatin and Radiotherapy for Head and Neck Cancer
    Akihiro Homma, Naoya Inamura, Nobuhiko Oridate, Seigo Suzuki, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Satoshi Kano, Tomohiro Sakashita, Rikiya Onimaru, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 41, 8, 980, 986, Aug. 2011, [Peer-reviewed]
    English, Scientific journal
  • Superselective arterial cisplatin infusion with concomitant radiation therapy for base of tongue cancer
    Satoshi Kano, Akihiro Homma, Nobuhiko Oridate, Fumiyuki Suzuki, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Jun Furusawa, Tomohiro Sakashita, Daisuke Yoshida, Rikiya Onimaru, Hiroki Shirato, Satoshi Fukuda
    ORAL ONCOLOGY, 47, 7, 665, 670, Jul. 2011, [Peer-reviewed]
    English, Scientific journal
  • 個別化を目指す薬物療法 HPV陽性中咽頭癌に対する個別化治療戦略               
    水町 貴諭, 畠山 博充, 加納 里志, 坂下 智博, 鈴木 清護, 本間 明宏, 折舘 伸彦, 福田 諭
    頭頸部癌, 37, 2, 191, 191, (一社)日本頭頸部癌学会, May 2011
    Japanese
  • 頭頸部癌におけるNF-kBパスウエイの活性化とセツキシマブ耐性               
    畠山 博充, 鈴木 清護, 坂下 智博, 加納 里志, 水町 貴諭, 本間 明宏, 折舘 伸彦, 福田 諭
    頭頸部癌, 37, 2, 230, 230, (一社)日本頭頸部癌学会, May 2011
    Japanese
  • 頭頸部扁平上皮癌N+症例における放射線動注化学療法後の頸部評価 Wait and See Policyは成立するか               
    坂下 智博, 本間 明宏, 折舘 伸彦, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 古沢 純, 稲村 直哉, 福田 諭, 吉田 大介, 鬼丸 力也, 安田 耕一, 白土 博樹
    頭頸部癌, 37, 2, 231, 231, (一社)日本頭頸部癌学会, May 2011
    Japanese
  • 頭頸部進行癌に対する集学的治療 "導入化学療法→化学放射線同時併用療法"               
    本間 明宏, 清水 康, 折舘 伸彦, 鬼丸 力也, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 安田 耕一, 秋田 弘俊, 白土 博樹, 福田 諭
    頭頸部癌, 37, 2, 233, 233, (一社)日本頭頸部癌学会, May 2011
    Japanese
  • 唾液腺悪性腫瘍におけるEGFR、HER2、c-KITの発現解析               
    加納 里志, 鈴木 清護, 折舘 伸彦, 本間 明宏, 畠山 博充, 水町 貴諭, 坂下 智博, 福田 諭
    頭頸部癌, 37, 2, 270, 270, (一社)日本頭頸部癌学会, May 2011
    Japanese
  • TRIM32 facilitates cell growth, migration and anti-apoptosis
    Satoshi Kano, Shigetsugu Hatakeyama, Satoshi Fukuda, Hiromitsu Hatakeyama
    CANCER RESEARCH, 71, Apr. 2011, [Peer-reviewed]
    English
  • Concomitant weekly cisplatin and radiotherapy for head and neck cancer.
    Homma A, Inamura N, Oridate N, Suzuki S, Hatakeyama H, Mizumachi T, Kano S, Sakashita T, Onimaru R, Yasuda K, Shirato H, Fukuda S
    Jpn J Clin Oncol, 41, 8, 980, 6, 2011, [Peer-reviewed]
  • Oral care for patients with head and neck cancer in Hokkaido University Hospital
    Hironobu Hata, Yutaka Yamazaki, Kenji Imamachi, Chika Murai, Jun Sato, Takathugu Mizumachi, Satoshi Kanou, Akihiro Honma, Satoshi Fukuda, Yoshimasa Kitagawa
    Japanese Journal of Head and Neck Cancer, 37, 4, 486, 493, (一社)日本頭頸部癌学会, 2011
    Japanese, Scientific journal
  • Strategy for personalized treatment of human papillomavirus-positive oropharyngeal squamous cell carcinoma
    Takatsugu Mizumachi, Hiromitsu Hatakeyama, Satoshi Kano, Tomohiro Sakashita, Seigo Suzuki, Akihiro Homma, Nobuhiko Oridate, Satoshi Fukuda
    Japanese Journal of Head and Neck Cancer, 37, 3, 394, 397, (一社)日本頭頸部癌学会, 2011
    Japanese, Scientific journal
  • Clinical analysis of malignant submandibular tumor
    Kyoko Kitao, Akihiro Homma, Nobuhiko Oridate, Seigo Suzuki, Fumiyuki Suzuki, Toshihiro Hara, Satoshi Káno, Takatsugu Mizumachi, Shigenari Taki, Naoya Inamura, Satoshi Fukud
    Journal of Otolaryngology of Japan, 114, 3, 126, 132, Oto-Rhino-Laryngological Society of Japan Inc., 2011, [Peer-reviewed]
    Japanese, Scientific journal
  • Strategy for personalized treatment of human papillomavirus-positive oropharyngeal squamous cell carcinoma
    Takatsugu Mizumachi, Hiromitsu Hatakeyama, Satoshi Kano, Tomohiro Sakashita, Seigo Suzuki, Akihiro Homma, Nobuhiko Oridate, Satoshi Fukuda
    Japanese Journal of Head and Neck Cancer, 37, 3, 394, 397, 2011
    Japanese, Scientific journal
  • Oral care for patients with head and neck cancer in Hokkaido University Hospital
    Hironobu Hata, Yutaka Yamazaki, Kenji Imamachi, Chika Murai, Jun Sato, Takathugu Mizumachi, Satoshi Kanou, Akihiro Honma, Satoshi Fukuda, Yoshimasa Kitagawa
    Japanese Journal of Head and Neck Cancer, 37, 4, 486, 493, 2011
    Japanese, Scientific journal
  • 下咽頭癌 喉頭機能温存治療 超選択的動注療法
    本間 明宏, 折舘 伸彦, 鈴木 章之, 原 敏浩, 真栄田 栄行, 加納 里志, 水町 貴諭, 瀧 重成, 稲村 直哉, 古沢 純, 福田 諭
    耳鼻と臨床, 56, Suppl.1, S66, S70, 耳鼻と臨床会, Nov. 2010
    Japanese
  • 中咽頭側壁・前壁癌に対する放射線化学療法の検討               
    加納 里志, 本間 明宏, 折舘 伸彦, 福田 諭
    口腔・咽頭科, 23, 3, 373, 373, 日本口腔・咽頭科学会, Aug. 2010
    Japanese
  • 北海道大学における中咽頭癌症例の検討
    加納 里志, 折舘 伸彦, 本間 明宏, 鈴木 清護, 鈴木 章之, 原 敏浩, 水町 貴諭, 稲村 直哉, 福田 諭
    耳鼻咽喉科展望, 53, 補冊1, 6, 7, 耳鼻咽喉科展望会, Jun. 2010
    Japanese
  • 化学放射線治療後の頸部郭清の必要性について               
    本間 明宏, 折舘 伸彦, 鈴木 章之, 鈴木 清護, 原 敏浩, 加納 里志, 水町 貴諭, 古沢 純, 稲村 直哉, 福田 諭, 吉田 大介, 鬼丸 力也, 安田 耕一, 白土 博樹
    頭頸部癌, 36, 2, 191, 191, (一社)日本頭頸部癌学会, May 2010
    Japanese
  • 中咽頭扁平上皮癌におけるHPV感染と治療成績の検討               
    水町 貴諭, 加納 里志, 原 敏浩, 鈴木 章之, 鈴木 清護, 本間 明宏, 折舘 伸彦, 福田 諭
    頭頸部癌, 36, 2, 205, 205, (一社)日本頭頸部癌学会, May 2010
    Japanese
  • 頭頸部癌に対するweekly cisplatinと放射線同時併用療法の検討               
    稲村 直哉, 本間 明宏, 折舘 伸彦, 鈴木 清護, 鈴木 章之, 原 敏浩, 真栄田 裕行, 加納 里志, 水町 貴諭, 福田 諭, 鬼丸 力也, 長谷川 雅一, 安田 耕一, 白土 博樹
    頭頸部癌, 36, 2, 206, 206, (一社)日本頭頸部癌学会, May 2010
    Japanese
  • 【耳鼻咽喉・頭頸部画像アトラス】 鼻副鼻腔 嗅神経芽細胞腫               
    加納 里志, 福田 諭
    JOHNS, 26, 3, 402, 403, (株)東京医学社, Mar. 2010
    Japanese
  • Prevalence and prognosis of human papillomavirus in oropharyngeal cancer
    Takatsugu Mizumachi, Satoshi Kano, Toshihiro Hara, Fumiyuki Suzuki, Seigo Suzuki, Akihiro Homma, Nobuhiko Oridate, Satoshi Fukuda
    Toukeibu Gan, 36, 4, 498, 501, 2010
    English, Scientific journal
  • Ubiquitin-Conjugating Enzyme UBE2Q2 Suppresses Cell Proliferation and Is Down-Regulated in Recurrent Head and Neck Cancer
    Hiroyuki Maeda, Naoto Miyajima, Satoshi Kano, Tadasuke Tsukiyama, Fumihiko Okumura, Satoshi Fukuda, Shigetsugu Hatakeyama
    MOLECULAR CANCER RESEARCH, 7, 9, 1553, 1562, Sep. 2009, [Peer-reviewed]
    English, Scientific journal
  • ユビキチン結合酵素UBE2Q2の頭頸部悪性腫瘍に対する調節機能の分子生化学的解析(Ubiquitin-conjugating enzyme UBE2Q2 suppresses cell proliferation and is down-regulated in recurrent head and neck cancer)               
    真栄田 裕行, 宮島 直人, 加納 里志, 築山 忠維, 奥村 文彦, 福田 諭, 畠山 鎮次
    日本生化学会大会プログラム・講演要旨集, 82回, 4P, 480, (公社)日本生化学会, Sep. 2009
    English
  • 化学放射線療法後の救済手術 問題点とその対策 喉頭下咽頭癌に対する化学放射線療法後の救済手術               
    鈴木 章之, 本間 明宏, 折舘 伸彦, 鈴木 清護, 水町 貴諭, 加納 里志, 瀧 重成, 稲村 直哉, 鬼丸 力也, 長谷川 雅一, 白土 博樹, 古田 康, 福田 諭
    頭頸部癌, 35, 2, 61, 61, (一社)日本頭頸部癌学会, May 2009
    Japanese
  • 臨床パネル「頭頸部癌とヒト乳頭腫ウイルス(HPV)」 頭頸部癌におけるヒト乳頭腫ウイルスによる発癌のメカニズムと検出について               
    水町 貴諭, 瀧 重成, 加納 里志, 原 敏浩, 鈴木 章之, 鈴木 清護, 本間 明宏, 折舘 伸彦, 福田 諭, 古田 康
    頭頸部癌, 35, 2, 68, 68, (一社)日本頭頸部癌学会, May 2009
    Japanese
  • UBE2Q2は細胞増殖を抑制し、再発性頭頸部癌においてはその発現が抑制されている(UBE2Q2 suppresses cell proliferation and is down-regulated in recurrent head and neck cancer)               
    真栄田 裕行, 加納 里志, 畠山 鎮次, 福田 諭
    日本耳鼻咽喉科学会会報, 112, 4, 315, 315, (一社)日本耳鼻咽喉科学会, Apr. 2009
    English
  • Salvage surgery for recurrent cases of laryngeal or hypopharyngeal cancer following concurrent chemoradiotherapy
    Fumiyuki Suzuki, Akihiro Homma, Nobuhiko Oridate, Seigo Suzuki, Takathugu Mizumachi, Satoshi Kanou, Shigenari Taki, Naoya Inamura, Satoshi Fukuda, Rikiya Onimaru, Masakazu Hasegawa, Hiroki Shirato, Yasushi Furuta
    Toukeibu Gan, 35, 4, 344, 349, (一社)日本頭頸部癌学会, 2009
    Japanese, Scientific journal
  • Detection and mechanism of HPV infection in human head and neck cancer
    Takatsugu Mizumachi, Shigenari Taki, Satoshi Kano, Toshihiro Hara, Fumiyuki Suzuki, Seigo Suzuki, Akihiro Homma, Nobuhiko Oridate, Satoshi Fukuda, Yasushi Furuta
    Toukeibu Gan, 35, 4, 356, 359, (一社)日本頭頸部癌学会, 2009
    English, Scientific journal
  • Detection and mechanism of HPV infection in human head and neck cancer
    Takatsugu Mizumachi, Shigenari Taki, Satoshi Kano, Toshihiro Hara, Fumiyuki Suzuki, Seigo Suzuki, Akihiro Homma, Nobuhiko Oridate, Satoshi Fukuda, Yasushi Furuta
    Toukeibu Gan, 35, 4, 356, 359, 2009
    English, Scientific journal
  • Salvage surgery for recurrent cases of laryngeal or hypopharyngeal cancer following concurrent chemoradiotherapy
    Fumiyuki Suzuki, Akihiro Homma, Nobuhiko Oridate, Seigo Suzuki, Takathugu Mizumachi, Satoshi Kanou, Shigenari Taki, Naoya Inamura, Satoshi Fukuda, Rikiya Onimaru, Masakazu Hasegawa, Hiroki Shirato, Yasushi Furuta
    Toukeibu Gan, 35, 4, 344, 349, 2009
    Japanese, Scientific journal
  • 頭頸部癌における集学的治療 頭頸部癌に対する超選択的動注療法・照射同時併用療法               
    本間 明宏, 折舘 伸彦, 鈴木 清護, 鈴木 章之, 原 敏浩, 水町 貴諭, 加納 里志, 瀧 重成, 浅野 剛, 吉田 大介, 西岡 健, 鬼丸 力也, 長谷川 雅一, 白土 博樹, 福田 諭
    日本癌治療学会誌, 43, 2, 284, 284, (一社)日本癌治療学会, Oct. 2008
    Japanese
  • Tripartite motif protein 32 facilitates cell growth and migration via degradation of Abl-interactor 2
    Satoshi Kano, Naoto Miyajima, Satoshi Fukuda, Shigetsugu Hatakeyama
    CANCER RESEARCH, 68, 14, 5572, 5580, Jul. 2008, [Peer-reviewed]
    English, Scientific journal
  • TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells
    Naoto Miyajima, Satoru Maruyama, Miyuki Bohgaki, Satoshi Kano, Masahiko Shigemura, Nobuo Shinohara, Katsuya Nonomura, Shigetsugu Hatakeyama
    CANCER RESEARCH, 68, 9, 3486, 3494, May 2008, [Peer-reviewed]
    English, Scientific journal
  • 北海道大学病院における口腔底癌の治療成績               
    瀧 重成, 本間 明宏, 折舘 伸彦, 鈴木 清護, 鈴木 章之, 加納 里志, 水町 貴諭, 古田 康, 福田 諭
    頭頸部癌, 34, 2, 229, 229, (一社)日本頭頸部癌学会, May 2008
    Japanese
  • 頭頸部扁平上皮癌におけるユビキチンリガーゼTRIM32の機能解析               
    加納 里志, 真栄田 裕行, 畠山 鎮次, 福田 諭
    日本耳鼻咽喉科学会会報, 110, 4, 326, 326, (一社)日本耳鼻咽喉科学会, Apr. 2007
    Japanese
  • 体外式酸素化装置を使用した気管内手術の2例               
    柏村 正明, 武市 紀人, 古沢 純, 加納 里志, 小原 修幸, 福田 諭
    日本耳鼻咽喉科学会会報, 109, 4, 368, 368, (一社)日本耳鼻咽喉科学会, Apr. 2006
    Japanese
  • Olfactory neuroblastoma: The Hokkaido University experience
    Satoshi Kano, Yasushi Furuta, Akihiro Homma, Nobuhiko Oridate, Eisaku Higuchi, Fumiyuki Suzuki, Tatsumi Nagahashi, Yutaka Sawamura, Satoshi Fukuda
    Journal of Otolaryngology of Japan, 109, 5, 433, 439, Oto-Rhino-Laryngological Society of Japan Inc., 2006, [Peer-reviewed]
    Japanese, Scientific journal
  • 当科における嗅神経芽細胞腫の治療経験               
    加納 里志, 古田 康, 本間 明宏, 折舘 伸彦, 樋口 榮作, 鈴木 章之, 永橋 立望, 福田 諭
    日本耳鼻咽喉科学会会報, 108, 4, 457, 457, (一社)日本耳鼻咽喉科学会, Apr. 2005
    Japanese
  • 当科における難治性外耳道炎及び中耳炎に対するブロー液の治療経験
    加納 里志, 山本 潤, 川浪 貢
    岩見沢市立総合病院医誌, 30, 1, 55, 58, 岩見沢市立総合病院, Apr. 2004
    Japanese
  • 舌に発生した異所性脳組織の1症例               
    加納 里志, 鈴木 清護, 劉 澤周, 木田 毅, 大湯 淳功, 渡辺 麻衣子, 山田 豊
    道南医学会誌, 37, 303, 305, 道南医学会, Jul. 2002
    Japanese
  • 先天性舌腫瘍(異所性脳組織)の1例               
    渡辺 麻衣子, 城 和歌子, 大湯 淳功, 木田 毅, 水上 晋, 屋敷 憲章, 山田 豊, 加納 里志, 鈴木 清護, 劉 澤周
    日本小児科学会雑誌, 106, 6, 817, 817, (公社)日本小児科学会, Jun. 2002
    Japanese
  • ESSにて治療した上顎含歯性嚢胞の1症例
    加納 里志, 加藤 明夫
    日本耳鼻咽喉科学会会報, 105, 1増刊, 93, 94, (一社)日本耳鼻咽喉科学会, Jan. 2002
    Japanese
  • 乳突充填型鼓室形成術にて治療した中耳コレステリン肉芽腫症例               
    加藤 明夫, 加納 里志
    日本耳鼻咽喉科学会会報, 105, 1増刊, 96, 96, (一社)日本耳鼻咽喉科学会, Jan. 2002
    Japanese
  • 当科におけるシスプラチンの超選択的動注療法               
    本間 明宏, 畠山 博充, 加納 里志, 永橋 立望, 八木 克憲, 古田 康, 福田 諭, 犬山 征夫
    日本耳鼻咽喉科学会会報, 104, 5増刊, 640, 641, (一社)日本耳鼻咽喉科学会, May 2001
    Japanese
  • 結核性頸部リンパ節炎の2症例               
    加納 里志, 加藤 明夫
    砂川市立病院医学雑誌, 18, 1, 63, 66, 砂川市立病院, Mar. 2001
    Japanese
  • 頸部原発脂肪肉腫の1症例               
    加納 里志, 飯尾 光博, 本間 明宏, 八木 克憲, 福田 諭, 犬山 征夫
    日本耳鼻咽喉科学会会報, 103, 5増刊, 699, 699, (一社)日本耳鼻咽喉科学会, May 2000
    Japanese

Other Activities and Achievements

Research Themes

  • 唾液腺高悪性度転化癌の病態解明と治療応用を踏まえた癌免疫微小環境の解析
    科学研究費助成事業
    01 Apr. 2022 - 31 Mar. 2025
    中黒 匡人, 長尾 俊孝, 多田 雄一郎, 加納 里志, 浦野 誠, 西尾 直樹
    日本学術振興会, 基盤研究(C), 名古屋大学, 22K06939
  • Molecular pathological analysis of salivary gland carcinomas promoting personalized medicine: A large-scale multicenter study
    Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)
    01 Apr. 2021 - 31 Mar. 2024
    稲垣 宏, 加納 里志, 中黒 匡人, 奥村 嘉英, 岩井 大, 丹生 健一, 草深 公秀, 櫻井 一生, 山元 英崇, 河田 了, 村瀬 貴幸, 田口 健一, 正木 彩子, 羽藤 直人, 多田 雄一郎, 川北 大介, 花井 信広, 大上 研二, 長尾 徹, 長尾 俊孝
    唾液腺癌は稀な腫瘍であるが、われわれは多施設共同研究組織を構築し、これまでに多数の症例を収集した。2021年度は以下の研究を行い、論文発表を行った。
    1. 粘表皮癌は唾液腺癌の中で最も頻度の高い腫瘍であるが、その組織学的多様性は十分明らかになっていない。我々は粘表皮癌117例を亜型分類したところ、Classical (74%), Clear/oncocytic (8%), Warthin-like (3%), Clear cell (3%), Oncocytic (2%), Spindle (2%), Sclerosing (2%), Mucinous (3%), Central (2%)であることを明らかにした。Ciliated, Mucoacinar, High-grade transformationは認められなかった(Histopathology, 2021, PMID: 34657306)。
    2. 粘表皮癌に次いで頻度の高い腫瘍である腺様嚢胞癌は、組織学的に、充実性腫瘍成分により悪性度を推定することが多いが、それを正確に判定することはしばしば困難である。われわれは腺様嚢胞癌195例を臨床病理学的に検討し、充実性腫瘍成分の短径が客観的な悪性度指標であることを明らかにした(Cancer Sci, 2021, PMID: 33377247)。
    3. 粘表皮癌は稀に胸腺に発生するが、その詳細は明らかではない。われわれは国際共同研究を行い、胸腺粘表皮癌の臨床病理学的、分子病理学的特徴を系統的に解析した。興味深いことに、CRTC1-MAML2融合遺伝子は56%の症例に認められ、患者の予後良好と関連した(Am J Surg Pathol, 2022, PMID: 35319525)。
    Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Nagoya City University, 21H02704
  • Development of less toxic radiotherapy using IMPT for head and neck cancer
    Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    01 Apr. 2019 - 31 Mar. 2023
    安田 耕一, 加納 里志, 水町 貴諭, 高尾 聖心, 田村 昌也
    後ろ向き観察研究の自主臨床計画書を作成し、当施設の審査会にて承認された。
    スポットスキャニングIMPTにおける皮膚、唾液腺、舌、粘膜の線量を大幅に低減させる手法の開発に取り組んだ。皮膚に関しては当院で過去に実施された放射線治療患者の線量分布および皮膚炎の程度を解析し、皮膚炎発症に最も関連する皮膚線量のパラメーターを解析した。DVH(dose-volume histogram)解析において、皮膚のV65Gy(65Gy以上照射される皮膚の体積)が皮膚炎グレード3発症に関連する独立因子であることを突き止めた。皮膚炎発症と線量に関するモデル作成について検討を開始した。スポットスキャニングIMPTにおいて、局所的な皮膚線量を低減するプランニング法の開発を開始した。耳下腺及び舌に関しても同様に、線量低減のプランニング法の開発を開始した。粘膜線量低減のために、頭頸部癌におけるPTV(planning target volume) margin(照射ターゲットの位置の不確かさのために付与するマージン)の検証を行った。照射中に撮像可能なCBCT(cone-beam CT)を用いて照射前後の頭頸部の各領域の動きの変化を検証した。各領域に最適なPTV marginを個別に付与する(variable PTV marginの設定)方法の基礎的知見を得た。従来の放射線治療法で治療された頭頸部癌患者に対しQOL調査を行った。四大副作用、つまり皮膚炎、口渇、味覚障害、粘膜炎に関して、患者が感じる「辛さ」を客観的に把握するための調査項目を決定し、調査を開始した。
    Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 19K08088
  • Molecular pathological analysis of salivary gland carcinomas focusing on personalized medicine: A large-scale multicenter study
    Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)
    01 Apr. 2018 - 31 Mar. 2021
    Inagaki Hiroshi
    Salivary gland carcinomas are rare tumors, and a large number of these carcinoma cases were collected through multicenter joint research and clinical pathological analysis was performed. We clarified that certain types of benign tumors are difficult to distinguish from adenoid cystic carcinoma, and proposed a novel grading system of adenoid cystic carcinoma. We reported that the prognosis of patients with specific fusion-positive mucoepidermoid carcinoma is extremely good, and that in these patients, postoperative radiotherapy can be omitted. It is hoped that these studies will promote molecular pathology of salivary gland carcinomas and that it will be directly and indirectly applied to the stratified and individualized treatment for patients with salivary gland carcinomas.
    Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Nagoya City University, 18H02633
  • Genetic analysis for high grade salivary gland cancer
    Grants-in-Aid for Scientific Research
    01 Apr. 2018 - 31 Mar. 2021
    Kano Satoshi
    The gene expression pattern was generally consistent with the corresponding immunostaining classification. The expression levels of VEGFA, ERBB2(HER2), IGF1R, RB1, and XBP1 were higher, while those of SLIT2 and PTEN were lower in Ca-ex-PA than in de novo. The functions of those genes were concentrated in angiogenesis and AKT/PI3K signaling pathway.
    Multiple machine learning methods show that VEGFA can be a candidate for the characteristic differences between Ca-ex-PA and de novo.
    Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 18K09309
  • The development of tailor-made treatment for high-grade salivary gland cancer
    Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    01 Apr. 2013 - 31 Mar. 2016
    KANO SATOSHI
    We analyzed the expression of proteins in salivary gland cancer. The results showed that the expression of EGFR, HER2 and c-KIT was 76%, 20% and 38%, respectively. Among them, the patients with HER2-positive tumors had significantly unfavorable prognosis. Furthermore, we found the activation of the PI3K pathway in HER2-positive tumors. HER2 was mainly overexpressing in salivary duct carcinoma, and was detected more frequently in carcinoma ex pleomorphic adenoma than in de novo tumors. This result suggested that HER2 could be involved in carcinogenesis from pleomorphic adenoma. Based on these results, we planned to develop a HER2-targeted therapy in salivary gland cancer.
    Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 25462672
  • activation of micro-RNA in head and neck cancer cell
    Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)
    2010 - 2012
    KANO Satoshi
    has-miR-134 was identified as a micro RNA specifically binding to TRIM32. has-miR-134 has been reported to express highly in tongue cancer. VEGF-A and ABCC1 were considered as the target gene of has-miR-134. However, we could not confirm an activation of has-miR-134 by TRIM32. Furthermore, we could not confirm an activation and change in the expression level of has-miR-134 in cell lines overexpressed or knocked down TRIM32.
    Japan Society for the Promotion of Science, Grant-in-Aid for Young Scientists (B), Hokkaido University, 22791561